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Abstract 
Late onset Alzheimer’s disease (LOAD) is the commonest form of dementia, affecting 
approximately 850,000 patients in the UK alone, predicted to exceed one million by 2025. 
The cause of LOAD is complex, but several large Genome Wide Association Studies have 
highlighted 21 genetic loci associated with this devastating disease and the ATP-Binding 
Cassette Protein, family A, member 7 (ABCA7) is one of these genetic loci. However, the 
exact reasons behind this association are still unknown, focusing work on identifying 
functional, pathogenic mutations within this locus.  
A total of 240 exonic variations within ABCA7 were therefore annotated in order to identify 
ones potentially altering the functionality of ABCA7. A total of five variants were predicted 
to be damaging by in silico annotation tools: rs3752233; rs59851484; rs3752237; 
rs114782266 and a novel mutation at genomic position 19:1056958. These were genotyped in 
the ARUK DNA Bank resource and three (rs59851484, rs3752239 and 19:1056958) showed 
tentative association with LOAD. However, lack of power in this study prevented any 
definitive associations from being formed. A further two variants were examined within 
functional cell assays. rs881768 had been predicted to affect the splicing of the ABCA7 
protein and appeared to do so within minigene cellular assays. However, this did not appear to 
be the case when RNA from brain tissue harbouring this variation was examined. rs2020000 
was examined through the dual luciferase assays, with the minor allele seeming to down 
regulate the reporter protein by approximately 30% (p<0.02) in these in vitro assays.  
Functional variations within the ABCA7 locus do play a role in LOAD risk and improvements 
within functional databases and annotation programmes will assist in identifying these 
causative mutations, in order to put a halt to LOAD, as well as other destructive complex 
disorders. 
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1 Introduction 
1.1 Alzheimer’s Disease 
n 1906 Alois Alzheimer first defined Alzheimer’s disease (AD) in a 51-year-
old patient of his (Auguste D) who exhibited symptoms of worsening cognitive 
impairment, delusions and impaired social functions. On post-mortem 
examination he identified neurological amyloid plaques and neurofibrillary tangles, 
now known as the hallmarks of this disease (Alzheimer et al., 1995). These 
neuropathological markers of AD are thought to cause neurotoxicity, inflammation 
and neuronal dysfunction, thus leading to cognitive impairment (Eikelenboom et al., 
2006). Initially the neuronal and synaptic damage is in the parahippocampal regions, 
the area of the brain which is predominantly responsible for forming new memories. 
However, pathology subsequently spreads, eventually causing cortical atrophy and 
ventricular enlargement, commonly reducing total brain mass by up to 35% as shown 
in Figure 1.1 (Alves et al., 2012; Farfara et al., 2008).  
 
 
 
 
 
 
I 
Figure 1.1 - Comparison between a healthy brain and a brain 
with Alzheimer's disease. 
 i  re     
Comparison between a healthy brain and a brain with Alzheimer’s 
disease. In AD the neural cortex shrinks, especially in the hippocampal 
region which is responsible for forming new memories.  he ventricles 
 fluid filled cavities in the brain  consequently enlarge.  aken from 
https:  www.alz.org braintour images alzheimer brain.jpg 
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AD is the commonest cause of dementia, attributing 77% of the demented population 
 Alzheimer’s Association, 2015 . This accounted for an estimated 820,000 people 
living with dementia in the UK in 2008, 32% of all UK residents over the age of 85 
and one third of Americans over the age of 85. This figure is expected to double every 
20 years, reaching 131.5 million worldwide by 2050, partly due to life expectancies 
continuing to raise  Alzheimer’s Association, 2015; Ferri et al., 2005; Lewis and 
Torgerson, 2016).  
The risk of AD in individuals over the age of 85 is 11% in males and 17% in females 
(Genin et al., 2011). Those diagnosed at the age of 80 experience a reduction in 
lifespan of 39%, increasing to 67% if they are identified earlier at the age of 65 
(Brookmeyer et al., 2002). In the UK, these patients cost the economy £23 billion a 
year (on average $47,752 per patient), half of which is met by unpaid carers, 
commonly family members, as patients lose the activities of daily living. The global 
cost of AD is likely to exceed US $1 trillion by 2018 (Wimo et al., 2016). This 
demonstrates that AD has not only a large impact on the family members caring for 
these patients, but also on the national – and international - economy. It is an 
increasingly common cause of death: where the number of deaths due to other major 
diseases, such as heart disease and stroke, has decreased significantly, deaths due to 
AD have increased by 71% between 2000 and 2013. However it has the lowest 
number of compounds progressing to therapeutic trials, showing the lack of 
pharmaceutical progress made towards treating this disease  Alzheimer’s Association, 
2015; Lewis and Torgerson, 2016). 
1.1.1 Alzheimer’s Disease Patholo ical “Hallmarks” 
AD is often very difficult to distinguish clinically from other forms of dementia and 
cannot be definitively diagnosed until post-mortem upon identification of amyloid 
plaques and tau neurofibrillary tangles within the brain (see Figure 1.2). 
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Unfortunately, therefore, a diagnosis of only probably or possible AD can be made 
during a patient’s lifetime, based on symptoms and cognitive assessments. This makes 
diagnosing, treating and managing suspected AD extremely problematic and, 
consequently, a vast area of ongoing research is on trying to image these markers, as 
well as other biomarkers, in live patients.  
AD, like many neurodegenerative diseases, is characterised by the aggregation of 
certain misfolded proteins. The two proteins distinguishing AD are summarised in text 
below and in pictorially in Figure 1.2.  
 
1.1.1.1 Aβ Plaques 
For many years, it has been accepted that pathological amyloid plaques  Aβ  are the 
primary event in the AD disease process (Hardy and Allsop, 1991). These plaques are 
formed from the proteolysis of Amyloid Precursor Protein (APP) by α-, β- and γ-
secretases (Bu, 2009) producing the hydrophobic Aβ peptide. This, in combination 
with other proteins, including apolipoprotein E (apoE) and apolipoprotein J, also 
known as clusterin, form the pathological plaques (Liao et al., 2004).   
Figure 1.2 - Comparison between a healthy neuronal cell and a neuronal cell from an individual with 
AD pathology. 
 i  re     
A healthy neuronal cell  left  and a neuronal cell from an individual with AD pathology 
 right , showing the extracellular amyloid plaques and intracellular tau neurofibrillary 
tangles.  aken from http:  www.alzheimersresearchuk.org brain-tour  
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APP is a protein located in cellular membranes, expressed in a variety of tissues but 
especially in neuronal synapses. APP’s most defined role is in synapse formation and 
transmission (Priller et al., 2006) although its primary function still remains unknown 
(Turner et al., 2003). This postulated role in synapse function is questioned by the lack 
of expression it has in synaptic-rich tissues when examined in expression databases 
(for example, Protein Atlas) (Uhlen et al., 2010). The full role of this protein, 
therefore, remains to be established.  
When APP is cleaved, it can follow either the amyloidogenic or non-amyloidgenic 
pathway depending on which secretase enzymes are involved (summarised in Figure 
1.3) (Thinakaran and Koo, 2008). It is the amyloidgenic pathway, involving the β- and 
γ-secretases, which generates Aβ: either Aβ40 or Aβ42 depending on where γ-
secretase cleaves APP. Aβ42 is more likely to aggregate and form plaques and 
therefore a higher proportion of this is likely to be damaging, to both neurones and 
synapses (Holtzman et al., 2012). Aβ can exist in both soluble and insoluble forms but 
studies in rat brains have shown it to be the soluble Aβ dimers that are neurotoxic, 
disrupting learned behaviour and inhibiting long-term potentiation (Shankar et al., 
2008).  
There are several theories as to why Aβ accumulates and causes plaques. These 
include: increased production; decreased clearance; a higher Aβ42:Aβ40 ratio; altered 
Aβ metabolism or even a mixture of all of these.  Higher levels of β-secretase (coded 
for by the BACE1 gene) have also been known to increase the likelihood of the 
amyloidgenic pathway being followed  see Figure 1.3 . Aβ mainly aggregates in the 
post-synaptic compartment of synapses, resulting in both synaptic and dendritic loss 
(Minati et al., 2009; Shankar et al., 2008). Recently, Aβ42 has also been implicated in 
gene transcription, altering the expression of some of the other disease modifying 
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genes, perhaps playing a part in AD pathology through this mechanism (Barucker et 
al., 2014). 
 
Figure 1.3 - Amyloid Precursor Protein proteolysis. 
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Amyloid Precursor Protein  APP  proteolysis and the two alternate pathways. In the non-amyloidogenic pathway, 
 – and  -secretase cleave APP to form the secreted APP ectodomain  APPs   , p3 and APP Intracellular, 
Cytoplasmic Domain  AICD . In the amyloidogenic pathway,  – and  -secretase cleave APP to form A , APPs  
and, again, AICD. A   when in combination with other proteins, then goes on to form the neuropathological 
plaques. Modified from  hinakaran and Koo 200 , Martins       200  and Blennonw       2010. 
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1.1.1.2 Neurofibrillary Tangles 
Tau is a microtubule binding protein, stabilising neuronal microtubules as well as 
encouraging axonal growth and activity, and is the main component of these 
pathological neurofibrillary tangles (NFTs) (Roy et al., 2005). It is coded for by the 
microtubule associated tau (MAPT) gene and it is functionally modulated by its 
phosphorylation status. When the balance of phosphorylated to unphosphorylated 
protein is disrupted, hyperphosphorylation of the protein occurs causing it to 
accumulate and form paired helical filaments. These go on to form β-pleated sheets, 
which aggregate within the cell cytoplasm, blocking nutrient transport and (see Figure 
1.2) forming the neurotoxic tangles (Mandelkow and Mandelkow, 1998). The quantity 
of NFTs within an AD brain correlates with the disease severity, whilst Aβ load does 
not (Arriagada et al., 1992). Neuronal studies have also shown that NFTs need to be 
present in order for Aβ plaques to be neurotoxic (Rapoport et al., 2002). 
It is not entirely defined as to why tau hyperphosphorylates. Some theories include 
abnormal developmental regulation, upregulated protein kinases (Tolnay and Probst, 
1999) and abnormal oxidation (Mandelkow and Mandelkow, 1998). Rare variants in 
the MAPT gene have been linked disease, including several other neurodegenerative 
disorders such as frontal temporal dementia (FTD) (Jin et al., 2012; Neumann et al., 
2009). MAPT has also, recently, been genetically linked with AD when a previously 
existing dataset (the International Genomics of Alzheimer’s Project (IGAP) 
consortium GWAS data) was meta-analysed, association signals were accounted for 
between a locus near the MAPT gene and AD risk (Jun et al., 2016).  
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1.1.2 Amyloid Cascade Hypothesis 
The suggestion that Aβ plaques are the initiating event in AD pathology – known as 
the amyloid cascade hypothesis – was based on evidence that genetic alterations to the 
APP gene cause a severe, early onset form of AD, while similar alterations to MAPT 
do not (Hardy and Allsop, 1991; M. Lee et al., 2014). The fact that individuals with 
 risomy 21  commonly known as Down’s syndrome , where the APP gene is located, 
also supports this hypothesis with these individuals developing age-related Aβ plaques 
(Hartley et al., 2014; Musiek and Holtzman, 2015). It has been suggested that the 
oxidative stress and ionic homeostasis disrupted by Aβ may create an imbalance of 
Figure 1.4 - Amyloid Cascade Hypothesis. 
 he hallmarks of Alzheimer’s Disease are now evident - Aβ plaques and Neurofibrillary Tangles
Further neuronal and synaptic damage
This causes additional oligomerisation of Aβ as well as hyperphosphorylation of tau
Neuronal homeostasis is affected, increasing oxidative stress and spreading the toxicity to 
further synapses and neurones
The immune system is activated against these deposits, forming the characteristic amyloid 
plaques
These Aβ42 deposits begin to cause synaptotoxicity
Aβ42 forms oligomers and deposits
Aβ increases due to an increase in production, altered metabolism, altered Aβ42/Aβ40 ratio 
and/or decreased clearance 
Figure 1.4 
Flow chart summarising the Amyloid Cascade Hypothesis, where the formation of Aβ oligomers are the initiating 
event in Alzheimer’s Disease pathology. Modified from Haass and Selkoe (2007).
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phosphatases and kinases, stimulating the hyperphosphorylation of tau (Haass and 
Selkoe, 2007). This hypothesis is summarised in Figure 1.4. 
Although these two signature markers are descriptive of AD cases, it is not clear 
whether they are the direct cause of the consequential neuronal loss. Alongside them, 
AD brain frequently exhibit activated immune cells (Eikelenboom et al., 2006), 
mitochondrial dysfunction (Reddy, 2011), cerebral inflammation (Wyss-Coray, 2006) 
and vascular involvement (Marchesi, 2011). However, protein aggregates, specifically 
Aβ, may also contribute to this chronic inflammation of the neurones itself by 
activating microglia (Fan et al., 2014). This then goes on to accelerate the protein 
aggregates spread throughout the brain, as well as upregulating the expression of APP 
and tau, most likely aggravating the pathology (Guo and Lee, 2014; M. Lee et al., 
2014). 
1.1.3 Signs & Symptoms 
Commonly, initial presentation of AD patients will be to primary care facilities, such 
as General Practitioners (GPs), with gradual worsening of memory loss. Dementia is, 
generally, a progressive and mostly irreversible condition with widespread loss of 
mental function. However, AD is, more specifically, defined as memory loss in 
combination with loss of activities of daily living (Alves et al., 2012). The 
pathophysiology of AD may, in fact, begin up to 20 years before symptoms begin to 
manifest and, on average, is fatal four to eight years after an AD diagnosis 
 Alzheimer’s Association, 2015; Holtzman et al., 2012 .  
As the disease progresses, patients may experience some, or all, of the following: 
memory loss; language impairment; disorientation; challenges in planning and 
problem solving; changes in personality; difficulties with activities of daily living; 
self-neglect; psychiatric symptoms or generally developing out-of-character 
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behaviour. The rate of disease progression varies from individual to individual and 
more of these symptoms may worsen or increase in number until patients are largely 
unable to care for themselves. They therefore require full-time care in order to 
complete the activities of daily living, frequently becoming dysphagic, aphasic and 
incontinent as well as the symptoms previously mentioned  Alzheimer’s Association, 
2015).   
The reasoning behind the time lag between pathology occurring and symptoms 
becoming apparent is thought to be the idea of “cognitive reserve.” This implies that, 
patients with a higher number of neurons to start with, being able to withstand higher 
levels of neurological Aβ plaques before cognition begins to decline due to a higher 
number of “reserve” neurones.  his implies they will be able to increase their 
neurological function (assessable on functional magnetic resonance imaging (fMRI)) 
in proportion to the amount of Aβ plaques present, possibly providing an early 
diagnostic tool (Beecham et al., 2014; Elman et al., 2014). 
Advancement of AD often results in individual’s having difficulties moving, leaving 
them vulnerable to infections, most commonly pneumonia. This, and other acute 
conditions, are frequently the contributing factors to AD-related deaths with a very 
blurred distinction between “death with dementia” and death from dementia” 
 Alzheimer’s Association, 2015 .  
1.1.4 Diagnosis 
As mentioned before, presentation of dementia is commonly to the GP with memory 
loss. However, only 50% of AD patients are diagnosed correctly in the general 
community, outside of specialist centres. Therefore patients showing signs of Mild 
Cognitive Impairment (MCI – memory loss without loss of the activities of daily 
living) should be referred to memory assessment services (Mayeux et al., 2011). 
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Within these dedicated facilities, diagnosis of dementia caused by AD can increase to 
95% accuracy when monitored longitudinally (Alves et al., 2012; Villemagne et al., 
2008). 
A comprehensive assessment of all suspected AD patients should take place, 
including history taking (both from the patient and from a close family member), 
cognitive and mental state assessment, physical examination and a review of current 
medications to rule out drug induced cognitive impairment, as well as any condition 
which may present with dementia-like symptoms  Alzheimer’s Association, 2015; 
Villemagne et al., 2008). The cognitive examination commonly involves the Mini 
Mental State Examination (MMSE) which examines attention and concentration, 
orientation, short and long-term memory, praxis, language and executive function. 
However, other standardised devices can also be used including the 6-item Cognitive 
Impairment Test (6-CIT), the GP Assessment of Cognition (GPCOG) and the 7-
minute screen.  
Baseline measurements should also be performed in order to rule out other causes of 
dementia. These can include routine haematology, biochemistry tests, thyroid function 
tests, serum vitamin B12 and folate levels as well as syphilis or human 
immunodeficiency virus (HIV) serology and midstream urine tests if the patient 
history suggests these may be necessary.  
Following assessment of demented patients, they can be classified as Probable AD, 
Possible AD or Unlikely AD.  These categories are defined in the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease 
and Related Disorders Association (NINCDS-ARDA  Alzheimer’s criteria. Possible 
AD is a dementia syndrome with an atypical onset but no other co-morbidity which is 
likely to have caused the dementia. Probable AD is cognitive impairments being 
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apparent in two or more areas of cognition that are progressive. The age of onset is 
typical for AD patients and there are no other diseases present which are likely to have 
caused the syndrome. Definite (or confirmed) AD can only be diagnosed with 
histopathological evidence of AD upon post-mortem (McKhann et al., 1984). 
Neurological imaging may also be utilised in order to exclude other cerebral 
pathologies. Magnetic Resonance Imaging (MRI) is the preferred modality but 
computed tomography (CT) can also be used. More specific functional scanning, such 
as perfusion scans, can also be used to help differentiate from other dementia 
subtypes. In current guidelines (NICE 2014), cerebrospinal fluid (CSF) examination is 
not recommended as routine investigation for dementia. However, it may increase the 
accuracy of diagnosis if it is unsure, as discussed below. Amyloid position emission 
tomography (PET) scans have also recently become a very good predictor of true AD 
suffers, detecting early stages of amyloid deposition, providing a good indicator of 
cognitive decline although this is yet to be recommended by NICE (Dubois et al., 
2016). 
1.1.5 Biomarkers 
As previously mentioned, pathology of Alzheimer’s disease can exist for many years 
prior to becoming symptomatic. However, most of the successful disease-modifying 
therapeutic agents are likely to be their most effective very early on in the disease 
process. Therefore, a method needs to be identified for detecting AD patients at this 
point, perhaps when only MCI is apparent or even pre-symptomatically. Accuracy of 
AD diagnosis is also a problem, with diagnosis based purely on clinical criteria 
offering a sensitivity of only 70.9-87.3% and a specificity of 44.3-70.8% depending 
on weather the diagnosis is of probable or possible AD (Beach et al., 2012). 
Consequently, biomarkers are required in order to assist in AD diagnosis, monitor 
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reactions to any treatments given whilst also improving the quality of patient cohorts 
in AD clinical trials (Blennow et al., 2010).  
Due to CSF being in direct contact with the Central Nervous System (CNS), the 
principle site of AD pathology, it is logical that its contents are influenced by the 
neurological environment (Kauwe et al., 2014). Therefore, levels of AD related 
proteins in the CSF may report on the patients AD status. CSF biomarkers for AD 
include total tau, phosphorylated tau and Aβ1-42 and, in combination, these do increase 
the sensitivity and specificity of an AD diagnosis, therefore influencing patient 
management, when compared to a diagnosis based on clinical symptoms alone (Duits 
et al., 2014; Molinuevo et al., 2014). So far, they have been proven to reliably 
diagnose AD patients (with a sensitivity and specificity of 80-90% and increasing 
diagnostic confidence from 84% to 89%) as well as predicting future AD patients in 
MCI cohorts (with an accuracy of >80%). However, they are not as successful in 
discriminating AD cases from other forms of dementia, with the exception of FTD 
(Ewers et al., 2014). Until recently these methodologies were also ineffective in 
predicting AD patients from the pre-symptomatic patient groups (Blennow et al., 
2010).  However, a recent study has identified that the ratio of CSF Aβ42 to Aβ40 to 
be more sensitive to the level of cortical atrophy then Aβ42 levels alone, especially in 
the preclinical stages. However, hippocampal volumes can be predicted by Aβ42 
levels alone (Lindberg et al., 2016). This Aβ42:Aβ40 ratio may, therefore, provide an 
early diagnostic tool of cortical atrophy. Unfortunately, obtaining CSF through a 
lumbar puncture is an invasive process and may not even be possible in a community 
health care setting.  
A further suggested biomarker is imaging. This includes imaging of Aβ within the 
brain itself via position emission tomography, performing fMRI as well as measuring 
the level of cortical atrophy, again through MRI (Simmons et al., 2009; Small et al., 
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1999). However, all of these modalities are rather expensive and repeat 
measurements, as with CSF sampling, are problematic. In contrast, Blood and plasma 
are a lot more accessible and repeat sampling is comparatively easy as well as being 
available in a community setting.  
Until recently, no plasma biomarkers had been identified which correlated to AD 
status. Due to the blood-brain barrier, proteins present in the CNS are not reflected in 
the plasma. This is clear in the literature where conflicting evidence on plasma levels 
of both tau and Aβ levels show that they are not reliable biomarkers (Rosén et al., 
2013). Other markers have been looked at, including inflammatory markers due to the 
known role of inflammatory processes in the pathophysiology of AD (Lueg et al., 
2014). However, more recently the idea of a panel of molecular markers has gained 
ground. Due to the fact that AD is a multifactorial disease, being influenced by both 
genetics and environment, as well as lifestyle factors, one single molecule may not be 
able to provide the biomarker capabilities required (Richens et al., 2014). This concept 
has been proven recently with two studies putting forward suggested panels of plasma 
proteins, both published in 2014. One presents a set of ten lipids which predict 
conversion of MCI to AD within 2 to 3 years with an accuracy of 90% (Mapstone et 
al., 2014). The other proposes a different panel of ten plasma proteins, with only 
clusterin and apoE being identified as being related to AD previously. This study 
again predicts disease progression as well as disease severity with an accuracy of 87% 
(Hye et al., 2014).  
Current guidelines for diagnosing AD primarily utilise neurological imaging, with 
CSF biomarkers if further modalities are required to increase the accuracy of 
diagnosis. MRI is the preferred assessment to detect cortical changes, although CT 
scanning may also be used if there are existing contraindications. However, due to 
recent clinical studies, it is looking increasingly likely that plasma protein panels will 
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become the future in diagnosing AD and assessing disease progression and severity as 
well as the outcome of any treatments given. 
1.1.6 Treatments 
As the primary cause of AD is still largely a mystery, it is difficult to develop 
successful treatments. AD is the only one of the top ten causes of death to not have a 
disease-altering treatment (Ridge et al., 2016). Many current therapies target 
symptoms of the disease, with the aim of delaying disease progression, primarily 
through increasing the amount of neurotransmitters present neurologically. The 
current National Institute for Health and Care Excellence (NICE) guidelines (2014) 
recommend acetylcholinesterase (AChE) inhibitors for mild to moderate AD patients, 
assessed on their cognition score. The three AChE inhibitors commonly used in AD 
are donepezil, galantamine and rivastigmine while memantine, an N-methyl-D-
aspartate (NMDA) receptor antagonist, is recommended in more severe cases or if 
patients cannot tolerate AChE inhibitors. However, both of these lines of therapy do 
not target the cause of the disease itself, merely providing symptomatic relief and not 
altering the progression of the pathology. AChE inhibitors aim to increase the amount 
of acetylcholine (ACh) available at synapses by inhibiting its degradation, as there is a 
characteristic loss of cholinergic neurons in the basal forebrain on AD patients 
(Davies and Maloney, 1976). Alternatively, memantine, works by blocking the action 
of glutamine, which is seen to be increased in AD patients and is thought to contribute 
to neuronal dysfunction (Reisberg et al., 2003). However, these drugs only provide a 
slight improvement in the cognitive function of AD patients and have no effect on 
disease progression itself (Rang, 2008). 
If any of these treatments are utilised, NICE recommends beginning on the lowest 
dose possible, reviewing therapies as often as possible, including any apparent side 
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effects, only continuing therapies if they are making a marked improvement, as well 
as always treating non-cognitive symptoms in combination.  
As mentioned previously, all of these therapies provide only symptomatic relief, 
whilst the ideal AD treatment would be one that prevents further neurodegeneration, 
idyllically targeting the pathological pathways in AD: the amyloid cascade and tau 
hyperphosphorylation (Hanenberg et al., 2014). 
Inhibitors of both β- and γ-secretase have been developed. β-secretase inhibitors (also 
known as BACE1 inhibitors) have shown much promise and examples include CTS-
21166, which has been successful in Phase I clinical trials, and nilvadipine (an 
established anti-hypertensive medication) which, not only inhibits BACE1 expression, 
but also lowers tau phosphorylation and reduces inflammatory markers in AD model 
mice (Panza et al., 2009; Paris et al., 2014). In late 2014 another BACE1 inhibitor, 
AZD3293, began in Phase II/III clinical trials, scheduled to be completed by May 
2019. However, γ-secretase inhibitors, such as semagacestat, have shown much less 
promise. Semagacestat reached Phase III clinical trials before they were halted due to 
the treatment group showing worsening cognitive function in comparison to the 
control group (Samson, 2010). γ-secretase is involved in other signalling pathways as 
well as Aβ formation suggesting it is not, perhaps, such a promising therapeutic target 
as other molecular mechanisms.  
In 1    the idea of Aβ immunisation was first suggested. AD mouse models 
immunised with the Aβ protein, incredibly, had Aβ plaque formation reversed. 
However, this has not been replicated in human trials as a neuroinflammatory effects 
were found in human test subjects (Schenk et al., 1999) although treatment with the 
humanised anti-amyloid IgG monoclonal antibody Solanezumab has shown more 
success in clinical trials. In a preliminary Phase II results presented in 2015, the 
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EXPEDITION trial saw individuals suffering from mild AD who began Solanezumab 
treatment earlier had a slowing of both cognitive and functional decline (by 34% and 
18% respectively) in comparison to those who were either in the placebo test group or 
who started it later as part of the delayed-start study design (Liu-Seifert et al., 2015; 
Siemers et al., 2015). However, Phase III trial results were reported in November 
2016 which presented no significant slowing of memory and cognitive decline in mild 
AD cases in comparison to placebo intervention (McCartney, 2015). A further Phase 
III trial is planned involving prodromal AD patients with results expected in 2021. In 
spite of these setbacks, Solanezumab remains the most promising disease modifying 
treatment for AD to date.   
Immunotherapy against tau has also been suggested and tested in mouse models. 
Development of these treatments has been more problematic due to tau being located 
intracellularly and therefore it is not as easy for antibodies to access (Mably et al., 
2014). However, in 2015, three monoclonal antibodies against tau were reported to 
reduce tau pathology in mice and showed, in cell lines, to modify cellular uptake of 
tau as well as alter the clearance of it via microglia cells (Funk et al., 2015).  
Therapeutic antibodies may therefore be a potential therapy in the future. However, 
their exact functionality still needs to be determined as well as to ascertain as to 
whether they are therapeutically active in vivo.  
There have also been several studies concentrating on modifying risk factors for the 
disease, for example, non-steroidal anti-inflammatories (NSAIDs), taken for other co-
morbidities during life, lower the chances of getting AD in later life (Stewart et al., 
1997) as do statins (cholesterol reducing drugs) (Zamrini et al., 2004). NSAIDs 
specifically have been shown to reduce neuronal inflammation, reducing both MAPT 
and APP expression due to a negative feedback loops, as well as increasing the 
amount of APP cleaved by β-secretase rather than α-secretase (M. Lee et al., 2014). 
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Further work on the immune system has shown that exogenously injected exosomes 
are taken into microglial cells, increasing the clearance of Aβ and, although injecting 
exosomes is perhaps not a practical therapy for AD patients, it does provide a novel 
therapeutic target (Yuyama et al., 2014). Work into non-pharmacological therapies 
has also recently shown promise but have not been shown to alter the course of AD. 
Exercise and cognitive activity approaches have shown promise in improving quality 
of life (Sink KM et al., 2015). However, additional research is needed into these 
therapies to better evaluate their effectiveness  Alzheimer’s Association, 2015). 
Recently a highly personalised therapeutic approach has been suggested, tailoring the 
optimization of dozens of metabolic parameters in individual patients, through both 
therapeutic interventions and lifestyle changes including serum vitamin B12 levels, 
fasting insulin levels, GI health and sleep quality among many others. However, this 
programme is not only extremely demanding on both patients and health care 
professionals, it has also only been trialled in ten patients, all appearing to exhibit 
improvements, if subjectively (Bredesen, 2014).   
Thus far, no disease-modifying drugs for AD have made it past clinical trials due to 
various adverse side effects or non-significant findings, although there is at least one 
promising Phase III trial continuing (Siemers et al., 2015). All conclusive studies so 
far, including those involving NSAIDs, have shown that drugs are required to be 
taken years in advance of symptoms becoming apparent, making treating AD a real 
problem. Currently, all that can be done is to treat this disease symptomatically, 
utilising AChE inhibitors and memantine.  
1.1.7 Types of Alzheimer’s Disease 
AD is divided into early onset and late onset depending if symptoms are first 
exhibited before or after the age of 65. 
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1.1.7.1 Early Onset Alzheimer’s Disease 
Early onset AD (EOAD) is thought to only cause 1% or less of the total AD cases 
 Alzheimer’s Association, 2015  and itself can be divided into Early Onset Familial 
AD (EOFAD) or Early Onset Sporadic AD (Antonell et al., 2013).  
Phenotypically and pathologically, EOFAD and late onset AD are very similar. 
However, EOFAD has very defined genetic causes, with mutations in the genes 
coding for APP, presenilin (PSEN) 1 and 2 being found in 80% of EOFAD patients 
(Goldman et al., 2011). These mutations are inherited in an autosomal dominant 
fashion with age of onset often being very young and close to fully penetrant. All of 
these proteins are involved in APP metabolism: PSEN1 and 2 are part of the activated 
γ-secretase complex (Alves et al., 2012), increasing the amount of Aβ formed, or 
altering the Aβ42:Aβ40 ratio. Both of these result in plaques accumulating at an 
earlier age. The majority of mutations in APP are clustered around the α-, β- and γ-
secretases cleavage sites (Shewale, 2012). In total, 24 APP, 185 PSEN1 and 15 
PSEN2 mutations have been mapped (Schellenberg and Montine, 2012; Tanzi and 
Bertram, 2005) with mutations in MAPT and progranulin (GRN) also linked to 
EOFAD (Jin et al., 2012). In addition, APP is located on chromosome 21, causing a 
70% increased risk of developing EOAD in patients with trisomy 21 (Hardy and 
Higgins, 1992). Symptoms frequently present during patients’ third decade due to the 
increased production of Aβ as a consequence of carrying this extra APP gene (Hartley 
et al., 2014).  
On the other hand, 40% of EOAD cases are sporadic with no previous family history, 
and the causes of these are largely unknown. This implies there is a complex 
interaction of genetic and environmental factors or there may even be genetic risk loci 
that have yet to be identified (Alves et al., 2012; Campion et al., 1999).  
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1.1.7.2 Late Onset Alzheimer’s Disease 
Compared to EOFAD the causes of Late Onset AD (LOAD) are less well defined, 
despite it being far more common, as it is a significantly more complex disorder with 
considerable environment interactions which contribute to the phenotype of any 
complex disease (Buil et al., 2014). In 2013 Shewale et al split the causes of LOAD 
into three domains: genetics; epigenetics and environment, all of which can alter the 
phenotypic expression and therefore the pathology of AD (Shewale, 2012). Each of 
these three domains will be discussed below. 
Genetics 
It has been estimated, through both monozygotic and dizygotic twin studies as well as 
sequencing projects, that LOAD is somewhere between 37 and 80% heriditable and, 
therefore, genetics must play a large part in a complex inheritance pattern (Ebbert et 
al., 2014; Medway and Morgan, 2014; Morgan, 2011). In the 1990s the first step in 
unravelling the genetics behind LOAD was taken when it was found that carriers of 
the ε4 allele of the gene coding for apolipoprotein E (APOE) had a far greater chance 
of developing LOAD whereas carriers of the ε2 allele had a much lower risk (Farrer 
LA et al., 1997; Saunders et al., 1993). The APOE haplotypes are defined by two non-
synonymous variants (at amino acid positions 112 and 158), resulting in the ε2, ε3 or 
ε4 haplotypes, summarised in Table 1.1. This link was seen in familial genetic linkage 
studies and was also replicated in APOE knock-out, APOE allele-specific and 
humanized mice (Roses and Saunders, 2006). Other, rarer, variants have since been 
identified, some of which further sub-define the haplotypes and alter LOAD disease 
risk yet again (Medway et al., 2014).  
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It has been established that carriers of the ε4 APOE haplotype have an additive risk, 
with the risk of LOAD increasing by an odds ratio of 2. 4 with each additional ε4 
carried. This risk haplotype also decreases the age of onset and the average survival of 
the disease, as well as doubling the amount of Aβ stained neurologically post-mortem 
(Corder et al., 1993; Strittmatter et al., 1993). It is now known that the ε4 isoform also 
affects brain function much earlier in the carrier’s life span, decades prior to any 
clinical symptoms becoming obvious, associating it with both altered neurological and 
metabolic function as well as anatomical differences (Filippini et al., 2009; 
Michaelson, 2014). It is thought that between 40 and 60 percent of people diagnosed 
with LOAD carry at least one copy of the APOE ε4 gene. However, carrying this ɛ4 
haplotype does not guarantee that an individual will develop LOAD  Alzheimer’s 
Association, 2015).  
Human apoE is a 299 amino acid glycoprotein which is highly expressed in the liver, 
as well as in the brain, where it is primarily expressed in astrocytes and microglia. It is 
known to function as a receptor during the endocytosis of lipoprotein particles, as well 
as being involved in cholesterol release, and therefore plays a role in neurological 
synaptic maintenance. It is also the chief apolipoprotein within the CNS (Kim et al., 
2009). 
Table 1.1 - APOE Haplotypes. 
MAF
rs429358 C/T Cys112Arg 0.15
rs7412 T/C Arg158Cys 0.07
Major (T) Haplotype Frequency Minor (C) Haplotype Frequency
Major (C) TC ε3 77.9% CC ε4 13.7%
Minor (T) TT ε2 8.4% CT ε1 -
rs7412
Table 1.1
APOE  haplotypes, defined by allelic combinations. rs429358 is a C to T change coding for a cysteine to arginine substitution at 
amino acid position 112 with a minor allele frequency (MAF) of 0.15 and rs7412 is a T to C change resulting in a arginine to 
cysteine replacement at amino acid position 15  with a MAF of 0.07. ε3  is taken to provide a risk level for LOAD of 1.0. ε4 is a 
major risk factor with odds ratios of 3 and 12 for carriers of one or two copies respectively. ε2  has a protective effect irrespective 
of the presence of a ε4 allele, decreasing LOAD risk by a factor of 4. ε1 i  the combination of the two minor alleles and is, 
therefore, very rarely seen. Adapted from Farrer et al  (1997) and Corder et al.  (1994).
rs429358
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Various reasons for APOE’s association with AD have been suggested, the main 
theories falling into the following categories with different apoE haplotypes: affecting 
synaptic plasticity and repair (Teter, 2004); altering cholesterol transport and its lipid 
binding capabilities (Hirsch-Reinshagen et al., 2008; Martins et al., 2009); handling 
Aβ slightly differently resulting in modified clearance, deposition or aggregation 
(Bales et al., 1999; Shibata et al., 2000); altered formation of Aβ due to APP 
processing changing (Bu, 2009; Kim et al., 2009) or this even altering NFT formation 
(Holtzman et al., 2012). The variants dictating the isoform of apoE will alter the 
structure of the protein, therefore it is not surprising that its function is altered. 
However, it is discovering how that changed function impacts on LOAD pathology 
that still needs to be ultimately defined. It is estimated that APOE accounts for 27.3% 
of the Population Attributable Risk for LOAD which, although accounting for the 
strongest genetic risk factor, still leaves a substantial portion for others (Medway and 
Morgan, 2014). 
Epigenetics 
Epigenetics generally refers to alteration of gene regulation by something other than 
the DNA sequence (Laird, 2010). One of these alterations is methylation of DNA, 
primarily in cytosine guanine dinucleotide repeat rich regions of the genome, known 
as CpG islands (Bock et al., 2006). Methylation has been shown to play an important 
role in gene expression and silencing, chromosome stability, differentiation, cellular 
identity and, consequently, human disease (Roadmap Epigenomics Consortium et al., 
2015). Several of the genes involved in AD (APP, PSEN1, and BACE1) have a 
proportionally high GC content and are therefore potential targets for methylation 
regulation (Shewale, 2012). 
Recently the idea that epigenetics can cause phenotypical changes is gaining ground 
and an increasing number of studies are being done in this area. Hypermethylation 
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patterns (specifically CpG methylation) of several AD-related genes are seen in AD 
patients when compared to age-matched controls (Yu et al., 2015). This strengthens 
the notion that methylation alterations are associated with the LOAD pathology 
(Chouliaras et al., 2013). One recent report has also associated the level of 
methylation in the CpG islands of ABCA7 and BIN1 – known genes associated with 
LOAD –demonstrating that they are significantly associated with the level of 
neurological pathology (De Jager et al., 2014; Lord and Cruchaga, 2014). This has 
been repeated in the SORL1, ABCA7, BIN1, HLA-DRB5 and SLC24A4 genes, with 
altered neurological DNA methylation in the these genes being associated with 
pathological AD (Yu et al., 2015). The APP gene has also been shown to be 
hypermethylated in AD patients, altering downstream gene expression in combination 
with transcription factors (Lunnon et al., 2014). This indicates that epigenetic changes 
can also alter disease pathology and studies have shown that these epigenetic changes 
can manifest as an alteration in cognition and, specifically, memory formation (Day 
and Sweatt, 2011; Zovkic et al., 2013). Epistatic interactions between variants in 
different genes identified through genome wide association studies (discussed in more 
detail later) have also been identified, suggesting that the genetic causes of LOAD are 
not as straight forward as carrying a variant or not, but the haplotype carried may be 
of more importance (Gusareva et al., 2014).  
Further areas of epigenetics include histone modification, chromatin remodelling and 
noncoding ribonucleic acid (RNA) interactions. Histone modification may also be 
involved in AD as the AICD peptide produced intracellularly  by APP proteolysis (see 
Figure 1.3) has been shown to recruit peptides involved in histone modification and, 
consequently, gene expression (Abel and Zukin, 2008). 
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Environment 
There are many environmental factors which increase the risk of LOAD, far too many 
for the scope of this thesis. It is known that oxidative stressors (caused by things like 
traumatic brain injury, inflammation, sleep apnoea etc.) can cause epigenetic changes 
impacting on the pathogenesis of AD. However, many other environmental factors 
also have an impact such as diet, chemical exposure, smoking, body mass index, 
folate intake and lack of exercise can alter an individual’s chances of developing 
LOAD. Whether this is because they alter epigenetics, or for other reasons, it is still 
unknown (Shewale, 2012). 
By far the largest risk factor for developing LOAD is age, with the risk of disease 
approximately doubling every 5 years after the age of 65 (Schellenberg and Montine, 
2012). Alongside this, genetics appears to be the next largest risk factor, particularly 
in carriers of the apolipoprotein ε4 allele, as discussed above (Martins et al., 2009). 
However, many other hormonal, environmental and lifestyle factors have also been 
identified as contributing to an increased risk of LOAD. The first of these identified is 
that of vascular and metabolic disorders, suggesting that hypertension, especially 
variable systolic blood pressure, hypercholesterolemia, coronary artery disease and 
obesity all increase the risk of AD in later life (Kivipelto et al., 2005; Skoog et al., 
1996). Atherosclerosis also falls under this umbrella and it is thought that 
atherosclerotic plaques, especially in the extracranial carotid arteries, causes chronic 
or episodic cerebral hypoperfusion, increasing the risk of cognitive decline (Hofman 
et al., 1997). Stroke, atrial fibrillation and history of traumatic brain injury, have also 
shown to be proven risk factors of developing LOAD, and they are also thought to 
contribute to a very similar pathway: causing hypoperfusion of susceptible brain areas 
(Honig et al., 2003; Ott et al., 1997). Hypercholesterolemia is thought to alter the 
metabolism, cleavage or transport of Aβ, altering the development of the neurological 
amyloid plaques (Kuller and Lopez, 2011). Obesity, diabetes mellitus and impaired 
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glucose metabolism also seem to increase the susceptibility towards LOAD, thought 
to be through the effects of hormone compounds or the effects of glucose toxicity on 
amyloid metabolism (Kivipelto et al., 2005).  
Further risk factors have also been suggested: vitamin D deficiency (Pogge, 2010); 
history of depression (Geerlings et al., 2008); high intake of saturated fat (Luchsinger 
and Mayeux, 2004); peripheral inflammation (Engelhart et al., 2004) as well as high 
serum homocysteine and fibrinogen concentrations (Bots et al., 1998; Kalmijn et al., 
1999). Education level has also been suggested as modulating the degree to which AD 
neuropathology is expressed phenotypically. However, the evidence suggests that, 
although milder AD symptoms may be masked by an increased cognitive reserve in 
those who are more highly educated, there is no difference in cognitive function when 
AD neuropathology is more advanced (Koepsell et al., 2008). 
In the most recent Alzheimer’s Association recommendations  in conjunction with the 
World Dementia Council) they state that, should individuals wish to reduce their risk 
of cognitive decline and dementia, they should partake in regular physical activity and 
manage the cardiovascular risk factors associated with dementia (for example 
diabetes, obesity, smoking and hypertension). Along with this a healthy diet (such as 
the Mediterranean diet) and lifelong learning or cognitive training are also 
recommended in order to reduce the disease risk (Baumgart et al., 2015).  
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1.2 Genome Wide Association Studies 
As mentioned previously, LOAD is highly heriditable but a vast proportion of its 
genetic risk was unknown until the advent of Genome Wide Association Studies 
(GWAS). GWAS aim to identify variants’ associated with a certain phenotype, 
commonly one of a disease status. The methodology involves comparing allele 
frequencies of polymorphisms between groups of cases and controls. When the 
frequencies alter significantly, the gene that contains that polymorphism is identified 
as being associated to that phenotype. This is in comparison with linkage studies 
which are used to identify markers and traits in families, linking these markers to the 
trait. These kinds of studies are extremely powerful when identifying highly penetrant 
phenotypes, such as EOAD, linked with rare alleles, such as the PSEN and APP 
variations. In comparison, association studies, such as GWAS, are significantly more 
powerful in identifying common, low penetrance variants in these lower penetrance 
phenotypes, such as LOAD, provided there are enough cases and matched controls. 
However, GWAS so far are only estimated to have accounted for less than 50% of 
heriditability in a variety of complex diseases. It is thought that low allele frequency 
variants (ones with a minor allele frequency (MAF) below 1%) and rare variants 
(MAF of below 0.01%) also provide a major contribution towards these disease risks’ 
and variants such as these cannot be picked up by association testing such as GWAS, 
which focuses on more common variants (Zuk et al., 2014). A large proportion of 
GWAS identified loci are also located in gene deserts or within introns. The 
functional effect of these variants is much more difficult to elucidate but as many as 
80% of GWAS signals may be regulatory variants, therefore still affecting phenotype 
(Buil et al., 2014; Schierding et al., 2014). GWAS, therefore, can provide the basis for 
many future studies, for example large-scale exome sequencing projects, in order to 
reveal the rare causative variants in the genes or the surrounding areas they highlight. 
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However, for many complex traits, such as LOAD, heriditability may be distributed 
over thousands of variants with small effect sizes meaning identifying disease 
associated variants could continue indefinitely. 
In the 2000’s, several GWASs were undertaken in an attempt to identify genetic risk 
loci for LOAD. These identified Single Nucleotide Polymorphisms (SNPs) in 11 
genes which may be involved in LOAD; ABCA7, BIN1, CD2AP, CD33, CLU, CR1, 
EPHA1, MS4A6A, MS4A4E, MS4A4A and PICALM (Harold et al., 2009; 
Hollingworth et al., 2011; Lambert et al., 2009; Adam C Naj et al., 2011; Seshadri et 
al., 2010). In 2013 a large meta-analysis of these GWAS was undertaken by IGAP, 
identifying a further 11 susceptibility loci (CASS4, CELF1, FERMT2, HLA-
DRB5/HLA-DRB1, INPP5D, MEF2C, NME8, PTK2B, SLC24A4/RIN3, SORL1 and 
ZCWPW) involved in LOAD as well as confirming all of the GWAS loci with the 
exception of CD33 (Lambert et al., 2013). Although GWAS has played a large part in 
identifying common genetic variants with small effect size on disease risk, alternative 
methodologies are required in order to recognize low-prevalence variants with a 
moderate to high effect size on disease risk. Next Generation Sequencing (NGS) has 
gone on to identify further variants both within these GWAS genes and others. These 
include rare variants in TREM2 (Guerreiro et al., 2013), UNC5C (Wetzel-Smith et al., 
2014) PSEN1 and PSEN2 (also associated with EOFAD), as well as rare protective 
and risk variants in APP (Jonsson et al., 2012). All of these projects utilised similar 
methodologies: all performed whole-genome or whole-exome sequencing before 
performing quality-control, alignment and variant calling. Some projects (Guerreiro et 
al., 2013) then predicted pathogenicity of said variants utilising PolyPhen2 before 
carrying out direct genotyping, whilst others performed direct genotyping on the 
variants associated most strongly with disease status before examining their 
pathogenicity through in vitro assays (Jonsson et al., 2012; Wetzel-Smith et al., 2014), 
identifying any possible loss-of-function variants.  
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All of the variants associated with LOAD are shown in Table 1.2 with the ones 
identified through GWAS and the meta-analysis coloured in white, the loci identified 
through sequencing studies in blue and the APOE variants, the first established genetic 
risk factor of LOAD, shown in red.  
 
Table 1.2 - Alzheimer's disease susceptibility genes from GWAS. 
Table 1.2 
Gene Genomic Location SNP p -value OR (CI) Minor Allele Effect
ABCA7 19:1063444 rs4147929 1.06E-15 1.15 (1.11-1.19) Risk
19:44908822 rs7412 
19:44908684 rs429358
APP 21: 25880550 - 26171128 Multiple - - Protective/Risk
BIN1 2:127135234 rs6733839 6.94E-44 1.22 (1.18-1.25) Risk
CASS4 20:56443204 rs7274581 2.46E-08 0.88 (0.84-0.92) Protective
CD2AP 6:47520026 rs10948363 5.20E-11 1.10 (1.07-1.13) Risk
CD33 19:51224706 rs3865444 2.97E-08 0.94 (0.91-0.96) Protective
CELF1 11:47536319 rs10838725 1.12E-08 1.08 (1.05-1.11) Risk
CLU 8:27610169 rs9331896 2.77E-25 0.86 (0.84-0.89) Protective
CR1 1:207518704 rs6656401 5.69E-24 1.18 (1.14-1.22) Risk
DSG2 18:31508995 rs8093731 1.05E-04 0.73 (0.62-0.86) Protective
EPHA1 7:143413669 rs11771145 1.12E-13 0.90 (0.80-0.93) Protective
FERMT2 14:52933911 rs17125944 7.94E-09 1.14 (1.09-1.19) Risk
HLA 6:32610753 rs9271192 2.94E-12 1.11 (1.08-1.15) Risk
INPP5D 2:233159830 rs35349669 3.17E-08 1.08 (1.05-1.11) Risk
MEF2C 5:88927603 rs190982 3.23E-08 0.93 (0.90-0.95) Protective
MS4A6A 11:60156035 rs983392 6.14E-16 0.90 (0.87-0.92) Protective
NME8 7:37801932 rs2718058 4.76E-09 0.93 (0.90-0.95) Protective
PICALM 11:86156833 rs10792832 9.32E-26 0.87 (0.85-0.89) Protective
PSEN1 14: 73136418 - 73223691 Multiple - - Risk
PSEN2 1: 226870184 - 226896105 Multiple - - Risk
PTK2B 8:27337604 rs28834970 7.37E-14 1.10 (1.08-1.13) Risk
SLC24A4/RIN3 14:92460608 rs10498633 5.54E-09 0.91 (0.88-0.94) Protective
SORL1 11:121564878 rs11218343 9.73E-15 0.77 (0.72-0.82) Protective
TREM2 6:41161514 rs75932628 1.43E-07 4.59 (2.49-8.46) Risk
UNC5C 4:95170280 rs137875858 9.50E-03 2.15 (1.21-3.84) Risk
ZCWPW1 7:100406823 rs1476679 5.58E-10 0.91 (0.89-0.94) Protective
Alzheimer's Disease susceptibility genes and the most significant associations identified within these genes. Most 
have been identified through Genome Wide Association Studies and replicated in a meta-analysis in 2013 (white 
rows in table). APOE  haplotype has been a long established genetic risk factor of LOAD, coded for by two 
variants (highlighted in red). Additional rare variants in several other genes have also been associated with this 
disease, highlighted in blue. p -value, Odds Ratio (OR) and Confidence Interval (CI) are shown as well as the effect 
of the minor allele (protective or risky for developing LOAD). Modified from Lambert  et al (2013), Ridge et al 
(2016), Guerreiro et al  (2013) and Wetzel-Smith et al  (2014). 
APOE 1.04E-295 2.53 (2.41-2.66) Protective/Risk
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In 2016, Ridge et al attempted to calculate the amount of genetic variance of LOAD 
which is explained by the known AD risk genes as shown in Table 1.2. Using data 
from 9,699 individuals and 8,712,879 SNPs they assessed genetic variance shown in 
AD case samples and what proportion of this variance is accounted for by known 
markers. They established that the genetic variance explained by the known GWAS 
AD risk SNPs, those red and white in Table 1.2, only explained 30.62% of the total 
genetic variance exhibited in AD cases. Of this, 25.21% was the APOE SNPs (red in 
Table 1.2) leaving only 5.41% to be accounted for by the sentinel SNPs identified 
through GWAS (white in Table 1.2). However, when variation in the regions 
surrounding all the variants listed in Table 1.2 (50 kilo base pairs (kbp) upstream and 
downstream) but not including the known risk variant itself was included, 28.63% of 
genetic variance was accounted for (Ridge et al., 2016). This highlights that it is not 
necessarily the SNP itself identified through GWAS that is causing the association but 
its surrounding region. Despite this, the majority of the genetic variance of LOAD 
remains unknown and novel approaches may be necessary in order to identify the 
additional variants and loci. 
Despite this, having identified a selection of loci associated with LOAD, a pattern 
does begin to develop in which pathways and mechanisms are associated with the 
disease process. These pathways can be seen in Figure 1.5 and may provide areas to 
target in the search for therapeutic interventions (Beecham et al., 2014; Karch et al., 
2012; Morgan, 2011). A recent pathway analysis of these GWAS loci, performed by 
IGAP, again highlighted the importance of the immune system in AD pathology. It 
specifically highlighted endocytosis regulation, protein ubiquitination and cholesterol 
metabolism processes  International Genomics of Alzheimer’s Disease Consortium 
 IGAP  and International Genomics of Alzheimer’s Disease Consortium IGAP, 2014 . 
The immune system and inflammation association has also since gained ground with 
the theory that, instead of an immune reaction being a pathophysiological response to 
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AD neurological events, it may instead contribute to and exacerbate AD pathogenesis 
(Heppner et al., 2015). More recently, inflammatory changes have also been seen 
much earlier in the disease process, present even at the MCI stage of the disease. The 
amyloid cascade hypothesis suggests immune changes are a result of Aβ deposition. 
However, recent findings suggest that the immune processes may, in fact, drive AD 
pathology as opposed to purely being a result of it (Heppner et al., 2015).Once a 
definitive causative variant in each locus is identified, it may assist in contributing to 
clinical management of patients. This may be either through diagnosis and premature 
preventative treatment, guiding treatment selection (once improved therapies have 
been developed), or even predicting an individual’s disease risk, phenotype and 
disease progression through a genetic panel screen (Schellenberg and Montine, 2012).  
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Figure 1.5 - Disease pathways implicated in AD based on genetic studies. 
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1.3 ABCA7 
The ATP-Binding Cassette (ABC) transporters are a family of proteins thought to be 
one of the largest gene families (Iida et al., 2002; Klein et al., 1999) and are highly 
conserved, both evolutionary (85% conserved from bacteria all the way through to 
homo sapiens) (Higgins, 1992)  and amongst the family itself (averaging 60% 
conserved) (Allikmets et al., 1998; Broccardo et al., 1999). They are known to 
transport a large variety of substrates across both intracellular and plasma membranes, 
switching between inward- and outward-facing conformations, against the substrates’ 
electrochemical gradient by utilising the energy produced by ATP hydrolysis 
(Vasiliou et al., 2009; Zoghbi et al., 2016). In humans, there are 49 ABC proteins in 
total, as well as 21 pseudogenes, split into 7 subgroups labelled A-G based on 
phylogenetics, amino acid and protein sequence identity as well as the organization of 
their nucleotide binding domains (Dean and Annilo, 2005; Iida et al., 2002; 
Langmann et al., 2003; Vasiliou et al., 2009). This family of proteins have become a 
large area of research since several proteins have been linked with diseases, such as 
ABCC7, also known as CFTR, the cystic fibrosis gene (He et al., 2009).  
The ABCA sub-family itself contains 12 members (ABCA1-13) with ABCA11 known 
to be a pseudogene (Kaminski et al., 2006).  he “A” family are the biggest 
subfamilies of the ABC transporters although they do not exhibit genetic clustering, 
being spread throughout the genome (Kim, 2004).  
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1.3.1 Identification of ABCA7 
The 7
th
 member of the A family - ABCA7 was first identified in 2000 in human 
macrophages. cDNA of ABCA7 was extended stepwise using primers designed from 
known sequences of other genes in the ABCA family, establishing its sequence. This 
same study assessed the mRNA tissue distribution, identifying ABCA7 in myelo-
lymphatic tissue, such as leukocytes, thymus, spleen and bone marrow, as well as in 
other peripheral blood cells. The amino acid sequence obtained contained all of the 
hallmark features of ABC transporters, which are described later (Kaminski et al., 
2000a). In 2001, the transcriptional start sites were also predicted utilising 
MatInspector and 5’ rapid amplification of cDNA ends (Broccardo et al., 2001). 
1.3.2 The ABCA7 Gene 
ABCA7 itself is located on chromosome 19p13.3 (Chr19:1,040,101-1,065,572 in 
human genome assembly GRCh38, as shown in Figure 1.6A), assigned by genomic 
probe in 2001, and has no known pseudogene (Broccardo et al., 2001; Zheng and 
Gerstein, 2006). Neighbouring ABCA7 within 1.7kbp of its 3’ end is the gene HA-1, 
coding for the human minor histocompatibility antigen, and 1kbp upstream of its 5’ 
end is CNN2, coding for calporin, as seen in Figure 1.6B (Kaminski et al., 2000b).  
ABCA7 was originally thought to consist of 46 exons (Kaminski et al., 2006, 2000b), 
although in 2006, a 47
th
 exon was identified, 1019 base pairs upstream of exon one, 
shown in Figure 1.6C (Iwamoto, 2006). The gene size is now known to be 32kbp (a 
remarkably condensed genomic area) resulting in cDNA of 6.8kbp coding for 2146 
amino acids of a molecular weight of 220 kilo Daltons (kDa) (Kaminski et al., 2006; 
Piehler et al., 2012).  
 
Page | 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i 
 
re
  
  
 
A
: 
 
L
o
ca
ti
o
n
 o
f 
th
e 
 
 
 
 
 
 o
n
 c
h
ro
m
o
so
m
e 
1
 
 p
o
si
ti
o
n
 1
3
.3
  
sh
o
w
n
 a
s 
a 
re
d
 b
ar
 .
 I
m
ag
e 
ta
k
en
 f
ro
m
 t
h
e 
U
C
S
C
 H
u
m
a
n
 G
en
o
m
e 
B
ro
w
er
, 
R
ef
S
eq
 a
cc
es
si
o
n
  
N
M
 
0
1
 
1
1
2
.3
  
h
tt
p
: 
 g
en
o
m
e-
eu
ro
.u
cs
c.
ed
u
 .
 
 
: 
 
L
o
ca
ti
o
n
 o
f 
g
en
es
 n
ei
g
h
b
o
u
ri
n
g
  
 
 
 
 
 o
n
 c
h
ro
m
o
so
m
e 
1
 
p
1
3
.3
. 
Im
ag
e 
ta
k
en
 f
ro
m
 N
C
B
I 
w
eb
si
te
, 
R
ef
S
eq
 a
cc
es
si
o
n
 N
M
 
0
1
 
1
1
2
.3
  
h
tt
p
: 
  
w
w
w
.n
cb
i.
n
lm
.n
ih
.g
o
v
  
 
: 
 
P
o
si
ti
o
n
 o
f 
th
e 
4
7
 e
x
o
n
s 
w
it
h
in
  
 
 
 
 
. 
Im
ag
e 
ta
k
en
 f
ro
m
 t
h
e 
N
C
B
I 
w
eb
si
te
, 
R
ef
S
eq
 a
cc
es
si
o
n
 N
M
 
0
1
 
1
1
2
.3
  
 h
tt
p
: 
 w
w
w
.n
cb
i.
n
lm
.n
ih
.g
o
v
 .
 
A
 
 
 
 
 
Page | 39 
 
1.3.3 The ABCA Proteins 
All 48 ABC proteins share a similar structure (see Figure 1.7) which was originally 
identified in 1999 (Klein et al., 1999). They are comprised of four domains in total; 
two Nucleotide Binding Domains (NBDs) and two Trans-Membrane Domains 
(TMDs) (Dean, 2002). Half-size transporters also exist within the family, formed by 
one NBD and one TMD which are expressed separately before dimerising in order to 
form a functional unit (Barbet et al., 2012; Geillon et al., 2014). However, all of the 
ABCA family are “full-size” transporters meaning they are encoded in a single 
polypeptide chain (Kaminski et al., 2006). They are also the largest proteins within the 
ABC family (Piehler et al., 2012).  
Figure 1.7 - Schematic of an ABCA full-size transporter. 
 i  re     
Schematic of an ABCA full-size transporter  of which ABCA7 is one  containing two 
 ransmembrane Domains  blue , which are made up of six  – helices each and anchor the 
transporter in the lipid membrane, and two Nucleotide Binding Domains which contain the 
 alker A  pink  and alker B  yellow  motifs as well as the A P signature sequence, also 
known as alker C  green .  his is where A P binds to and is hydrolysed to ADP to provide 
the energy in order to transport substrates across the membrane.  he characteristic hydrophobic 
loop  HH1  is also shown  circled—red  as well as the characteristically large Extracellular 
Domains  ECD .  hese are both features which are specific to the ABCA proteins. Figure 
modified from Albrecht and Viturro        2005 , Piehler        2012  and Kim        200  . 
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 The two TMDs are hydrophilic and comprise of six α-helices each (blue in Figure 
1.7), anchoring the transporter in the lipid membrane (Kim et al., 2008; Piehler et al., 
2012). One thing which is unique to the ABCA sub-family are the large extracellular 
domains (ECD) located between the first and second transmembrane helices in each 
TMD (see Figure 1.7) (Bungert et al., 2001; Kim et al., 2006; Tanaka et al., 2001) as 
well as a hydrophobic domain (HH1) between the two TMDs (highlighted in red in 
Figure 1.7) (Albrecht and Viturro, 2007). The substrates are transported across 
membranes (either intracellular or extracellular membranes) through a pore formed by 
these TMDs. This pore is stabilised by metal ions, often between pore-lining cysteine 
residues on TMDs 1, 6 and 12 (El Hiani and Linsdell, 2014). 
 Each NBD contains three highly conserved motifs (Kim, 2004): the Walker A motif 
(pink in Figure 1.7); a Walker B motif (orange) and the ABC signature sequence or C-
motif (green). The conserved sequences of these domains are shown in Table 1.3. 
These areas are where ATP binds to and is hydrolysed in order to transport the 
substrates across the membrane. The range of substrates within the ABC family is 
large and includes: metal ions; peptides; amino acids; sugars; xenobiotics; inorganic 
ions; polysaccharides; vitamins; lipids as well as a variety of hydrophobic compounds 
and cell metabolites (Borst et al., 2000; Borst and Elferink, 2002; Dean, 2002; Sasaki 
et al., 2003; Takahashi et al., 2005; Vasiliou et al., 2009). However, the ABCA family 
are more specialised, transporting just lipid molecules (Kim et al., 2008). As it is the 
NBD area to which ATP binds, any non-synonymous mutations in these regions cause 
a loss of functionality (Hrycyna et al., 1999). 
Table 1.3 - Residues of the conserved regions of ABCA proteins. 
Table 1.3
Walker A Walker B C Motif
NBD1 GQ****LGHNGAGKTTT LDEPT*G*DP LSGGM*RK
NBD2 GECFGLLGVNGAGKSTT LDEPTTGMDP YSGG*KRK
Residues of the conserved regions of ABCA proteins shown in single-letter amino acid code. 
* corresponds to variable residues, residues shown underlined are conserved in all subclasses of 
the ABC transporter family. Modified from Broccardo et al  1999.
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The Walker A, Walker B and C-Motifs are the areas which are highly conserved 
throughout the whole ABC family, and especially the ABCA group of proteins. The 
amino acid sequences of these particular motifs are given in Table 1.3 including the 
residues which are highly conserved throughout all subclasses of the ABC family 
(Broccardo et al., 1999). It is known that, in any ABC protein, if either the lysine  
residue in the Walker A motif (K in Table 1.3) or the aspartic acid residue in the 
Walker B motif (D in Table 1.3) are altered, then ATP cannot hydrolyse and therefore 
protein function is lost (Hrycyna et al., 1999).  
1.3.4 The ABCA7 Protein 
The ABCA7 protein specifically is a 220kDa protein and shares a 54% homology 
with its sibling protein ABCA1 (Kaminski et al., 2000a) . It was this similarity which 
initially suggested that the two proteins shared a degree of functional properties. 
ABCA7 also shares a 49% homology with ABCA4 (also known as ABCR) 
(Broccardo et al., 2001; Kaminski et al., 2000a).  
ABCA7 Expression Patterns 
When ABCA7 was originally identified, mRNA master blots were performed on 
multiple human tissues in order to identify its expression pattern. The majority of 
ABCA7 expression was found to be in myelo-lymphatic tissues including peripheral 
leukocytes (lymphocytes, granulocytes and monocytes), thymus, spleen and bone 
marrow as well as foetal tissues (Kaminski et al., 2000a). This expression pattern is 
remarkably different to that of ABCA1 despite their sequence homology. In 2003, 
ABCA7 RNA levels were also quantified using real-time Reverse-Transcription 
Polymerase Chain Reaction (RT-PCR), finding very similar results with the exception 
of high levels in the trachea (Langmann et al., 2003). 
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In 2004 Western blotting to examine the tissue expression of ABCA7 showed that the 
highest levels were found to be in the brain and this is now thought to be the primary 
site of ABCA7 expression. The exact regions of the brain where ABCA7 is 
predominant are, nonetheless, still to be determined. In human neuronal cells, ABCA7 
was found to be expressed chiefly in microglia cells (which are principally involved in 
the immunological defence of the CNS) but they have also been shown to be highly 
expressed in CA1 neurones within the hippocampal area of the brain (Kim, 2004; Kim 
et al., 2006; Kreutzberg, 1995).  
The expression pattern of ABCA7 within tissues are summarised in Figure 1.8 from 
the BioGPS resource. This resource has mapped the expression patterns of many 
proteins using Affymetrix Arrays and protein specific probes (219577_s_at for 
ABCA7) (Wu et al., 2009). Quantitative real-time PCR on cDNA prepared from RNA 
extracted from Human Embryonic Stem Cells (hESC) has also shown that ABCA7 is 
highly expressed in a variety of pluripotent stem cells, suggesting that it may also play 
a vital role during cellular maturation (Barbet et al., 2012). 
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Cellular Location of ABCA7 
The location of ABCA7 on the subcellular level is also a matter of some debate. In 
2003, the protein was located on the plasma membrane of human embryonic kidney 
(HEK293) cells using western analysis and anti-ABCA7 antibodies (Wang, 2003) and 
this was verified in 2006 (Iwamoto, 2006). However, a year later, and in the same cell 
line, ABCA7 was found to be present on both the intracellular membranes and the 
extracellular plasma membrane (Abe-Dohmae et al., 2004). Despite this, upon 
immunofluorescent imaging of mouse macrophages, the protein was only present 
intracellularly, although they did locate it to the plasma membrane in renal tubule 
tissues from mice (Linsel-Nitschke et al., 2005), suggesting that ABCA7’s subcellular 
location may be tissue specific.  
Figure 1.8 - Tissue specific expression for ABCA7 mRNA. 
 i  re     
 issue specific expression for       mRNA determined by the probe 21 577 s at by the GeneAtlas Affymetrix U133A array 
  u        200  . M   median, 3xM   3 x median, 10xM   10 x median.  he coloured bars represent  the interquartile ranges of 
comparative enrichment of ABCA7 in the indicated tissues on a log2 scale.  he greatest expression was apparent in the pineal 
gland  light blue  followed by cells of the immune system  purple  and precursors  light green . Image taken from  the BioGPS 
tool  http:  biogps.org  goto genereport id 10347 . 
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Splicing 
When ABCA7 was first identified in 2000, it was apparent that ABCA7 has a series of 
relatively small introns, all consisting of multiples of three, suggesting the possibility 
of alternative splicing products (Kaminski et al., 2000b). Since then, at least two 
isoforms of ABCA7 have been identified due to alternative splicing (Ikeda et al., 
2003). The Type II splice variant was shown, in 2003, to be formed by splicing out 
exon 5B. It was also shown that this variant is only located in the membrane of the 
endoplasmic reticulum of HEK293 cells whereas the Type I variant – containing exon 
5B – is present in both intracellular and extracellular membranes (Ikeda et al., 2003). 
Exon 5B contains two termination codons with a methionine (initiation) codon 
following the second one, therefore, the Type II variant contains a novel N-terminus 
of 28 amino acids as opposed to the 166 amino acids of the Type I variant (Abe-
Dohmae et al., 2006). The fact that the Type II variant is only located intracellularly 
may suggest that this loss is the reason the protein cannot localise to the plasma 
membrane (Abe-Dohmae et al., 2004). However, in both variants, the large ECD loop 
between the first and second transmembrane domain (known as ECD1) remains in the 
same orientation, exposed to the outer membrane area (Ikeda et al., 2003). 
The two variants are also expressed differently in different tissues. Type I is found 
more abundantly in the brain and bone marrow, whereas Type II has a higher 
expression in lymph nodes, the spleen, thymus and trachea. Functional differences 
have also been identified between the two splice variants. HEK293 cells expressing 
the Type I ABCA7 variant demonstrated apolipoprotein A1 (apoA-I) mediated 
cholesterol release, whereas Type II transfected cells did not (Ikeda et al., 2003). The 
function of ABCA7 as a protein will be discussed in more detail later. However, this 
suggests the presence of a non-functional, intracellular splice variant.   
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In RefSeq there is also another transcript listed: NM_033308.1. This transcript is 
referred to as obsolete and is missing the first 138 amino acids, including the first 
TMD, resulting in a final protein of 2008 amino acids.  
1.3.5 Transcriptional Regulation of ABCA7 
High-Density Lipoprotein 3 & Low-Density 
Lipoprotein 
It was known that ABCA1 expression increased in the presence of cholesterol 
(Venkateswaran et al., 2000) and, given their homologies, it was thought that ABCA7 
may have a similar pattern. This was supported when ABCA7 mRNA and protein 
levels where found to increase in the presence of low-density lipoprotein (LDL), and 
fell by as much as 70.6% in the presence of high density lipoprotein 3 (HDL3), which 
removes cholesterol from cells (Iwamoto, 2006). This supports the suggestion that 
ABCA7 is inversely regulated by cholesterol levels within the macrophage cells, 
similar to the reaction of ABCA1, meaning it is sterol-regulated and may function as a 
lipid exporter (Iida et al., 2002; Kaminski et al., 2000a).  
Liver X Receptor & Retinoid X Receptor 
As mentioned before, ABCA1 is known to be positively regulated by cholesterol 
levels within cells and this is through a pathway involving the liver X receptor (LXR) 
system, a system which also regulates transcription levels of apoE (Oram and 
Heinecke, 2005; Skerrett et al., 2015). This works in tandem with the retinoid X 
receptor (RXR) system, where LXR agonists are activated by binding to RXR 
agonists (Repa et al., 2000). In 2003, the effect of LXR agonists (with and without 
RXR agonists) on the effect of Abca7 mRNA levels in mouse peritoneal macrophages 
were looked at and it was found that the levels were not altered at all (Abe-Dohmae et 
al., 2006; Wang, 2003). These results were replicated in bone-marrow macrophages 
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with free cholesterol, LXR and RXR agonists having no effect on ABCA7 protein 
levels (Kim, 2004).  
Sterol Regulatory Element Binding Proteins 
When the genomic organisation of ABCA7 was investigated, a sterol regulatory 
element binding protein 1 (SREBP1) binding motif at its 5’ end was discovered 
(Kaminski et al., 2000b). This family of transcription factors are frequently involved 
in moderating transcription of genes which regulate cholesterol metabolism (Horton 
and Shimomura, 1999) so it may not be surprising that it is involved in regulating the 
ABCA family.   
It has been found that when the mouse cell line BALB/3T3 are forced to express 
SREBP1a and SREBP2, they both increase the expression of ABCA7 mRNA and 
protein by 19% and 50% respectively (Iwamoto, 2006). However, this is the opposite 
of what happens with ABCA1, as when forcing Human Umbilical Vein Endothelium 
Cells (HUVEC) to express SREBP2, ABCA1 mRNA expression is decreased by 50% 
(Zeng et al., 2004).   
1.3.6 Function of ABCA7 
General ABCA Function and Pathogenesis 
The ABC family are generally known to transport molecules across membranes (Borst 
et al., 2000), using energy from ATP hydrolysis to move these substrates against their 
gradient. The range of molecules is vast as mentioned previously. However, ABCA 
transporters are known to specifically specialise in transporting lipids (Kim et al., 
2008).  
Many of the ABCA transporters have now been linked with pathology and disease 
due to the lipid transport pathway they are involved in. For example: ABCA1 
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transports cholesterol and contains the causative variants contributing to Tangier 
Disease, playing a vital role in maintaining plasma HDL levels (Assmann et al., 2001; 
Rust et al., 1999); ABCA3 transports the lipid rich pulmonary surfactant and is linked 
to neonatal respiratory failure (Shulenin et al., 2004); ABCA4 mutations can cause 
abnormal lipid accumulation in the retina causing Stargadt’s macular degeneration 
(Kielar et al., 2003; Lewis et al., 1999); ABCA12 has been connected with the rare 
keratinization disorder lamellar ichthyosis type 2 implying it is involved in lipid 
trafficking within keratinocytes in the skin (Akiyama, 2005; Lefèvre et al., 2003) and 
ABCA13 has been associated with schizophrenia and related diseases However the 
exact biological pathways behind this association are unknown, meaning the reason(s) 
why ABCA13 is associated with these diseases remains a question, as it does for 
ABCA7 and LOAD (Knight et al., 2009).  
From these disease causing mutations, it can be implied that ABCA7 may be linked to 
disease pathways. However, the exact biological function of ABCA7 has not yet been 
characterised in detail. The following few sections will merely summarise the 
literature currently available on ABCA7’s function. 
Transport of Cholesterol and Phospholipids 
As mentioned before, ABCA1 is known to be involved in cholesterol and 
phospholipid transport, exporting them to apolipoprotein receptors such as apoA-I or 
apoE to form HDL (Michael L Fitzgerald et al., 2004). As ABCA7 is 54% 
homologous with ABCA1 it was originally hypothesised that they may have similar 
functions. This idea is supported by the fact that ABCA7 mRNA is up-regulated by 
cholesterol loading and down-regulated by cholesterol efflux in macrophages 
(Kaminski et al., 2000a), as well as the fact that it is regulated by SREBP1a, a 
transcription factor known to be involved in cholesterol metabolism (Iwamoto, 2006; 
Kaminski et al., 2000b).  
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The studies that have been performed in order to analyse ABCA7’s transport of 
cholesterol and phospholipids are summarised in Table 1.4. Some agree with this 
original theory and some do not. However, all provide methological differences so the 
comparisons that can be drawn between these studies may be limited.  
 
In 2003, it was suggested that ABCA7 covalently binds to apoA-I when they are in 
proximity (Wang, 2003). However, further work went on to establish that, although 
ABCA7 does efflux phospholipids to apoA-I (specifically phosphatidylcholine and 
sphingomyelin) it does not efflux cholesterol to the same receptor (Wang, 2003). This 
contraindicates several other studies all of whom agree, to various degrees, that 
ABCA7 effluxes cholesterol out of HEK293 cells onto apoA-I (Abe-Dohmae et al., 
2004; Hayashi et al., 2005; Ikeda et al., 2003). However, one study in 2012, 
performed on Abca7 knock-out mice, proposing that Abca1 may compensate for 
Abca7 deficiency by becoming up-regulated (Meurs et al., 2012). 
The idea that ABCA7 has a role in phospholipid transport is also supported by 
confirmation that, in liposomes, ABCA7 transports phospholipids (specifically 
phosphatidylserine) by flipping them from the cytoplasmic to the exocytoplasmic 
membrane leaflets when visualised fluorescently (Quazi and Molday, 2013). 
Table 1.4 - Lipid release by ABCA7 in different studies. 
Table 1.4
Reference Cell Line Cholesterol Release Phospholipid Release
Hayashi et al.  (2005) HEK293 ↑ ND
Ikeda et al.  (2003) HEK293 ↑ ↑
Wang (2003) HEK293 ↓ ↑
Chan et al.  (2008) HEK293 ↑ ND
Abe-Dohmae et al.  (2004) HEK293 ↑ ↑
Kim (2005) Mouse macrophages ↓ ↓
Linsel-Nitschke et al.  (2005)
Human ABCA7  in 
mouse macrophage
↓ ↑
Quazi & Molday (2013) Liposomes ND ↑
Lipid release by ABCA7 in different studies. here ↑ is an upregulation in release, ↓ is a downregulation in 
release  and ND is Not Described. This table demonstrates the conflicting literature available on ABCA7's 
transporter function.
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In 2005, Abca7 null (-/-) mice were developed (Kim, 2004) – despite reports that these 
mice could not be bred as this knockout was embryonically lethal (Jehle et al., 2006; 
Linsel-Nitschke et al., 2005). However, the macrophages taken from these mice 
showed no difference in cholesterol or phospholipid efflux when compared to Abca7 
wild-type mouse macrophages (Kim, 2004). Instead, they did report that the females 
of these Abca7 -/- mice had up to 50% less white adipose tissue than their male 
counterparts or wild-type. This suggested that Abca7 may be involved in fat 
metabolism, a theory backed up by the fact that when 3T3L1 cells (a pre-adipose, 
fibroblast-like, mouse embryonic cell line) differentiate to mature adipocytes, their 
Abca7 expression greatly increases (Kim, 2004). 
As many of these studies involved mouse Abca7, human and mouse ABCA7 
functionality have been compared to see if that is where the differences in 
experimental results were originating. However, it was found that both human and 
mouse ABCA7 in HEK293 cells caused an increase of phospholipid efflux to apoA-I 
but neither of them transported cholesterol to the same apolipoprotein. In this same 
study ABCA7 function was also knocked down using both small interfering RNA 
(siRNA) and heterozygote, knock-out mouse macrophages. In both of these cell lines 
there was no alteration in the phospholipid or cholesterol efflux to apoA-I in resting 
macrophages (Linsel-Nitschke et al., 2005).  
All of these results (see Table 1.4) suggest that ABCA7 is involved in apolipoprotein 
mediated phospholipid release to lipid-free apolipoproteins such as apoA-I and apo-II 
(Abe-Dohmae et al., 2006, 2004; Kim, 2004; Linsel-Nitschke et al., 2005; Wang, 
2003). However, it does not seem to play a significant role in plasma HDL levels, 
suggesting it may be involved in a more subtle role, perhaps in cellular cholesterol 
homeostasis in specific tissues, such as macrophages (Abe-Dohmae et al., 2006, 
2004).  
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Immune Function and Phagocytosis 
As mentioned previously, the genomic position of the ABCA7 gene is within close 
proximity of the human minor histocompatibility antigen HA-1 with its 5’ end being 
within 1.7kbp of ABCA7’s 3’ end  see Figure 1.6 ) (Kaminski et al., 2000b). HA-1 is 
involved in host defence and immune response, especially in response to Graft-versus-
host disease (Mutis et al., 1999). It is known that genes within close proximity may 
share a similar function, for example, the α- and β-globin gene clusters (Lauer et al., 
1980) and the Tumour Necrosis Factor gene pair on Chromosome 6 (Carroll et al., 
1987), so it could be possible that ABCA7 and HA-1 also share a functional 
relationship although there is little homology between the two genes, suggesting there 
is no evolutionary relationship between them. This is also supported by the fact that 
they both have transcription factor binding sites for c-myb which plays a role in 
haematopoiesis (Gewirtz and Calabretta, 1988; Kaminski et al., 2000b) and they have 
similar tissue expression patterns (Kaminski et al., 2000b). The highest expression of 
ABCA7 is also in cells with immune function: macrophages in the body and microglia 
in human brain cells (Kim et al., 2006). Microglia make up 20% of the glial 
population within the CNS and are the resident macrophages within this system 
(Kreutzberg, 1995). There is therefore a high chance that ABCA7 is involved in the 
immune system in some way. 
Both in 1996 and more recently in 2006, it has been found that ABCA1 was highly 
homologous with the CED-7 gene from the Caenorhabditis elegans nematode’s and 
was thought to be its functional orthologue (Broccardo et al., 1999; Luciani and 
Chimini, 1996; Wu and Horvitz, 1998). This gene is part of the CED family which 
controls engulfment of cell corpses and phagocytosis (Ellis et al., 1991). They are 
structurally similar to the ABCA proteins, containing 2 NBDs and located in the 
plasma membrane (Wu and Horvitz, 1998). As it had been found that CED-7 and 
ABCA1 are highly homologous, in 2006, ABCA7 was also compared with CED-7. It 
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was found that ABCA7’s amino acid structure is 25% identical and 43% similar to 
CED-7 meaning it is the most homologous mammalian gene to CED-7 (Jehle et al., 
2006).  There was, therefore, a likelihood of it being involved in human phagocytosis 
as it had already been identified at high levels in macrophages whose primary role is 
phagocytosis (Kreutzberg, 1995). 
During phagocytosis, ABCA7 localises to the plasma membrane, specifically into 
phagocytic cups, focusing along with low-density lipoprotein receptor-related protein 
1 (LRP1) which has a similar sequence and function to CED and plays a role in 
phagocytosing apoptotic cells (Ogden et al., 2001; Su et al., 2002).  
When ABCA7 was silenced in mouse peritoneal macrophages using siRNA (by 60-
80%), it decreased phagocytosis of apoptotic cells by as much as 50-70%. However, 
this had no impact on FcR-mediated phagocytosis (Jehle et al., 2006). This inhibition 
of phagocytosis is replicated in Abca7+/- mice (reducing phagocytosis by 41%) and 
when macrophages are stimulated with apoptotic cells, Abca7 levels on the cell 
surface are raised (Jehle et al., 2006). Levels of SREBP1a and SREBP2, and therefore 
ABCA7 levels, are also increased during phagocytosis (Castoreno et al., 2005), 
indicating that SREBPs are a regulator of membrane biogenesis during phagocytosis 
due to their high phospholipid content. ABCA7 may, therefore, be involved in 
regulating phagocytosis (Iwamoto, 2006).  
In 2010, it was demonstrated that Abca7 is stabilized by helical apolipoproteins, 
specifically apoA-I and apoA-II, in mouse peritoneal macrophages (Tanaka et al., 
2010). They prevent Abca7 being broken down on the cell surface membrane by 
calpain, a calcium dependant protease (Goll et al., 2003).  This increases the rate of 
phagocytosis, suggesting that the host defence system is enhanced by HDL 
components (Tanaka et al., 2010; Wang, 2003). One year later a report was also 
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published on the effect of HMG-CoA reductase inhibitors (statins) on phagocytosis as 
well as ABCA1 and ABCA7 mRNA levels. Statins are known to lower plasma LDL 
levels by up-regulating the LDL receptor through the SREBP system (Goldstein and 
Brown, 2009). Statins were found to increase ABCA7 expression and, through this, 
increase cellular phagocytic function both in vitro, in J774 cells, and in vivo in Abca7 
knockout mice. It was also found that statins lowered ABCA1 mRNA levels (Tanaka 
et al., 2011).  This implies that there is a link between cholesterol homeostasis and 
phagocytosis and that ABCA7 is involved in, and perhaps regulated by, this pathway.  
From these studies it looks increasingly likely that ABCA7 is involved in 
phagocytosis, one of the substrates of which is apoptotic debris. There are an 
increasing number of autoimmune disorders which have been linked to insufficient 
removal of apoptotic cells as they go on to cause an inflammatory reaction (Lauber et 
al., 2004). This may be a clue to a pathological process in which ABCA7 is involved, 
especially as immune function is a known pathway associated with LOAD pathology 
(see Figure 1.5). 
Epidermal Lipid Reorganisation 
In 2003, mRNA expression profiling of all the ABC proteins during differentiation of 
both keratinocyte cells and Normal Human Epidermal Keratinocytes was performed. 
It was found that ABCA7 was highly expressed in both of these cell lines and, when 
they were forced to differentiate in vivo, ABCA7 mRNA levels increased three-fold. 
Overexpression of ABCA7 in HeLa cells (a cervical cancer cell line) also increased 
the cellular ceramide expression levels, a lipid molecule found in high concentrations 
within the cell membrane involved in inhibiting cell proliferation and inducing cell 
death. This lipid is derived from sphingomyelin, a phospholipid which ABCA7 is 
known to transport (Wang, 2003). This suggests that ABCA7 may be involved in 
regulating cellular ceramide transport, as well as keratinocyte differentiation during 
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which intense lipid rearrangements occur (Abe-Dohmae et al., 2006; Kielar et al., 
2003). However, no further work has been done on ABCA7’s involvement in this 
area.  
In summary, ABCA7 is known to transport phospholipids across cell membranes to 
extracellular apoA-I and apoE. It also has the capability of transporting cholesterol but 
to a much lesser extent (Abe-Dohmae et al., 2004; Chan et al., 2008; Wang, 2003). 
However, it also potentiates phagocytosis (Jehle et al., 2006; Kaminski et al., 2000a) 
which is a logical follow on from its high expression in both macrophages and 
microglia (Kaminski et al., 2000a; Kim et al., 2008). 
1.4 The ABC Family and Disease 
As mentioned previously, the ABC protein family have been linked with a variety of 
diseases. However, it was in 2004 when the ABCA sub-family was first linked to AD, 
with a conclusion that increasing expression of ABCA2 increases the amount of APP 
and Aβ proportionally in neuroblastoma cells (Chen et al., 2004).  Based on these 
results, as well as the fact that increased plasma cholesterol levels increase AD risk 
(Puglielli et al., 2001) and that ABCA2 is a cholesterol responsive gene (Kim et al., 
2006), ABCA2 was the sequenced in 230 EOAD cases. A synonymous SNP was 
identified, rs908835, as being associated with early onset AD, although the reasons 
behind this association are still unknown (Macé et al., 2005). Recently ABCA5, which 
has no known neurological function, was shown to be highly expressed in neurones 
and, to some degree, moderated Aβ production in cell systems through its function as 
a cholesterol transporter (Fu et al., 2015). 
ABCA1 has also been linked to increased AD risk as ABCA1 polymorphisms have 
been linked to altered CSF apoE and cholesterol levels. Lipid homeostasis is known to 
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be a large contributor to neuronal degeneration and may, therefore, increase the risk of 
AD as well as other neuro-degenerative conditions (Kim et al., 2006; Koldamova et 
al., 2005; Wollmer et al., 2003). 
As mentioned previously, ABCA1’s function has been well defined as a cholesterol 
and phospholipid transporter to HDL apolipoproteins, primarily apoA-I in plasma and 
apoE in the CNS (Wahrle et al., 2004). Neurologically, it is thought to prevent the 
accumulation of cholesterol in neurons by interacting with apoE to transport 
cholesterol across the blood-brain barrier to the periphery (Koldamova et al., 2003). 
ABCA1 deficiency leads to Tangier disease, a severe reduction of plasma HDL, 
leading to increased intracellular cholesterol deposits and a significantly increase risk 
of cardiovascular disease (Assmann et al., 2001; Bodzioch et al., 1999; Rust et al., 
1999). This process has also been seen in patients infected with the HIV type I which 
inhibits ABCA1 function, increasing atherosclerosis in these patients (Jennelle et al., 
2014). However, deficiency of neuronal Abca1 reduces apoE by about 80%, with the 
remaining apoE being poorly lipidated, consequently increasing the amyloid load in 
AD mouse models (Jiang et al., 2008; Koldamova et al., 2005).   his suggests that Aβ 
processing and clearance is strongly influenced by the lipidation status of apoE and 
ABCA1 plays a role in this lipidation step. Loss-of-function mutations within the 
ABCA1 gene have also been linked to low plasma apoE levels, increasing the risk of 
LOAD as well as other cerebrovascular diseases (Nordestgaard et al., 2015). 
However, further exploration of this relationship is required to provide all the details, 
possibly even providing therapeutic insights (Hirsch-Reinshagen et al., 2008). 
As highlighted already, there is a distinct relationship between certain ABCA genes 
and disease. However, the genetic inheritance patterns of these associations are 
variable: ABCA1 is inked to Tangier disease in an autosomal dominant manner (Rust 
et al., 1999). This had been identified a year previously when, through genome-wide 
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graphical linkage exclusion strategies, the genomic region containing ABCA1 
 chromosome  q31  had been linked to  angier’s disease (Rust et al., 1998). Exonic 
sequencing of ABCA1 subsequently identified several variants within this gene to be 
associated with the disease, including truncating and insertion/deletion (INDEL) 
variants (Rust et al., 1999). ABCA3 has also been linked to neonatal surfactant 
deficiency in an homozygous loss-of-function pattern (Shulenin et al., 2004); ABCA4 
to Stargadt’s disease in a recessive manner (Shulenin et al., 2004) and ABCA12 to 
lamellar ichthyosis type 2 and ABCA13 to schizophrenia in both compound 
heterozygous and homozygous relationships (Akiyama, 2005; Knight et al., 2009). 
The association between ABCA13 and schizophrenia and other complex neurological 
conditions is of particular interest. Originally a chromosome abnormality was 
identified in one schizophrenic patient before exome sequencing was performed in 
100 cases and 100 controls. This recognized multiple rare, coding variants which were 
then sequencing in a much larger cohort (>1600 cases and >950 controls), establishing 
that, in combination, the frequency of these rare variants was significantly higher in 
cases when compared to controls (OR = 1.93, p = 5.70e-03) (Knight et al., 2009). 
Due to this variety it is therefore very difficult to predict the genetic inheritance 
patterns which ABCA7 would exhibit with any disease it may be associated with. 
However, most of the genetic variants associated with LOAD thus far are common 
variants (most with a MAF of greater than 5%), behaving as risk factor variants, as 
opposed to causal factors, similar to the pattern seen in ABCA13 for schizophrenia and 
bipolar disorder as mentioned above (Farrer, 2015; Knight et al., 2009). The 
likelihood is, therefore, that any disease-associated ABCA7 variants will act in a 
similar pattern: that of common variants altering disease risk.   
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1.5 ABCA7 and Disease 
1.5.1  jö re ’s  y  rome 
Sjögren’s syndrome is an organ-specific autoimmune disease (Jacobsson et al., 1989), 
mainly affecting the salivary glands and tear ducts and, in its primary form, causing 
dry eyes and salivary glands (Sjögren, 1935; Sood et al., 2000) but, in its secondary 
form, can also cause connective tissue disease, most commonly, rheumatoid arthritis 
(Bloch et al., 1992). Sjögren’s syndrome is surprisingly common with a prevalence of 
between 0.5% and 2.7% depending on the population (Jacobsson et al., 1989). In 
1994, the autoantigen SS-N was found to be associated with Sjögren’s syndrome  the 
“Sjögren’s epitope”  (Lopez-Longo et al., 1994) and in 2001, it was found that the 
amino acid sequence of this autoantigen is identical to residues 186-360 of ABCA7 
which codes for its large first ECD (ECD-1: “ABCA-SSN”  (Tanaka et al., 2001). 
This implies that ABCA7 is somehow involved in the pathogenesis of this 
autoimmune disease within the exocrine glands, the hypothesis being that the ECD-1 
region of the protein can be cleaved off and circulated to act as this autoantigen 
(Tanaka et al., 2001). This involvement is supported by the fact that ABCA7 is 
expressed in the salivary glands of patients suffering from Sjögren’s syndrome, 
detected by monoclonal antibodies against the ECD-1 region of the protein (Toda et 
al., 2005), an area which, normally, does not express ABCA7 at a high level (see 
Figure 1.8).  
1.5.2  ate  set Alzheimer’s Disease 
ABCA7 itself was first associated with LOAD in March 2011 when two GWAS were 
simultaneously published (Hollingworth et al., 2011; Adam C Naj et al., 2011). 
rs3764650 was identified as being associated with LOAD, achieving genome-wide 
significance. This is a SNP in intron 13 with a MAF of 0.10 (Hollingworth et al., 
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2011). It was also found to be in Linkage Disequilibrium (LD) with rs3752246 with a 
D` of 0.89. This SNP is in exon 32, encoding a glycine to alanine substitution at 
amino acid position 1527. However, this is predicted to be a benign change (Adzhubei 
et al., 2010). In 2013, a further GWAS study identified another SNP, rs4147929, to be 
associated with LOAD (see Table 1.2). This SNP is in intron 42 with a MAF of 0.19 
(Lambert et al., 2013). All of the above studies were completed in American and 
European populations although in 2013 the association of rs3764650 with AD was 
replicated in the African-American population and in 2014 it was replicated in the 
Han Chinese population in Taiwan as well as the Korean population (Chung et al., 
2014; Liao et al., 2014; Reitz et al., 2013). All minor alleles of the variants within 
ABCA7 associated with LOAD are related to an increased risk of disease. 
It is known that GWAS signals identify loci associated with a phenotype, although it 
may not be that particular loci which is causing the signal, but also any neighbouring 
genes, which may cause the association. However,  in 2014 association studies of 
collapsed (that is to say many rare variants, treated as one allele) loss-of-function 
ABCA7 mutations proved that it was ABCA7 involved in LOAD pathology as opposed 
to any surrounding genes (Steinberg et al., 2015). The fact that these variants were 
loss-of-function also indicates that it is a reduction of ABCA7 function that may 
contribute to AD risk. However, only rare variants were examined (that is ones with 
MAF of less than 0.5%) which, in combination associated with AD (Odds Ratio (OR) 
= 2.12, p = 2.2x10-13), but none located in combination with GWAS SNP (Steinberg et 
al., 2015). This study therefore does not account for the common variant association 
and therefore there are still hereditary gaps to be filled.  
ABCA7’s association with LOAD has also been validated by a study in 2014 where a 
GWAS was performed based on the neuropathological definition of AD as opposed to 
the clinical definition. Here, ABCA7 was associated with the neuropathological 
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“hallmarks” of AD with an even stronger association then has been previously 
described (OR = 1.32, p = 0.01) (Beecham et al., 2014).  
rs3764650 is now the GWAS tag SNP for ABCA7 but the functional effect, if there is 
any, is still unknown. The  minor allele (G) has been shown to decrease ABCA7 
expression, perhaps explaining a pathological link (Vasquez et al., 2013). 
Conflictingly, it has been shown that ABCA7 expression is actually increased in AD 
cases and, in fact, expression increases in parallel with cognitive decline decreasing, 
but the authors suggest that this increase is a compensatory change after disease onset 
(Karch et al., 2012; Vasquez et al., 2013). This cognitive decline is also associated 
with increased ABCA7 expression levels in peripheral blood in rs3764650 risk allele 
(G) carriers (Ramirez et al., 2016). This minor allele of rs3764650, although an 
intronic variant, has also been linked to a later age of onset of disease as well as 
shorter disease duration when compared with major allele (T) carriers. Nonetheless, 
both of these studies are flawed with only 57 samples being used in the first and there 
being only marginal associations in the second, which may not survive multiple 
correction testing (Karch et al., 2012; Vasquez et al., 2013). However, in 2014 a larger 
study consisting of over 2,000 American individuals associated the minor allele of 
rs3764650 with increased rates of memory decline in both LOAD and MCI patients 
(Carrasquillo et al., 2014). This variant has also been associated with neuritic plaque 
burden with the burden increasing by 0.18 per minor allele (G) dosage (Shulman et 
al., 2013), as well as being linked to a greater cortical thinning in the frontal cortex 
and hippocampus (Ramirez et al., 2016). An alternative GWAS tag SNP (rs3752246) 
has also been linked, in the CG genotype, with a 2-fold increase with the odds of 
being Aβ plaque positive, similar to the risk of carrying the ε4 allele of APOE 
(Hughes et al., 2014). 
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The aim of GWAS is to pinpoint candidate genes which are then to be followed up, 
with the actual GWAS signal not necessarily having any functional significance, as in 
ABCA7 with rs3764650 (Holmen et al., 2014). However, the GWAS signals 
themselves may not always be relevant and may merely indicate a nearby functional 
variant in a neighbouring gene (Sanna et al., 2011). It is therefore important to keep 
looking into these genes, and genes neighbouring them, in order to identify disease 
causing variants (Holmen et al., 2014).  
1.6 A  A  a   Alzheimer’s Disease Path ays 
GWAS and subsequent studies have therefore linked ABCA7 to LOAD. However, the 
reasons behind this association are still unknown (Piehler et al., 2012). 
It has been shown that ABCA7 plays a minor role in cholesterol and phospholipid 
transport (Abe-Dohmae et al., 2004; Chan et al., 2008; Wang, 2003). As the brain 
contains 25% of the bodies cholesterol (which itself is only 2% of body weight) it 
follows that ABCA7 may well have a role here in the brain if is part of the cholesterol 
cycle (Dietschy and Turley, 2001). apoE is the primary cholesterol carrier 
neurologically (Hirsch-Reinshagen et al., 2008), as well as being the primary genetic 
risk factor for AD (Holtzman et al., 2012), therefore they all may be linked. 
ABCA7 is also known to colocalise with the LRP1 when it moves to the cell surface 
membrane as part of the phagocytic cup, a process which is defective in the absence 
of ABCA7 (Jehle et al., 2006). LRP1 is also known to localise with apoE as well as 
other AD associated proteins, such as CLU (which has also been associated with 
LOAD, see Table 1.2), in order to transport cholesterol into cells as well as uptake 
cellular debris (Neher et al., 2012) and APP, where it becomes internalizes in order to 
produce Aβ (Satoh et al., 2015). It is thought that if this process of absorbing 
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cholesterol is disrupted and neurones are starved of cholesterol, AD may develop (Liu 
et al., 2007). However, it is unknown if ABCA7 is also involved in this process. 
Overexpression of ABCA7 has also been show to decrease the secretion of Aβ from 
APP secreting cells by retaining APP in perinuclear locations (Chan et al., 2008). 
ABCA7 may also have a role in increased Aβ accumulation as it has been shown that 
lipidated apoE normally reduces Aβ build up. However, if it is abnormally lipidated 
 which ABCA7 may have a small role in  then Aβ may accumulate (Wahrle et al., 
2004). ABCA7 loss-of-function, in several cell lines as well as Abca7 knockout mice, 
has also been shown to significantly increase the proteolysis of APP, due to the loss of 
ABCA7-LRP1 interaction, therefore increasing Aβ production, perhaps providing the 
most direct link between ABCA7 and LOAD to date (Satoh et al., 2015). So far, these 
suggestions all work on the basis that ABCA7’s primary role is cholesterol transport. 
However, as shown above, ABCA7 also plays a role in phagocytosis.  
Deletion of Abca7, has been proven to double cerebral Aβ accumulation in AD mouse 
models, so far correlating with the above two theories. Although there was no 
alteration in APP or apoE levels, the mouse models did have significantly reduced 
spatial reference memory problems. They also showed that macrophages taken from 
these mice had reduced phagocytic activity and their ability to take up Aβ was 
reduced by 51% (Kim et al., 2013). This suggests that Abca7 regulates Aβ cerebral 
levels through its phagocytic and immunological function and could explain the link 
to AD. 
Further studies support this. For example, ABCA7 has the highest expression 
neurologically in microglia (Kim et al., 2006) which contribute to phagocytic removal 
of apoptotic debris from the brain (Kreutzberg, 1995). It is known that microglia 
contribute to neuronal loss in AD mouse models as activated microglial cells surround 
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Aβ plaques phagocytosing viable neurones in the neighbouring area, contributing to 
neurodegeneration (Fuhrmann et al., 2010; Griffin et al., 1998). However, what has 
not been clarified is whether this abnormal immune response is an initiating event or a 
consequence of AD pathology.  
If microglia cannot phagocytise dead or dying neurones than they may go on to 
release inflammatory markers contributing to AD pathology (Neher et al., 2012). 
Alternatively, high levels of Aβ  are known to be toxic to neurones and this could 
initiate phagocytosis of otherwise viable neurones and synapses (Neher et al., 2012; 
Piehler et al., 2012). Phagocytosis may also be functioning abnormally, generating 
atypically folded protein plaques, leading to a variety of neurodegenerative disorders 
(Piehler et al., 2012).  
In conclusion, there are several pathways by which ABCA7 may be linked to AD, 
whether this is through cholesterol and phospholipid transport or through 
phagocytosis although this link cannot be defined for sure. What therefore needs to be 
established is whether variants within ABCA7 alter its function and contribute to AD 
pathology (Carroll et al., 1987). 
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1.7 Study Aims 
This study therefore aims to: 
 Create a catalogue of ABCA7 exonic variants utilising previous 
sequencing projects as well as online catalogues. 
 Analyse these exonic variants in silico to see if they are predicted to affect 
ABCA7 function.  
 Perform genotyping assays on these variants to see if they are associated 
with late onset Alzheimer’s disease. 
 Design and carry out in vitro assays to investigate if variants alter 
ABCA7’s function and how they do so.  
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2 Examining ABCA7 Exonic Variants 
2.1 Introduction & Background 
enome Wide Association Studies (GWAS) do not identify causative 
variants but merely associate genomic loci with a particular phenotype. 
However, these loci can theoretically be examined in further detail in 
order to elucidate the true causative variants of disease. These causative variants are 
commonly in linkage disequilibrium (LD - the lack of independence between alleles at 
different loci (Barnes, 2007)) with or in close proximity to the single nucleotide 
polymorphisms (SNPs) identified through GWAS. Indeed, it has been shown that the 
causative variant of a disease is less likely to be the SNP identified through GWAS, 
but more probably a variant in LD with it (Rosenthal et al., 2014). GWAS, therefore, 
links a certain LD block, or genomic location, with a phenotype rather than a specific 
variant (Visscher et al., 2012). Through identifying variants within these loci it also 
means rarer variants are also catalogued which may not have been identified through 
GWAS due to methodological limitations.  
G AS examines the hypothesis of “common variant - common disease,” where the 
accumulation of a selection of common variants leads to a disease phenotype. 
However, rarer variants may still implicate disease risk, in the “common disease - rare 
variant” hypothesis.  hese rare variants may have a larger effect, causing disease in a 
small number of individuals, or a smaller effect, acting in combination with each other 
creating “disease haplotypes” (Gibson, 2012; Pabinger et al., 2014; Rivas et al., 2011). 
Examples of this “rare variant” hypothesis have been found specifically in 
Alzheimer’s disease: carriers of a rare variant (MAF of 0.002) within the gene TREM2 
G 
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(a protein involved in regulating microglial phagocytosis), coding for the amino acid 
substitution R47H, have been shown to have a significantly greater risk of developing 
LOAD in a small number of individuals upon whole exome sequencing of 281 LOAD 
patients and 504 control subjects (Guerreiro et al., 2013). The TREM2 gene was 
originally linked with other, much rarer forms of dementia through pedigree studies in 
2002 (Paloneva et al., 2002) before first being linked with LOAD in 2009. This was 
through a meta-analysis of the existing linkage studies of LOAD patients at the time. 
Despite the fact that there were only a very small number of included studies (n=5), 
meaning no regions reached genome-wide significance, the genomic region 
containing TREM2 (6p21.1-q15) was one of the strongest signals (p = 0.0169) (Butler 
et al., 2009). This paved the way for rare, single variants, such as R47H, to be directly 
associated with LOAD through more high-throughput methodologies (Guerreiro et al., 
2013). However, it cannot be said for sure that all of LOAD cases are caused by 
individual, rare mutations. Common variants must, therefore, also be examined, both 
individually and in haplotypes. 
In a recent re-sequencing project involving Icelandic, European and American 
populations, loss-of-function ABCA7 variants increased AD risk with a combined 
odds ratio (OR) of 2.03 and p-value of 6.8 x 10-15 (Steinberg et al., 2015). This has 
also been replicated in a Belgium cohort (OR = 4.03 and p = 0.0002) (Cuyvers et al., 
2015). This implies that these loss-of-function variants may be the explanation behind 
ABCA7’s association with LOAD. As such, variants which are predicted to have a 
functional affect will be examined in more detail in this chapter. 
Next Generation Sequencing (NGS) has been used previously in order to identify 
variants in risk loci identified by GWAS, which contribute to the risk of inflammatory 
bowel disease and type I diabetes, both complex diseases like LOAD (Nejentsev et al., 
2009; Rivas et al., 2011). NGS was, therefore, utilised in this lab in 2011 (providing 
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the basis for previous PhD projects - Dr Jenny Lord, Dr James Turton and Dr Anne 
Braae) in order to catalogue the lower frequency genetic variants (ones with minor 
allele frequency of 1-5%), screening the eight original GWAS loci (ABCA7, BIN1, 
MS4A, CD2AP, CD33, APOE and CR1 - see Table 1.2). NGS was selected as being 
the correct platform to perform this targeted re-sequencing due to its cost efficiency 
and ability to target specific loci. Several NGS platforms were researched before the 
Illumina HiSeq 2000 (Illumina, California, USA) was selected based on cost 
efficiency and its relatively low error rate of about 0.4% (Quail et al., 2012).  
Ninety-six samples underwent whole genome NGS in total; all LOAD cases 
confirmed using the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) criteria and all collected with ethical approval and consent of all 
individuals. These individuals had DNA extracted from whole blood samples which 
were quality and quantity assessed using 1% agarose gel electrophoresis, as per lab 
protocol, and the Nanodrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA), as per manufacture protocol. Eight pools of 12 samples each were 
generated, making sequencing cheaper - by up to 20% - when compared to bar-coding 
and creating unique libraries for individual samples (Schlötterer et al., 2014). 
Although this methodology is cheaper, it does come with caveats, especially in 
relation to low frequency variants which need to be distinguished from sequence 
errors (Altmann et al., 2012). However, once this bioinformatical challenge has been 
overcome, variant detection and allele frequency approximation is not significantly 
altered in NGS pooled studies when compared to using individual bar coded samples 
(Ingman and Gyllensten, 2009). A sample size of 96 was selected in order to provide 
enough power to the study to be able to provide a 95% chance of detecting variants 
with a MAF of 1-2% whilst still being a manageable size in order to screen and 
validate these pooled samples for the variants of interest which come to light when the 
data is analysed. 
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Before sequencing itself was undertaken, target enrichment was performed in order to 
create the libraries. The Agilent SureSelect system (Agilent, Santa Clara, USA) was 
chosen, utilising the in-solution hybrid capture methodology. This has been shown to 
be the best enrichment method for pooled samples (Day-Williams et al., 2011). RNA 
sequences were designed complementary to the areas of interest within the fragmented 
DNA. Magnetic beads were then used to pull the targeted areas out of solution. This 
DNA was polymerase chain reaction (PCR) amplified and clusters generated. Clusters 
(groups of identical DNA fragments) were used in order to increase the number of 
reads, increasing the likelihood that rarer variants will be identified. These clusters 
were amplified on a solid surface, in this case a flow cell, creating eight DNA 
libraries, one for each pool, in readiness for sequencing.   
The Illumina HiSeq 2000 utilised Sequencing by Synthesis chemistry. This involved 
each cluster being sequenced base wise in real time by having all four 
deoxynucleotides (dNTPs) present, each with its own fluorescently labelled, 
reversible, terminator. These labels were detected as they became incorporated before 
they were cleaved off, allowing sequencing to continue. Sequencing was performed 
cyclically and, after a number of cycles, the clusters were regenerated and then 
sequenced in reverse using a second sequencing primer. This, again, increased the 
number of reads performed and meant data was generated from each end of the 
template, allowing context specific information to be captured upon the sequence 
being aligned through algorithms later in the process. The sequence data and quality 
scores were then produced in FASTQ files and sent to this lab where a bioinformatics 
pipeline was designed in order to analyse and annotate it.  
Under this pipeline, the raw data was subjected to various bioinformatics tools in 
order to quality control the reads, align them, visualise, call the variants, annotate 
them before validating the variants, imputing them and performing association tests 
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upon them. The formation of this pipeline formed a large part of Dr Turton and Dr 
Lord’s PhD projects and is summarised in Figure 2.1. As can be seen, once the 
sequence had been aligned and quality controlled, SNPs were called and frequencies 
calculated using the Comprehensive Read analysis for Identification of SNPs from 
Pooled sequencing (CRISP - Scripps Genomic Medicine, La Jolla, CA, USA) utility. 
These were quality checked again before being annotated using a variety of 
programmes. A number of variants called were then validated both in silico and in 
vitro. In silico validation involved utilising existing databases, the Exome project 
(Guerreiro et al., 2013) and the 1000Genomes browser (European Bioinformatics 
Institute, Cambridge, UK), comparing variants found, and their frequency, in order to 
corroborate the methodology used. SNPs were also validated in vitro, using Sanger 
sequencing methodology.  
Before filtering, CRISP called a total of 209 variants in ABCA7, including 18 
insertions and 17 deletions. This was reduced to 148 variants (6 insertions and 3 
deletions) once they had been filtered based on the quality and depth of the reads. This 
number also included 24 variants which did not map to ones found in dbSNP build 
137 (Bethesda, MD, USA, accessed in January 2013) or 1000Genomes and were 
therefore considered novel. This dataset was then imputed in order to establish if any 
of these rare NGS variants were associated with LOAD. In order to perform this, a 
control dataset (one not containing AD patients) was used as a reference 
(1000Genomes, Phase 1) and then association was measured using SNPtest.  
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As this chapter is focussing on the functional effect variants have on the protein, only 
the exonic variants from this NGS project will be examined. The first aim of this 
project is to create a catalogue of all exonic ABCA7 variants and annotate them, using 
bioinformatics tools, to provide a selection of variants which have a suggestive effect 
on protein function. In combination with this NGS data, variants from the Exome 
Variant Server (EVS - NHLBI, Seattle, WA) will also be utilised. This browser 
contains exonic NGS data from 2203 African-Americans and 6503 European-
Americans from a variety of phenotypes.  
Figure 2.1 - Bioinformatics pipeline used to analyse NGS data. 
Raw data
•Base calls and quality 
scores
Alignment
•BFAST to hg19
Sequence 
Processing
•SAMTools
Quality Control
•SAMTools
•SAMStat
Visualisation
• Integrative Genomics 
Viewer
SNP Calling
•CRISP
Filtering
•Quality <30
•Quality/Depth <2
•Homopolymer runs
TsTv Ratios
•VCFtools
Variant Annotation
•Variant Effect Predictor
•Encode
•UCSC
•Linkage Disequilibrium
Validation
• In silico (Exome project 
and 1000Genomes)
• In vitro (Sanger 
sequencing and TaqMan)
Imputation
• 1000Genomes
Association
•SNPtest
Functional Assays
• Splicing (see Chapter 4)
• Association Testing (see 
Chapter 3)
• Allelic Expression Imbalance
Figure 2.1
Simplified diagram of the bioinformatic pipeline which was applied to Next Generation Sequencing data in order to generate 
much of the data used in this current project. Adapted from Dr James  urton’s and Dr Anne Braae’s PhD theses. 
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2.2 Methods 
2.2.1 Catalogue Creation 
Lists of variants from the NGS data and the online EVS tool were first achieved and 
co-ordinates of these variants obtained from the reference human genome build 37 
(GRCh37). The EVS inventory was obtained by searching for the ABCA7 gene name. 
Variants within introns were excluded from both lists by comparing their genomic 
location to the exonic boundaries of ABCA7 as catalogued on the Ensembl database 
NM_019112.3 (EBI, Cambridge, UK). The exon number, cDNA location and 
consequential amino acid change caused by that variant were also recorded utilising 
Ensembl and EVS. rs ID numbers were obtained from the dbSNP database, build 137, 
if they existed. Variants which did not have a dbSNP ID were classed as “novel.” 
MAFs for each of the variants were then obtained. As there is such a variety of MAFs 
depending on the database used, and the population examined, four alternate figures 
were collated, as well as the MAF calculated in the CRISP programme for the NGS 
variants. These programmes included 1000Genomes, EVS (the average MAF from all 
populations were used for both of these databases), dbSNP and HapMap where the 
European population MAFs were used. All MAFs were presented in a percentage 
format as opposed to a decimal format.  
The effect these variants have on protein functionality was predicted using three 
different online tools: SeattleSeq (National Heart, Lung, and Blood Institute, 
Bethesda, MD, USA); Polyphen-2 (Harvard, MA, USA) and SIFT (La Jolla, CA, 
USA). These three programmes all make predictions on the effect these variants may 
have on the protein function based on the amino acid substitution they cause, 
methodology also utilised in previous studies (C. Sassi et al., 2014). SeattleSeq 
generates a Grantham Score based on the chemical properties and class differences (if 
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any) of the amino acid substitution.  his score is then classified: “conservative”  a 
score from 0 to 50 ; “moderately conservative”  a score from 51 to 100 ; “moderately 
radical”  a score 101 to 150  or “radical”  a score of 151 or more  (Li et al., 1984). 
PolyPhen-2 (Polymorphism Phenotyping v2) annotates variants based on multiple 
sequence alignment of the surrounding region to homologous proteins and whether 
the site of variation is in a CpG region or a hypermutable site. This results in a score 
from 0 to 1 which is then classified: a “probably damaging” variant is one with a score 
above 0. 5; “possibly damaging” is above 0.15 and “benign” for the remainder 
(Adzhubei et al., 2010). SIFT assigns scores based on conservation of the sequence 
surrounding the variation and gives a score ranging from 0 to 1. Any that score below 
0.05 are then classified as “damaging,” and all others are “tolerated” (Kumar et al., 
2009). For this purpose the SIFT Human Protein DB programme was used, utilising 
Ensembl build 63 with the ABCA7 protein ID of ENST00000263094. For the 
SeattleSeq programme the input involves the chromosome number, genomic location, 
as per hg37, and the alleles involved. All of this data was obtained from information 
already collated. For PolyPhen-2, the protein sequence in FASTA format was 
obtained from Ensembl (NP_061985.2), inputted along with the amino acid position 
and substitution effected, again, from data already collected.  
These data were all compiled between 6th February and 29
th
 March 2014. 
2.2.2 Catalogue Refinement 
The catalogue created was subsequently refined. However, before this initial 
refinement, in order to prevent potentially novel variants from being eliminated due to 
a lack of data (especially ones identified through the NGS), a separate list was created 
of only novel variants, with them being defined as ones without a dbSNP ID (rs 
number). Any of these novel variants which appeared in the NGS dataset and had a 
predicted damaging effect on protein function were included in the final list of 
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variants to be examined further. Only variants which had appeared in the NGS data 
were included as this meant they had been seen in our samples, increasing the 
likelihood of us being able to investigate them further, due to them being present in at 
least one sample in our DNA bank.  
The first refinement performed on the whole dataset was executed based on the MAF 
of the variants. Power calculations were carried out in order to calculate the minimum 
allele frequency that could be genotyped using the samples held in the lab 
(approximately 1500 cases and 1500 controls). These calculations were performed in 
QUANTO v1.2.4 (USC Biostats, California, USA) using the gene-environment 
interaction model (as LOAD has both environmental and genetic components) and a 
study design of matched case-controls.  Default settings were utilised except for the 
following which required manual configuration: 
 The allele frequency was inputted at 0.005 to 0.05 (0.5% ~ 5%) in increments 
of 0.005 (0.5%) in order to view the power that could be achieved at a variety 
of MAFs 
 The inheritance model was set as log additive 
 Population prevalence was set to 0.24 (representing an approximation of the 
environmental component of LOAD being equal to 24%) 
 Population risk was inputted to be 0.12 (12%) as an estimated risk of LOAD 
between the ages of 65 and 100 
 The genetic effect size was estimated to have an odds ratio of 2 
 The environmental effect size was estimated to have an odds ratio of 1.2 
 The sample size was inputted as 1500 cases and 1500 controls 
 Type I error rate was set to 0.05 (the maximum tolerated type I error rate) 
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 The programme was instructed to perform a 2df test as this enables the 
calculation of power whilst taking into account the effects from both genetic 
and environmental factors 
The catalogue was then refined based on the lowest MAF which provided a power of 
at least 70%. As the MAFs between different programmes sometimes differed largely, 
as long as one of the databases displayed a MAF of equal to or over this figure, the 
variant was included.  
As this project is focused on variants which have a functional effect on the ABCA7 
protein, the next refinement was to exclude all synonymous variants. It is 
acknowledged that these synonymous SNPs, which were excluded at this step, may 
have functional effects such as on splicing or protein regulation (Edwards et al., 
2012). However, at this stage, only SNPs affecting the protein function itself were 
selected. With this in mind, the next refinement was performed by also eliminating 
variants which were not expected to be damaging by at least one of the prediction 
programmes used. A damaging prediction was defined as a “Moderately Radical” or 
“Radical” Grantham Score, a “Possibly Damaging” or “Probably Damaging” 
PolyPhen-2 score or a “Damaging” score from SIFT. 
2.2.3 Annotation of Variants 
The final lists of variants, with the exception of any novel ones, were annotated with 
their LD scores in relation to the GWAS tag SNP – rs3764650. Novel variants were 
unable to be interrogated in this manner due their absence from the 1000Genomes 
database which was used to calculate these LD scores. This annotation was completed 
in a Linux environment where the 1000Genomes data for ABCA7 was extracted, 
utilising Tabix (a tool which indexes genomic position sorted files in TAB-delimitated 
formats (Li, 2011)) with the following command: 
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$tabix -hf ftp://1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/ALL.chr19. 
phase1_release_v3.20101123.snps_indels_svs.genotypes.vcf.gz 19:1040103-
1065569 > ABCA7raw1kGSNPs.vcf 
This produced a Variant Call File (VCF) containing all of the SNPs and 
insert/deletions (indels) within the base pairs 1,040,103 to 1,065,569 on chromosome 
19, the co-ordinates of ABCA7. The European gene frequencies were then extracted 
using a Perl script, written by Dr Christopher Medway, and comparing it to a list of 
samples in the GBR and CEU populations: 
$perl vcf-subset -c Phase1_Samples_GBR_CEU ABCA7raw1kGSNPs.vcf > 
ABCA7_CEU_GBR.vcf 
This also produced a VCF file which was then converted to a PLINK file using the 
vcftools software (Danecek et al., 2011): 
$vcftools --vcf ABCA7_CEU_GBR.vcf -plink-tped --out 
ABCA7_CEU_GBR 
PLINK was then used to calculate the LD between the SNP of interest  “rs1”  and the 
GWAS SNP - rs3764650. PLINK is another command-line programme frequently 
used to analyse large genetic data sets (Purcell et al., 2007). The following command 
line was used: 
 $plink -tfile ABCA7_CEU_GBR -ld rs3764650 rs1 
This command was repeated for all the variants of interest. Using this method, PLINK 
provides the D` score (the measurement of evidence of recombination between loci 
calculated from haplotype frequencies), r
2
 score (covariance in allelic value between 
the loci), the estimated haplotype frequency compared to the frequency expected 
under linkage equilibrium as well as the haplotypes which are in phase (Balding et al., 
2007).  
All variants, including any novel ones, were then visualised on the tertiary structure of 
ABCA7 utilising the TOPO2 online programme. The FASTA amino acid sequence of 
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ABCA7 was uploaded (NP_061985) along with transmembrane residue numbering 
acquired from UniProt (UniProt Consortium 2012, ID Q8IZY2). TOPO2 provides an 
image of the transmembrane protein. The amino acids of the variants of interest were 
inputted into the TOPO2 user interface to visualise where they are located on the 
protein. The locations of the three identifying motifs (Walker A, Walker B and ATP 
signature sequence or C motif) were also examined using the amino acids sequences 
as identified in Table 1.3 (Broccardo et al., 1999). Once the locations of these three 
motifs had been established, the full list of variants was re-examined to see if there 
were any variants of interest within these functionally vital areas.  
The effect these variants have on the structure of the transmembrane domains was 
scrutinised in order to analyse if they alter the transmembrane structure of the ABCA7 
protein. This was performed using the online programme TMHH Server version 2.0 
(Centre for Biological Sequence Analysis, Technical University of Denmark, Lyngby, 
Denmark), which predicts transmembrane regions utilising the hidden Markov model 
with the N-best algorithm (Krogh et al., 2001). This programme has been shown to be 
the most accurate transmembrane prediction programme (Möller et al., 2001). The 
wild type amino acid sequence of ABCA7 (NP_061985) was inputted into the 
programme as well as the sequence with the mutated amino acids for any variants 
which had been shown to be located within one of the transmembrane domains as 
demonstrated in the TOPO2 output. This resulted in a list of the transmembrane 
domains in numerical format as well as a graph of probabilities of these being correct. 
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2.3 Results 
The total number of ABCA7 exonic variants obtained from EVS was 238 and 38 from 
the NGS dataset. Both of these data groups contained the only exonic GWAS SNP, 
rs3752246 (19:1056492). When all of these were collated, a list of 240 variants was 
created, available in Appendix A. A breakdown of the whole catalogue can be seen in 
Figure 2.2, showing the refinement process and the number of variants excluded at 
each stage. In total, 204 variants were excluded due to their low MAF, 21 due to being 
synonymous variants, 11 due to being benign changes, leaving five variants as being 
potentially damaging.  he total list contained a total of 11 “novel” variants, available 
in Table 2.1. Of these, only two variants were present in NGS dataset although only 
one was predicted to be damaging by both PolyPhen2 and SIFT (present at 
19:1056958) and will therefore be included in the final list of variants to be annotated 
further. 
 
Figure 2.2 - Breakdown of all variants catalogued from EVS and NGS data. 
Novel Variants: 
11 
Variants with MAF  1%: 
36 
Missense Variants: 
15 
Synonymous Variants: 
21 
Variants Predicted as Damaging: 
5 
Variants Predicted as Benign: 
11 
Variants with MAF  1%: 
1 3 
Exonic Variants  Appendix A : 
240 
 i  re     
Breakdown of  the variants catalogued.  he final five variants will be analysed in more detail through genotyping assays.  he complete 
list of variants, as well as all their details, can be seen in Appendix A.  
Predicted damaging: 
1 
Benign variants and or variants 
not NGS study: 
10 
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The output of the power calculations in QUANTO can be seen in Figure 2.3. When 
this output was analysed, it is apparent that, with approximately 1500 cases and 1500 
controls, 76% power can be achieved when analysing a variant with a 1% MAF. A 
MAF of 1% or more in any of the databases analysed was therefore used in order to 
perform the first refinement. This shortened the list considerably to 36 variants, again 
including the GWAS SNP at a MAF of around 18% (see Table 2.2). Upon further 
refinement to only missense variants, this list was again shortened to 15, still 
containing the GWAS SNP which codes for a glycine to alanine change at amino acid 
position 1527 (see Table 2.3). Four of these variants were predicted to have a 
damaging effect on the protein and therefore made the final refinement (see Table 
2.4). Here the GWAS SNP was eliminated as it was not predicted by any of the 
programmes to be damaging. This provided a final list of four variants: rs3752233 
(R463H); rs59851484 (A676T); rs3752239 (N718T) and rs114782266 (R1812H), as 
well as one novel mutation from Table 2.1 (19:1056958, S1547P)), which was also 
predicted to be damaging.  
Figure 2.3 - Output from QUANTO upon performing power calculations. 
 i  re     
Output from  UAN O upon doing the power calculations.  he Interaction, Gene column is 
used when analysing the power as LOAD has both an environmental and genetic component 
which interact.  his shows that, with an allele with Minor Allele Frequency of 1%  0.01 , a 
power of 76.61%  0.7661  can be achieved with 1500 case samples matched with 1500 
controls  case-control pairs .  his 1% cut-off was therefore used.   
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 LD calculations were performed on the final five variants and the output from PLINK 
can be seen in Figure 2.4. However, the novel variant was not able to be included in 
the LD calculations at this stage due to it not being present in the 1000Genomes 
dataset as mentioned previously. Previous analysis has shown that D` is the most 
accurate way of describing LD as it does not take the allele frequencies of either loci 
into account (Devlin and Risch, 1995), therefore, this is the measure that will be 
analysed. As can be seen in Figure 2.4, two variants (rs59851484 and rs114782266) 
have a D` of 1, implying these loci are in complete correlation with the GWAS SNP 
rs3764650. However, the calculations for rs59851484 may not be totally accurate as 
the minor allele (A) does not appear to have been seen in the 1000Genomes dataset 
used to calculate these LDs (see Figure 2.4). Unfortunately, genotypes of rs3764650 
were not available for these samples so the true LD was unable to be ascertained: 
however, if more time had been permitted, this GWAS tag SNP would also have been 
genotyped in order to establish the true LD. 
Figure 2.4 - Results from the LD calculations performed between 
the variants of interest and the ABCA7 GWAS tag SNP. 
 i  re     
Results of the Linkage Disequilibrium calculations preformed between the variants of interest  rs3752233, 
rs375223 , rs5  514 4 and rs1147 2266  and the ABCA7 intronic G AS tag SNP rs3764650.  his G AS 
SNP codes for a G to   change.  hese present the r2 and D  scores for each allele as well as the haplotypes 
observed, their frequency in the dataset used  1000Genomes Phase I  against the frequency expected under 
linkage equilibrium  if they were totally dependant on each other and, therefore, have identical minor allele 
frequencies . rs5  514 4’s result may not be entirely representative, however, as the minor allele  A  is not 
present in the 1000Genomes dataset.  his may because it is rarer then predicted. However, rs1147 2266 is 
predicted to be in LD with the G AS tag SNP with a D  score of 1.  he frequency of the variants presented 
here are in decimal format. 
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 he location of these five variants, as well as the ABC motif’s within ABCA7, can be 
seen in Figure 2.5, visualised on the tertiary structure of ABCA7 from TOPO2. As 
can be seen, there is no commonality in the location of these variants within the 
protein, being spaced throughout the structure. However, there are two variants within 
one of the extracellular domains (ECD) between transmembrane domains five and six. 
 his may mean that this particular ECD is important in ABCA7’s function.  here is 
also one variant, rs3752233, within the first ECD which is known to be functionally 
important.  
Figure 2.5 - 2D representation of ABCA7's structure within the cell membrane 
including the location of the variants of interest. 
rs3752233 
R463H 
1 :1045174 
rs5  514 4 
A676  
1 :1047337 
rs375223  
N71   
1 :104753  
1 :1056 5  
S1547P 
rs1147 2266 
R1 12H 
1 :105 057 
 alker A Domains 
A P Signature Motifs 
 alker B Domains 
 i  re     
2D representation of ABCA7’s structure within the cell membrane, created using  OPO2  www.sacs.ucsf.edu  OPO2  .  he 
variants which will be examined in more detail  rs3752233, rs5  14 4, rs375223 . 1 :1056 5  and rs1174 2266  are highlighted 
along with the amino acid they affect.  he three motifs vital to ABCA function are also highlighted which are located within the 
Nucleotide Binding Domains  NBDs .  hese areas are vital to any ABCA protein’s function, primarily because they are where A P 
binds to and becomes hydrolysed in order to provide energy to transfer molecules across the membrane through a pore created by 
the transmembrane domains   MDs .  
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As can be seen in Figure 2.5, the novel variant 19:1056958 is located within 
transmembrane domain eight and was therefore analysed to see if it alters the 
transmembrane domains through analysis on the TMHMM server. The results from 
these are available in Figure 2.6 and suggest that this variant does not alter the overall 
structure of the transmembrane domains.  
As the locations of the functionally important domains in ABCA7 were mapped to its 
amino acid sequence in TOPO2, a list of variants in these areas was also created. This 
included ten variants in all six domains and can be seen in Table 2.5.  
Figure 2.6 - Prediction of the affect the variant at position 19:1056958 will 
have on ABCA7's transmembrane domains. 
 
 i  re     
 hese images contain the output from the  MHH server version 2.0  http:  www.cbs.dtu.dk services  MHMM  , 
predicting the transmembrane domains in the wild type amino acid sequence of ABCA7  ABCA7-    as well as 
the amino acid sequence where position 1547 is altered from Serine to Proline  ABCA7-MU  .  his change is 
caused by a mutation at genomic position 1 :1056 5  with a   to C change.  hese graphs show the probability 
of certain regions being transmembrane domains.  here is no difference between the two meaning that this 
variant does not appear to alter the transmembrane domain overall structure, however, it may still alter the pore 
structure within the cell membrane and may, therefore, still alter ABCA7’s transporter function.  
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2.4 Discussion 
From this bioinformatical interrogation of data acquired from our own NGS and from 
data freely available on the EVS, a list of 240 exonic variants within ABCA7 was 
reduced to a final list of five variants. Four of these are predicted to be damaging to 
the protein and have a minor allele frequency of at least 1%. The final variant on this 
list is a novel variant arising from the NGS data. Its MAF is therefore unknown 
(CRISP approximates it at 0.663%) but it is predicted to be functionally damaging by 
both the PolyPhen2 and SIFT programmes.  
The methodology behind this approach was validated by a colleague - Dr Christopher 
Medway in the Mayo Clinic, Jacksonville. He had also, independently, interrogated 
the EVS database, examining it for variants likely to be associated with Late Onset 
Alzheimer’s Disease in ABCA7. The approach he used, which involves examining 
haplotypes of different variants and therefore not just focussing on the variants 
predicted to be damaging to the protein function, produced a list of 27 variants. All of 
the variants in Table 2.4 are included in this list. The remaining 23 variants are all 
included in Appendix A, with the exception of two variants in the 5’ untranslated 
region  U R  area, one in the 3’ U R and two in intronic regions. Of the remainder, 
four have a MAF of less than 1%, nine are predicted to not be damaging to the protein 
structure or function and one is a synonymous amino acid substitution. Four in total 
are novel variants, all seen in Table 2.1. However, none are seen in our NGS data. 
Nevertheless, the fact that the variants in  able 2.4 are also included in Dr Medway’s 
list corroborates the approaches used here. 
When the catalogue was initially refined, eliminating variants with a MAF of less than 
1%, this reduced it drastically, removing 204 variants. The vast majority of these were 
present on EVS but not in any of the other databases analysed, such as 1000Genomes 
Page | 85 
 
or dbSNP. The variants within EVS have not all been validated, including all of the 
insertion/deletion (INDEL) calls reported. This implies that, when they do not also 
appear in any of the other databases, they may not be true variations, including the 
novel variants only seen in EVS, such as the majority of the variants in Table 2.1. All 
of these novel variants were not seen in HapMap, dbSNP or 1000Genomes and only 
two of the 11 were seen in our NGS data. As it is unlikely for novel variants only 
present in the EVS database to also be present in the samples held in this lab, only 
ones present in the NGS dataset were examined in more detail. Of these, two possible 
variants existed although only 19:1056958 is predicted to be damaging to the protein 
and therefore, this one has been interrogated further. The removal of such a high 
number of rare variants increases the chances that any singleton coding variants which 
may contribute to risk would be missed. Methods of examining these rare variants 
exist, for example, burden analysis of rare variant load programmes. However, in 
order to carry out these tests, full genetic data of each individual is required in order to 
“collapse” all the rare variants into one score and test association between this score 
and the disease trait (S. Lee et al., 2014). This data was not available for any of the 
study subjects included in this analysis at the time this project was done and, 
therefore, this option could not be explored. 
When looking purely at the NGS dataset, a 1% cut off for MAF seems extremely low, 
especially as only 96 individuals were sequenced. However, when these samples are 
supplemented with the data from EVS, 1000Genomes and dbSNP, the results may be 
more reliable, increasing the power. Indeed, some of the variants present in Appendix 
A with a MAF of less than 1% have been shown to be real and in association with 
disease. However, both of these studies were performed in much bigger datasets, 
massively increasing the power and, therefore, the ability to reliably establish the 
association between these rare variants and disease (Dykxhoorn, 2016; Xia, 2016).  
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This project is specifically looking at variants which affect the structure and function 
of the ABCA7 protein. However, intronic variants - as well as ones in the UTR of the 
gene - cannot be ignored. Variants in these areas have been linked to many things 
affecting the protein, mainly splicing and regulation of mRNA, and therefore protein 
levels (Pagani and Baralle, 2004). Annotation of these variants has proven to be very 
difficult, especially due to the extremely high numbers of these variants (the NGS 
project produced a list of 96 intronic SNPs tentatively associated with LOAD, a great 
deal more than the 38 exonic ones). Synonymous variants have also been excluded 
from analysis in this process. However, again, they can similarly alter the protein. 
This can also be through affecting splicing but may again alter transcription, mRNA 
transport and translation, rendering these so-called “silent mutations” far from silent 
(Goymer, 2007). Frequently, more data than just genomic data is required to annotate 
these variants, both intronic and synonymous. For example, transcriptomic and 
proteomic data is needed in order to analyse the functional significance of these 
variants on protein levels and alternate isoforms, far beyond the scope of this project 
(Ritchie et al., 2015). However, this type of analysis is going to become more and 
more vital as the amount of genomic data available increases. As many of the 
phenotypes under investigation are complex, and therefore arise from interactions 
among multiple factors, the complete biological model is only going to become 
apparent if all of these factors are considered within the analysis. The automatic 
elimination of intronic and synonymous variants is, therefore, a drawback of this 
analysis.  
As mentioned previously, commonly the GWAS tag SNP is not the disease-causing 
variants, but frequently it is a variant in LD with it (Rosenthal et al., 2014; Schaub et 
al., 2012). In Figure 2.4, it can be seen that two of the variants under investigation, 
rs114782266 and possibly rs59851484, are in strong LD with the GWAS tag SNP 
rs3764650. rs59851484 is only possibly associated as its’ minor allele is not seen in 
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the dataset, therefore the calculations may not be representative. This might imply that 
this variant may actually be rarer than first thought and is over-represented in the 
datasets used to obtain its MAF. This is supported by the fact that this is the only 
potentially pathogenic variant that does not appear in the NGS data. The other two 
variants examined, rs3752233 and rs3752239, both have a D` of 0.197 implying that 
these loci have been separated from rs3764650 through recombination. However, D` 
values of less than 1 are more difficult to interpret and therefore no conclusions as to 
the levels of recombination can be made from this data (Barnes, 2007). Unfortunately, 
the genotype of rs3764650 is not known for the majority of the samples that will be 
used in the next chapter so the accuracy of these in silico LD calculations could not be 
assessed. However, a future project is planned to acquire these genotypes, as well as 
the other GWAS tag SNPs listed in Table 1.2 through genotyping studies, in order to 
evaluate the true LD scores.  
The location of all the variants in Table 2.4, as well as the novel variant 19:1056958, 
can be seen in Figure 2.5, as well as the location of the functionally important areas 
mentioned in the ABCA7 protein. The location of variant 19:1056958 is of particular 
interest as it is located in one of the transmembrane domains of the ABCA7 protein, 
which are highly conserved both within the Homo Sapien ABCA family and between 
species, forming the pore the protein transports substrates through. This variant was 
therefore examined in further detail in order to see if is predicted to alter the physical 
structure of the transmembrane domains as there is a possibility a substitution in this 
region could affect the formation of the α-helix necessary to form the transmembrane 
domain (Kobayashi et al., 1990). From Figure 2.6 it can be seen that an alteration of 
amino acid number 1547 from Serine to Proline does not grossly affect the structure 
of the transmembrane domains in ABCA7. The programme predicts 11 
transmembrane domains, one fewer than the ABCA proteins are known to have, 
eliminating transmembrane domain six.  However this is consistent in both the wild 
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type and mutant versions of the protein. The fact that this variant introduces a serine 
to proline substitution is of particular interest as this particular kind of change is 
known to produce kinks in alpha-helical structures (such as the ones which make up 
the TMDs in the ABC proteins) (Barnes, 2007). Consequently, even if this variant 
does not alter the physical transmembrane structure, it may still alter the way 
substrates are transported through it by altering the pore conformation. An example of 
this is mutations in TMD 10 of the ABCC1 protein (a multidrug resistance protein) 
altering substrate specificity (Zhang et al., 2006a). The most accurate way of assessing 
this in the ABCA7 protein would be by performing functional assays, evaluating 
ABCA7’s transport function in both wild type and mutant (containing the S1547P 
substitution) versions of the protein.  
The location of variant rs3752233 is also of interest as it is within the first ECD. 
Variants within this region in other ABCA proteins, such as ABCA1, are known to 
cause disease, such as Tangier’s disease, and therefore mutations in the same area in 
ABCA7 may cause similar disease causing changes (M. L. Fitzgerald et al., 2004).  
Only two of the variants in Table 2.4 have been reported in the literature previously 
and, as mentioned earlier, the variant at position 19:1056958 has not been reported 
before. rs3752233 and rs3752239 were both reported in the same study examining 
common coding variants within LOAD GWAS loci, as this chapter does specifically 
for ABCA7 (Holton et al., 2013). However, although this report identifies these two 
variants as having been investigated within this study, the results for these individual 
variants are not presented and, therefore, the findings are not obvious (Holton et al., 
2013). When examining the location of all of these variants in the ABCAM database 
(a mutation knowledge base mining all of the ABC protein mutations from available 
literature and aligning them between the members of the family (Gyimesi et al., 
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2012)), it becomes apparent that there are no reported variants in any of these 
locations in other ABCA protein in the available literature.  
When specifically looking at variants which are in known functionally important areas 
of the ABCA7 protein, ten become apparent, available in Table 2.5. The majority of 
these are predicted to be damaging to the protein.  However, all apart from one of 
these are only present in the EVS database and may, therefore, not be real. Only one 
variant in this list, rs78320196 a synonymous mutation, is present in the NGS dataset. 
One variant - the novel one at co-ordinates 19:1061813 - is also included in Dr 
Medway’s list of potentially damaging variants. All of these variants have the 
potential to be extremely damaging to ABCA7’s function as a transporter if they are, 
in fact, genuine. Variants within these regions are known to cause disease in other 
ABC genes. For example, variants in the first Nucleotide Binding Domain (containing 
the first Walker A, B and ATP Signature Motifs) in the ABCA4 gene are known to 
cause Stargardt’s eye disease and in the CFTR gene (also known as ABCC7), Cystic 
Fibrosis (Sabirzhanova et al., 2015). The problem with the majority of these variants 
is that they are very rare with only two have a MAF of above 1%, implying that 
further analysis of these variants may be problematic. 
In relation to further functionally significant areas, recently a loss-of-function 
mutation in the ABCA1 gene was linked to low plasma levels of apoE and an 
increased risk of Alzheimer’s disease (Nordestgaard et al., 2015). The location of this 
mutation in the ABCA1 protein (N1800H) can be seen in Figure 2.7 (created 
following the same methodology as in Section 2.2.3) and, when compared to the 
location of variants shown in Figure 2.5, it can be seen that none of the variants of 
interest map to a similar region (the intracellular domain between transmembrane 
domains 10 and 11). However, the ABCA1 variant is very rare (seen in 1 in every 500 
individuals) and, when the full catalogue of variants (in Appendix A) is examined, 
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there are three variants within this intracellular domain which may, or may not, have 
the same loss-of-function affect as the N1800H ABCA1 variant. These three variants 
(19:1057946, rs141237099 and rs371036349) are also all very rare (all with a MAF of 
below 0.5%) and are all predicted to be damaging to the ABCA7 protein function. 
Therefore, these variants may prove to be potentially rare, loss-of-function mutations 
within ABCA7. However, sufficient power (i.e. increased patient samples) would be 
required in order to substantiate this hypothesis, something which is not achievable 
currently.  
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Figure 2.7 - 2D representation of ABCA1's structure within the cell membrane. 
 i  re     
2D representation of ABCA1’s structure within the cell membrane, created using  OPO2  www.sacs.ucsf.edu  OPO2   
and the transmembrane domain information retrieved from UniProt  http:  www.uniprot.org  - ID O 5477  and the 
three motifs as in Figure 2.5.  he variant highlighted in red can be seen in the intracellular region between the 
transmembrane domains 10 and 11.  his is reported to be a loss-of-function variant, increasing the risk for Alzheimer’s 
disease  Nordestgaard      , 2015 . However, none of the variants which have been highlighted in Figure 2.5 are in the 
equivalent region in the ABCA7 protein.  
rs1462 2 1  
N1 00H 
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In order to examine whether the final variants selected have an effect on the ABCA7 
protein, and therefore alter an individual’s risk of Late Onset Alzheimer’s disease, 
they must be first scrutinized to see if they have a putative association with disease. 
This will initially be done for the four variants in Table 2.4 (rs3752233, rs3752239, 
rs114782266 and rs59851484) as well as the novel variant 19:1056958 as these are all 
predicted to be damaging to the ABCA7 protein. If this genotyping does show an 
association of LOAD, functional experiments will then be designed in order to see the 
precise affect these variants do have.  
The variants in Table 2.5 and those present in the same intracellular domain as the 
loss-of-function ABCA1 variant would be investigated in an ideal world. However, 
with their frequency being as low as it is, a much bigger DNA bank then the one 
currently available would be necessary in order to perform any association tests with 
meaningful power. Furthermore, only one of the variants (rs78320196) has been seen 
in the NGS dataset and this is one of the few variants in this sub-catalogue which is 
not predicted to be damaging to protein function. This makes it increasingly unlikely 
(especially given their MAF) that any of these variants will be seen in the samples 
available to us. 
 
2.5  Conclusions 
In conclusion, the variants enumerated in Table 2.4 as well as 19: 1056958 from Table 
2.1 will be genotyped in both Late Onset Alzheimer’s disease cases and control 
samples in order to establish any potential association with disease.  
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3 Case-Control Genotyping of Putative 
Damaging ABCA7 Variants 
3.1 Introduction 
s shown in Chapter 2, there are five variants which, when analysed 
employing bioinformatic tools, have been shown to be potentially 
damaging to the function of the ABCA7 protein. Four of these variants 
(rs114782266, rs3792233, rs3792239 and rs59851484) are relatively common with all 
of them having a minor allele frequency (MAF) of 2% or more in the full contingency 
of databases examined, as well as being anticipated to be harmful to the protein 
function by at least one of the prediction tools used. The fact that these variants are all 
common increases the likelihood of power being achieved to detect any association 
with LOAD in the genotyping assays which will be carried out in this chapter.  
An additional variant is also predicted to be damaging to the ABCA7 protein: present 
at genomic position 19:1056958, this variant was highlighted in the Next Generation 
Sequencing (NGS) project performed in 2011. It is assumed to be much rarer than the 
previous variants mentioned as, not only is it novel and therefore not been catalogued 
previously, but it was also present only in one of the 96 samples which underwent 
NGS and even then in a heterozygous fashion. This would provide it with an 
estimated MAF of 0.663% (as calculated by the CRISP programme, employed to 
analyse the NGS data). However, it is also in a functionally important area of ABCA7 
– one of the transmembrane domains – and will therefore still be investigated further.  
A 
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In order to ascertain their association with disease, all of these variant will therefore 
be genotyped; both in cases (confirmed LOAD patients) and controls. This will 
inform as to whether the variants are more frequent in one of these two groups and 
may, therefore, cause a change in the ABCA7 protein which is associated with disease 
(if more frequent in the disease group) or protective against LOAD (if more frequent 
in the control group .  he samples used are part of the Alzheimer’s Research UK 
(ARUK) DNA Bank collected from a variety of centres (Belfast, Ireland; Bonn, 
Germany; Bristol; Leeds; Manchester; Nottingham; Southampton and Oxford, UK), 
all collected with ethical approval and consent of all individuals. All variants will be 
genotyped in 1984 samples (1013 case samples and 971 control samples). However, 
further samples are held of which stocks are low of (a total of 624 cases and 462 
controls from Bristol; Oxford and Southampton, UK) and will therefore only be used 
to genotype the rarer variant (19:1056958). For all samples, the following 
demographics are held: age of AD diagnosis (age of sampling is used for controls); 
sex; APOE allele status and the centre from which they were collected. These 
samples, having been extracted from brain and/or blood and stored at -80°C, are 
stored in 96-well plates at 20ng per well in a 2µl volume for use in genotyping assays. 
 In order to carry out the genotyping, Kompetitive Allele Specific Polymerase chain 
reaction (KASP
TM
, LGC Genomics, Middlesex, UK) assays were designed for each of 
the five variants. KASP
TM
 assays were utilised, as opposed to the more commonly 
used TaqMan® assays, as a result of comparison studies performed in this laboratory: 
contrasting the genotyping results achieved for both TaqMan® and KASP
TM 
assays 
for the same variant (Braae et al., 2014). The KASP
TM
 assay was shown, not only to 
be significantly cheaper to purchase and run, but also generated improved clustering 
of the genotype groups with fewer samples failing. This has also been repeated with 
other assays, including one of the assays discussed here: rs59851484. This was 
initially run as a TaqMan® assay by a student (Ahmed Alahmad). However, it failed 
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to distinguish the positive heterozygous and homozygous mutant controls as separate 
clusters. When a KASP
TM
 assay was designed instead, the clusters became much 
clearer and more distinguishable.  
The KASP
TM
 Genotyping system comprises of the KASP
TM
 Assay Mix and KASP
TM
 
Master Mix. Within the assay mix are two competitive allele specific forward primers 
and one common reverse primer. Incorporated into the two forward primers is one of 
two florescent resonance energy transfer (FRET) cassettes specific to either the FAM 
or HEX dye depending on which allele the primer is specific for. Within the KASP
 TM
 
master mix are the two FRET cassettes (FAM and HEX combined with a quencher 
molecule) as well as the reference dye (ROX), Taq polymerase, free nucleotides and a 
commercially optimised concentration of MgCl2 (0.2mM). During the thermocycle, 
the DNA under investigation is denatured and the forward primer relevant for its allele 
anneals. Upon the next denaturing step, the appropriate FRET cassette can then anneal 
to the DNA on the complementary sequence to the forward primer, causing the 
cassette to fluoresce at a specific frequency to the dye in question, allowing the 
genotype of each individual sample to be distinguished when read on a qPCR system. 
This methodology is summarised in Figure 3.1. 
All five assays were performed; four by students: rs3752239 and rs114782266 were 
carried out by Akili Mata, rs59851484 by Ahmed Alahmad and 19:1056958 by Sara 
Garin as part of their Masters projects. Their results will be presented as part of this 
chapter. 
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Figure 3.1 - Methodology of the KASP genotyping assay. 
Allele  A  specific forward primer 
Common reverse primer 
DNA denatured 
Elongation 
Signal generated by further 
B  KASP Master Mix 
Common reverse primer 
Allele  A  specific forward primer 
Allele  B  specific forward primer 
A  KASP Assay Mix 
C  DNA  emplate 
FRE  Cassette 
 allele specific  
 uencher 
 e e   
 i  re     
Methodology of the KASP M genotyping assays.  his is based on competitive allele-specific PCR. Components include the 
KASP M assay mix, containing two allele specific forward primers and one common reverse primer, and the KASP M master 
mix containing universal FRE  cassettes, one labelled with the FAM dye and one with the HEX dye. During PCR thermal 
cycling, the relevant allele-specific primer binds to the DNA template and elongates.  he primer also contains a tail sequence 
which corresponds to the FRE  cassette which, upon subsequent thermocycles, then becomes incorporated into the DNA 
sequence. As these are amplified, the FRE  cassette can bind to the sequence complimentary to this tail sequence, separating 
the dye from the quencher so it can therefore fluoresce.  In this example, allele B is not present so this florescent signal 
remains quenched. 
    
    
    
Common reverse primer 
Allele  A  specific forward primer 
    
  
  
Allele  A  specific 
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3.2 Materials & Methods 
3.2.1 Identification of Positive Controls 
Positive controls for all of the variants were required in order to ensure the genotyping 
assays were calling the genotypes correctly. Alongside No Template Controls (NTCs) 
these were used to clarify that the clusters within the genotyping assays were being 
formed accurately. A colleague (Dr Christopher Medway) developed a Perl script 
which imputed 1000Genomes and GWAS data of samples held by the lab, in order to 
identify samples which carried the heterozygous genotype for each of the variants, 
using the Genomes Phase 1 integrated variant set (v3) as a reference panel. This was 
performed for all four of the known variants. For the novel variant, the sample which 
was identified to carry the variant during the NGS study was used as the positive 
control. All of these samples were held as part of the ARUK DNA Bank with the 
exception of the samples for the variant rs59851484. Samples could not be identified 
within the ARUK DNA Bank which carried this variant so DNA was obtained from 
the Mayo Clinic, Jacksonville which had also genotyped and identified samples 
carrying this variation. The samples used, as well as the genotypes for the relevant 
variations and all demographics held for the samples, are shown in Table 3.1. All 
control samples (those with no clinical disease) were population controls that donated 
blood samples with a wide age range – from 38 to 100.  
Table 3.1 - Sample demographics of the samples used as controls in the genotyping assays. 
Table 3.1
Variant Ref./Alt. Sample ID Genotype Sex Centre of Origin Age at Death Age at Onset Disease Status ApoE Status
19:1056958 T/C M642 T C Female Manchester 66 NA Confirmed AD 3 3
rs3752239 A/C AD295 A C Female Belfast NA NA Confirmed AD 3 3
M544 A A Female Manchester 64 58 Confirmed EOAD 3 4
rs59851484 G/A 3356 A A Female Mayo, USA NA 86 Confirmed AD 3 2
11219 G A Female Mayo, USA NA 88 Confirmed AD 3 3
M134 G G Male Manchester NA 57 Probable EOAD 3 3
rs3752233 G/A AD111 G G Male Nottingham 88 NA Confirmed AD 3 3
M233 G A Male Manchester NA 58 Probable EOAD 2 3
rs114782266 G/A AD202 G G Female Nottingham 71 NA Confirmed AD 3 4
BN0636 G A Male Bonn, Germany NA NA Control 3 3
Sample demographics of the samples used as controls in genotyping assays. The variants the samples were used for are shown, as well as the 
major (Ref) and minor (Alt) alleles for each of these variants. The genotype assigned to each sample through Sanger sequencing is shown as 
well as all demographics held within the ARUK DNA database. The positive control samples used for the rs59851484 were acquired from the 
Mayo DNA bank (Jacksonville, USA), due to no positive controls being found in the ARUK DNA database. NA = data not available.
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3.2.2 Polymerase Chain Reaction Primer Design 
The positive controls identified above were Polymerase Chain Reaction (PCR) 
amplified and sequenced in order to ensure they did indeed carry the single nucleotide 
polymorphism (SNP) of interest. Primers were designed to include approximately 200 
base pairs (bp) both upstream and downstream of all the variants, resulting in an 
amplicon of at least 400bp for each assay. The sequences were obtained from UCSC 
Genome Browser (UCSC Genome Informatics Group, Santa Cruz, California, USA) 
and verified on the Ensembl Genome Browser (EBI, Cambridge, UK), release 74. 
These sequences were inputted into Primer3 (University of Tartu, Tartu, Estonia) to 
provide primer sequences. The UCSC in-silico PCR program (UCSC Genome 
Informatics Group) was used to ensure the specificity of the selected primers. The 
SNPcheck software (NGRL, Manchester, UK) was then used to check there were no 
SNPs in the primer binding sites. These were all performed in July 2014 and are 
shown in Table 3.2 along with the amplicon size achieved and the annealing 
temperature used during PCR. These primers will also be used to validate the 
genotypes called in the KASP™ Assays. 
Table 3.2 - Primer sequences used to amplify sample DNA to validate their genotypes for the variants of interest. Table 3.2
Primer Sequence
Amplicon Size 
(base pairs)
Annealing 
Temperature (°C)
ABCA7_novel_Forward CATCCTCATCCCACCAACCT
ABCA7_novel_Reverse TCAAGACTTTACCCAGGCCA
ABCA7_rs3752239_Forward GGCCTACTTCTCCCTCTACC
ABCA7_rs3752239_Reverse CACCCCTAGCTCAGCCTC
ABCA7_rs59581484_Forward GGTGACCCAGAGCTTCCTG
ABCA7_rs59581484_Reverse ACACAGCTTCCAGGTACCAG
ABCA7_rs3752233_Forward CAGTGCCTGTCCTTGGACA
ABCA7_rs3752233_Reverse TGGCTACCATACCACTGTTGA
ABCA7_rs114782266_Forward GGGGATGTGTTGGTGCTG
ABCA7_rs114782266_Reverse AGTAGGTGCCCAATAAAAGGTG
Table showing the primer sequences, amplicon size and annealing temperatures used for the PCR 
amplification of all variants.
299 62
494 58
421
425 61
65
370 62
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3.2.3 Polymerase Chain Reaction 
The amplification reactions for rs114782266, rs3792233 and 19: 1056958 consisted of 
1x Roche PCR Buffer (consists of 100mM Tris-HCl, 15mM MgCl2, 500mM KCl at a 
pH of 8.3 - Roche Diagnostics, Basel, Switzerland), 0.2mM dNTPs, 0.5pmol/µl of the 
relevant forward and reverse primers (designed previously), 1 unit (U) of Taq DNA 
Polymerase (Roche Diagnostics) and 10ng of the DNA before being made up to 30µl 
with dH2O. For the PCR involving the assay rs3752239, 1x of Q solution was also 
added (a DNA additive which modifies the melting behaviours of DNA in order to 
facilitate the amplification of problematic DNA regions, such as GC-rich areas, 
QIAGEN, Limburg, Netherlands).  For rs59851484, a hot start Taq was instead used 
as well as a different buffer (containing ammonium sulphate) in order to fluidise the 
DNA, increasing primer binding: 1x Fermentas Taq Buffer with (NH4)2SO4 (750mM 
Tris-HCl, 200mM (NH4)2SO4, pH 8.8 - Thermo Scientific, Pittsburgh, PA, USA), 
2mM MgCl2, 0.2mM dNTPs, 0.5pmol/µl of each primer, 1x Q solution and 2.5 units 
of Hot Start Taq (QIAGEN). The thermal cycles performed for each of the assays can 
be seen in Table 3.3. All were performed in a Veriti 96 Well Thermal Cycler (Applied 
Biosystems, Carlsberg, CA, USA). PCR products were examined by electrophoresis at 
80 volts (V) for 35 minutes in a 1% agarose gel (30ml 1x TAE buffer (40mM Tris, 
20mM acetic acid, and 1mM EDTA), 0.3g of peqGOLD Universal Agarose 
(PEQLAB, Wilmington, DE, USA) and 5μl ethidium bromide) in 1x TAE buffer 
alongside a 1kbp plus DNA ladder (Thermo Scientific). The electrophoresis gel was 
photographed under ultraviolet (UV) light to ensure only one product was present of 
the correct size.  
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3.2.4 Sanger Sequencing 
The PCR products were first purified using ExoSAP-IT (Affimetrix, Santa Clara, 
California, USA); Exonuclease I (ExoI) to remove primers and Shrimp Alkaline 
Phosphatase (SAP) to dephosphorylate excess dNTPs. This was done in a final 
volume of 7μl, containing 5μl of PCR product and 2µl of ExoSAP-IT. This reaction 
mix was incubated in the thermal cycler at 37C for 15 minutes followed by another 
15 minutes at 80°C to inactivate the enzymes. 
The sequencing reaction took place in a 10μl reaction volume consisting of 5µl of the 
ExoSAP product, 1x BigDye Terminator Sequencing Buffer (Applied Biosystems), 
2μl BigDye (contains DNA polymerase, deoxynuleotides and fluorescently labelled 
dNTPs), and 0.5pmol/μl forward primer. A thermal cycle was performed consisting of 
25 cycles of a denaturation step at 96°C for 30 seconds, an annealing step at 50°C for 
15 seconds and an extension step at 60°C for 4 minutes. This was performed in a 
Veriti 96 Well Thermal Cycler. 
The sequencing products were purified following the manufacturer’s protocol for the 
Performa DTR Gel Filtration Cartridges (EdgeBio, Gaithersburg, MD, USA): 
centrifuging the cartridges at 800 x g for 3 minutes before adding the Sanger 
sequencing products. The cartridges were again centrifuged at 800 x g for 3 minutes, 
filtering the products through the gel in order to remove unincorporated BigDye, 
dNTPs and salts. The elute was dried out at 90°C before being read by capillary 
electrophoresis on a 3130 Genetic Analyser (Applied Biosystems) provided by the 
Molecular Diagnostics Lab.  
The sequences were received as chromatogram files and analysed using the Chromas 
Lite software (Technelysium, South Brisbane, Australia), aligning the sequences with 
the reference sequence (obtained from UCSC when the primers were designed) using 
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the Clustal Omega online tool (EMBL-EBI, Wellcome Trust, Cambridge, UK). This 
aligned sequence was examined in order to elucidate their genotype for the variants of 
interest.  
3.2.5 KASPTM Assay Design 
The surrounding sequences for each of the variants (obtained from UCSC Genome 
Browser in July 2014) were submitted to LGC Genomics (Hoddesdon, UK) who 
designed and validated the allele specific primers. These primers, as well as version 
4.0 of the low ROX KASP
TM
 Master Mix, were then received from them. The 
sequences designed are shown in Table 3.4. 
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3.2.6 KASPTM Assays 
Each assay was performed initially with only 12 samples (including the previously 
identified positive controls and two NTCs). Each reaction contained 1x KASP™ 
Master Mix, 0.11µl KASP™ Primer mix and 20ng of each DNA sample. These were 
made up to 8µl with dH2O and then the following thermocycle was performed on a 
Veriti 96 Well Thermal Cycler: 15 minutes at 94°C for an initial incubation followed 
by 10 cycles of 94°C for 20 seconds, 65-55°C for 60 seconds (dropping 0.6°C every 
cycle) then 26 cycles of 94°C for 20 seconds and 55°C for 60 seconds before being 
held at 10°C. Each run could then be re-cycled (at 94°C for 10 seconds then 57°C for 
60 seconds) depending on how the genotype clusters appear when they are visualised.  
In order to visualise the clusters, the samples were read on a qPCR machine 
(Mx3000P, Stratagene, San Diego, California, USA) using the MxPro Software. An 
allele discrimination program was set up with all samples being set as “unknown 
genotype” with the exception of the N Cs which were set as such.  he fluorescent 
dyes were set as HEX (minor allele) and FAM (major allele) for bi-allelic 
discrimination and ROX as the internal control reference dye. The samples were read 
and then analysed in the Rn-post setting, generating a dual colour scatter plot. The 
allele clusters were set manually with the FAM axis displaying the major allele 
genotype and HEX the minor allele.   
Once the 12 initial samples had been run, they were also PCR amplified and Sanger 
sequenced, as described in Sections 3.2.3 and 3.2.4, in order to ensure the KASP™ 
assay distinguished the genotypes correctly. Once this was confirmed, 96-well assay 
plates were run. All assays were run on at least 1984 samples, as previously 
mentioned, as well as a subsequent 1086 samples being run for the variant at position 
19:1056958. All case samples had been diagnosed as probable or possible AD 
following the NINCDS-ADRDA or the CERAD guidelines. 
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3.2.7 Validation of Genotyping Results 
On average, approximately 3% of the samples genotyped were also PCR amplified 
and Sanger sequenced in order to validate the genotypes generated. This was 
performed utilising the conditions described previously in Sections 3.2.3 and 3.2.4. 
Generally samples which clustered closer to the positive control were sequenced (in 
order to validate their carrying a minor allele  as well as a “control” sample from the 
homozygous wild-type cluster.  
3.2.8 Statistical Analysis of Genotype Results 
Results from each genotyping assay were subsequently analysed using the command 
line program PLINK (Purcell et al., 2007), performing allelic association tests with 
both Fisher’s exact test and logistic regression analysis.  he latter also allows for 
covariate correction (in this case age, sex, centre of sample origin and APOE status). 
In order to analyse large datasets, PLINK accepts data in tab delimited file in the 
format of .map, .ped and .covar files. The .map files contain the details of all SNPs 
being analysed – a unique identifier (for example an rs number), the chromosome and 
base pair co-ordinates of the variant and the genetic distance specified in Morgans. 
The latter is set to zero in all cases described here as population separation was not 
being analysed. The .ped file contains the family ID and individual ID for all samples 
(these are identical in the population of samples utilised here), paternal and maternal 
ID (again, set to zero in all samples here as no family analysis was performed), sex (1 
was set to male, 2 was female), phenotype (1 was control samples, 2 was case 
samples) and the genotype of all variants listed in the corresponding .map file (where 
2 is the major allele and 1 is the minor allele so a 2 1 genotype would be heterozygote 
and 1 1 would be homozygous for the minor allele). For all of these fields an entry of 
0 or -9 meant the information was missing. The .covar file again contains the family 
and individual IDs, in order to map the samples to the ones contained in the .ped file, 
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as well as including the phenotype and sex using the same coding as previously 
described. Also included in this file were the centres the samples originate from (for 
coding used here see Table 3.5), age of AD diagnosis (in cases) or age of sampling (in 
controls) and number of ApoE4 alleles carried (0, 1 or 2 – established through two 
TaqMan® assays for variants rs429358 and rs7412, performed when the samples were 
first incorporated into the ARUK DNA Bank). Examples of all of these files can be 
seen in Figure 3.2. 
 
 
 
Table 3.5 - Coding used for geographical 
origin of samples used in the genotyping 
project. 
Code Centre
1 Bonn, Germany
2 Leeds, UK Table 3.5
3 Nottingham, UK
4 Manchester, UK
5 Belfast, Ireland
6 Oxford, UK
7 Southampton, UK
8 Mayo Clinic, USA
9 Bristol, UK
Table showing the codes used for the 
geographical origin of samples used in 
this genotyping project. This data is part 
of the .covar file (see Figure 3.2) in order 
to correct for sample origin. 
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Figure 3.2 - Examples of the file formats used to statistically analyse the 
genotyping results in PLINK. 
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.map, .ped and .covar files were therefore created for all of the variants before Fisher’s 
exact test and logistic regression analysis (both with and without the covariant 
correction) were performed on all data. The following commands were inputted into 
the command prompt in order to perform these respective tests: 
 plink --map mapfilename --ped pedfilename --fisher --allow-no-sex --ci 0.95 
 plink --map mapfilename --ped pedfilename --logistic --allow-no-sex --ci 0.95 
 plink --map mapfilename --ped pedfilename --covar covarfilename --logistic --allow-
no-sex   --ci 0.95 
The --allow-no-sex flag was also included, allowing the program to include in the 
analysis the individuals who were missing gender data. As this was a large number of 
individuals, this increased the power of the association tests. A command was also 
included (--ci) in order to include confidence intervals of 95% in the output. 
For the Fisher’s exact test a file entitled plink.assoc.fisher was generated as the output 
and for the logistic regression test, the output was a file entitled plink.assoc.logistic. 
These were then examined as text files in order to establish the association of each of 
the individual variants with LOAD.  
In order to increase power further (as the variants under investigation may not be as 
common as stated in databases) a further .ped file was obtained from colleagues in the 
Mayo Clinic, Jacksonville (Dr Christopher Medway and Professor Steven Younkin) 
who, as well as corroborating the bioinformatics approaches used here (see Chapter 2) 
also genotyped all of the variants (with the exception of 19:1056958) in their much 
larger cohort. This provided the genotypes of a further 7972 samples (4246 controls 
and 3726 cases). Statistical analysis was performed on just the Nottingham samples as 
well as a merged dataset using the command line prompts previously stated. 
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3.3 Results 
Positive controls for four out of the five assays were identified. These were confirmed 
through PCR amplification and Sanger sequencing. However, for one of the assays 
(rs59851484) a positive control within the DNA samples help in this lab could not be 
identified. Fortunately this variant had also been genotyped in the Mayo Clinic, 
Jacksonville by colleagues (Dr Christopher Medway and Professor Steven Younkin). 
Heterozygous and homozygous mutant positive controls were therefore obtained from 
them and confirmed again through Sanger sequencing.  
As the KASP™ assays were run; genotype plots were created by the MxPro Software 
for each 96 well plate. Examples of these plots, for the rs3752239 and 19:1056958 
variations, can be seen in Figures 3.3 and 3.4 respectively. The homozygous wildtype 
samples are highlighted on the FAM axis (blue circles), homozygous mutant samples 
on the HEX axis (red diamonds), heterozygous samples on the scale between the two 
(green squares) and no template controls or failed samples at the meeting of the two 
axis (yellow triangles). As can be seen, all assays provide clear, distinct clusters for 
the three genotypes. Samples which fail to amplify appear as a red cross (for example 
the samples clearly distinct from any genotype cluster in Figure 3.3) or within the 
NTC cluster. The total number of samples successfully genotyped for each assay is 
shown in Table 3.6. This also presents the success rate of each of the assays, showing 
that no more than a maximum 5.2% of samples failed in any of the assays. Most of 
these failures are presumed to be due to poor quality DNA as the majority of these 
samples also failed to amplify in PCR as shown in Figure 3.5 which demonstrates one 
of the PCRs performed to confirm the genotypes called by all of the five KASP™ 
assays. 
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Table 3.6 - Number of samples successfully genotyped for all varinats. 
Table 3.6
rs3752233 1933 97.53
rs3752239 1919 96.00
rs114782266 1937 97.20
rs59851484 1934 97.58
19:1056958 2912 94.82
Assay N
Success 
Rate (%)
Table showing the number of Nottingham samples successfully genotyped 
utilising the KASP™ assays  N . Success rate when compared to overall number 
of samples genotyped is also presented. As can be seen, all assay returned an 
impressive success rate, all being over 95% with the exception of 19:1056958. 
However, this is believed to be because this assay was run on extra plates which 
were known to contain poorer quality DNA.
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Figure 3.5 - Exmple of an agarose gel showing amplification of 
samples genotyped for rs3752233. 
 k p pl s la  er 
                                   AD    AD           AD    AD    
 k p pl s la  er 
       A           AD    AD    AD          T  A          
 i  re     
1% ethidium bromide stained agarose gel run at  0V for 45 minutes. Sample IDs for each 
lane are shown as well as the No  emplate Control  N C  and the 1kbp ladder they were 
run against.  hese samples were genotyped for the variant rs3752233 and were 
subsequently PCR amplified and Sanger sequenced in order to validate the genotypes 
called in the KASP™ assays.  Some of the samples  BN0424, AD041, BN1335, AD506 
and AD012  failed to amplify in these assays and were therefore PCR amplified to attempt 
to acquire a genotype. However, as can be seen here, they also failed to PCR, suggesting 
that the DNA for these samples was degraded.  he remaining samples all produced a band 
of the correct size  370bp , despite some staining faintly on the gel, and were Sanger 
sequenced to confirm the genotypes called in the KASP™ assays, demonstrating the high 
accuracy of this assay.  his was repeated for the other four variants also genotyped.  
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For rs3752239, 1919 samples were successfully genotyped with four homozygous 
mutant and 134 heterozygous samples being identified. The success rate of this 
genotyping assay was 96% and around 3% of samples were sequenced to verify the 
results, providing an accuracy of 97.7%. For rs114782266 1937 samples were 
genotyped with a 97.2% success rate, identifying one homozygous mutant sample and 
20 heterozygous samples. 2.7% of samples were sequenced in order to validate the 
results providing an accuracy of 92.3% for this genotyping assay. For rs3752233 1933 
samples were successfully genotyped giving a success rate of 97.53%. From these, 
144 heterozygous and five homozygous mutant samples were identified. For 
rs59851484 1934 samples were successfully genotyped but no minor alleles were 
found in either case or control samples. For the variant at genomic position 
19:1056958, 2912 samples were successfully genotyped. However there was a higher 
failure rate of 94.8% due to the poorer quality of the DNA of the extra samples 
genotyped for this variant. In total, five heterozygous samples were identified for this 
variation. 
The results outputted by PLINK can be seen in Tables 3.7-3.11. As can be seen, when 
the statistical tests are run only with “Nottingham” samples, none of the tests return 
significant results. However, when the American samples are merged with the 
Nottingham samples, a few of the statistical tests do return a p-value of less than 0.05. 
For rs375223 , both the Fisher’s exact and logistic regression test produce p-values  
< 0.05 - highlighted in red in Table 3.8. The odds ratios (OR) and confidence intervals 
(CIs) for these tests also reinforce these p-values (both OR = 0.86 (0.74-0.99)). In 
Table 3.10 it can be seen that, although no minor alleles for rs59851484 were found in 
the Nottingham samples whatsoever (hence the statistical tests on these samples 
returning a “NA” result - see Table 3.10), when this data is combined with the 
American samples, this variant appears to be associated with the phenotype. Both 
Fisher’s exact test and the logistic regression analysis result in p-values of less than 
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0.02 and 0.03 respectively. The odds ratios and confidence intervals also support this 
(both OR = 0.28 (0.09-0.83)). However, when these tests take into account covariates, 
these tentatively associated results do not withstand. Correction for multiple testing 
should also be considered. As five variants are being examined, a p-value of 0.01 
should be used to signify a significant result, therefore, none of these results withstand 
this correction. Also of interest in Table 3.11 is the difference of the minor allele 
frequency between cases (F_U) and controls (F_U) for the novel variant 19:1056958. 
Although this test is not significant there is a large difference in the MAFs between 
these two groups (MAF of 0.13% in cases and 0.04% in controls).  
      
 
 
Table 3.7 - Statistical results for the genotyping studies on variant rs3752233 outputted from PLINK. 
Table 3.7
Statistical Test Samples Used Covariates N(cases) N(controls) F_A F_U STAT P OR L95 U95
Fisher's Exact Nottingham - 1630 1403 0.03691 0.04184 - 0.4567 0.8775 0.6342 1.214
Fisher's Exact Nottingham & Mayo - 5356 5649 0.03717 0.04221 - 0.07718 0.876 0.7577 1.013
Logistic Regression Nottingham - 1630 1403 - - -0.7783 0.4364 0.8805 0.6392 1.213
ALL 1484 1338 - - 3.50E-17 1 1 0 inf
Phenotype 1484 1338 - - 0.03356 0.9732 2.61E+18 0 inf
Sex 1484 1338 - - 3.52E-16 1 1 0 inf
Age 1484 1338 - - 9.79E-16 1 1 3.74E-50 2.68E+49
Centre 1484 1338 - - 5.16E-17 1 1 1.87E-307 5.34E+306
ApoE4 Dosage 1484 1338 - - 6.36E-17 1 1 0 inf
Logistic Regression Nottingham & Mayo - 5356 5649 - - -1.79 0.07352 0.8758 0.7575 1.013
ALL 5208 5580 - - -0.05631 0.9551 0.0001466 5.14E-138 4.19E+129
Phenotype 5208 5580 - - 0.1221 0.9028 7.62E+29 0 inf
Sex 5208 5580 - - 0.04539 0.9638 1.70E+05 2.48E-221 1.17E+231
Age 5208 5580 - - -0.6962 0.4863 0.9137 0.7088 1.178
Centre 5208 5580 - - 0.06337 0.9495 59.29 8.59E-54 4.09E+56
ApoE4 Dosage 5208 5580 - - 1.364 0.1725 7.458 0.4157 133.8
Statistical results from the rests run on rs3752233 at genomic position 19:1045174. N = number of non-missing individuals used in analysis (for example, some may be 
removed from analysis due to incomplete covariant data), F_A = frequency of the minor allele in cases, F_U = frequency of minor allele in controls, STAT = coefficient t-
statistic (in Logistic Regression test), P = exact p -value or asymptomatic p -value for t-statistic (in logistic regression tests only), OR = Odds Ratio, L95 = Lower 95% 
Confidence Interval, U95 = Upper 95% Confidence Interval. As can be seen, none of these tests returned a p -value of < 0.05. 
Logistic Regression
Logistic Regression
Nottingham
Nottingham & Mayo
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Table 3.9 - Statistical results for the genotyping studies on variant rs114782266 outputted from PLINK. 
Table 3.9
Statistical Test Samples Used Covariates N(cases) N(controls) F_A F_U STAT P OR L95 U95
Fisher's Exact Nottingham - 1630 1403 0.004555 0.007376 - 0.2984 0.6157 0.2659 1.426
Fisher's Exact Nottingham & Mayo - 5356 5649 0.006786 0.007062 - 0.8623 0.9608 0.6833 1.351
Logistic Regression Nottingham - 1630 1403 - - -1.135 0.2563 0.614 0.2645 1.425
ALL 1484 1338 - - -7.74E-17 1 1 0 inf
Phenotype 1484 1338 - - 0.03354 0.9732 2.61E+18 0 inf
Sex 1484 1338 - - -2.61E-16 1 1 0 inf
Age 1484 1338 - - -6.63E-16 1 1 1.94E-50 5.16E+49
Centre 1484 1338 - - -2.08E-17 1 1 3.38E-307 2.96E+306
ApoE4 Dosage 1484 1338 - - -5.13E-17 1 1 0 inf
Logistic Regression Nottingham & Mayo - 5356 5649 - - -0.2311 0.8172 0.9605 0.6823 1.352
ALL 5208 5580 - - -0.03499 0.9721 0.0007856 9.75E-178 6.33E+170
Phenotype 5208 5580 - - 0.115 0.9085 2.88E+28 0 inf
Sex 5208 5580 - - 0.04463 0.9644 1.71E+05 2.61E-225 1.12E+235
Age 5208 5580 - - -0.6822 0.4951 0.9158 0.7113 1.179
Centre 5208 5580 - - 0.06482 0.9483 48.43 5.42E-50 4.33E+52
ApoE4 Dosage 5208 5580 - - 1.352 0.1764 7.453 0.4052 137.1
Statistical results from the rests run on rs114782266 at genomic position 19:1059057. N = number of non-missing individuals used in analysis (for example, some may be 
removed from analysis due to not having all of the covariant data present), F_A = frequency of the minor allele in cases, F_U = frequency of minor allele in controls, 
STAT = coefficient t-statistic (in Logistic Regression test), P = exact  p -value or asymptomatic p -value for t-statistic (in logistic regression tests only), OR = Odds 
Ratio, L95 = lower 95% Confidence Interval, U95 = upper 95% Confidence Interval. As can be seen, none of these tests returned a p -value of <0.05. 
Logistic Regression Nottingham
Logistic Regression Nottingham & Mayo
Table 3.8 - Statistical results for the genotyping studies on variant rs3752239 outputted from PLINK. 
Table 3.8
Statistical Test Samples Used Covariates N(cases) N(controls) F_A F_U STAT P OR L95 U95
Fisher's Exact Nottingham - 1630 1403 0.03347 0.04126 - 0.2325 0.8045 0.5755 1.125
Fisher's Exact Nottingham & Mayo - 5356 5649 0.03716 0.04302 - 0.04022 0.8584 0.7429 0.9919
Logistic Regression Nottingham - 1630 1403 - - -1.269 0.2045 0.8053 0.5764 1.125
ALL 1484 1338 - - 3.86E-15 1 1 0 inf
Phenotype 1484 1338 - - 0.03348 0.9733 2.61E+18 0 inf
Sex 1484 1338 - - -8.36E-17 1 1 0 inf
Age 1484 1338 - - -1.19E-16 1 1 3.39E-50 2.95E+49
Centre 1484 1338 - - 1.37E-16 1 1 3.00E-308 3.33E+307
ApoE4 Dosage 1484 1338 - - -2.19E-16 1 1 0 inf
Logistic Regression Nottingham & Mayo - 5356 5649 - - -2.069 0.03852 0.8585 0.743 0.992
ALL 5208 5580 - - -0.04154 0.9669 8.49E-05 6.60E-197 1.09E+188
Phenotype 5208 5580 - - 0.1203 0.9042 2.48E+29 0 inf
Sex 5208 5580 - - 0.04533 0.9638 1.70E+05 1.22E-221 2.37E+231
Age 5208 5580 - - -0.6873 0.4919 0.9151 0.7106 1.178
Centre 5208 5580 - - 0.06487 0.9483 52.87 4.59E-51 6.09E+53
ApoE4 Dosage 5208 5580 - - 1.356 0.1751 7.449 0.4087 135.8
Statistical results from the rests run on rs3752239 at genomic position 19:1047538. N = number of non-missing individuals used in analysis (for example, some may be 
removed from analysis due to not having all of the covariant data present), F_A = frequency of the minor allele in cases, F_U = frequency of minor allele in controls, 
STAT = coefficient t-statistic (in Logistic Regression test), P = exact p -value or asymptomatic p -value for t-statistic (in logistic regression tests only), OR = Odds Ratio, 
L95 = lower 95% Confidence Interval, U95 = upper 95% Confidence Interval. The tests returning a p -value  of 0.05 or less are highlighted in red although these results do 
not withstand correction for covariants or multiple testing.
Logistic Regression Nottingham
Logistic Regression Nottingham & Mayo
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Table 3.11 - Statistical results for the genotyping studies on variant at genomic position 19:1056958 outputted from 
PLINK. 
Table 3.10 - Statistical results for the genotyping studies on variant rs59851484 outputted from PLINK. 
Table 3.11
Statistical Test Samples Used Covariates N(cases) N(controls) F_A F_U STAT P OR L95 U95
Fisher's Exact Nottingham - 1630 1403 0.001293 0.000366 - 0.3797 3.533 0.3946 31.63
Logistic Regression Nottingham - 1630 1403 1 - 1.129 0.2589 3.536 0.3947 31.67
ALL 1484 1338 1 - 4.99E-14 1 1 0 inf
Phenotype 1484 1338 1 - 0.0416 0.9668 2.61E+18 0 inf
Sex 1484 1338 1 - -8.88E-16 1 1 0 inf
Age 1484 1338 1 - 3.13E-16 1 1 1.71E-41 5.86E+40
Centre 1484 1338 1 - -1.57E-15 1 1 1.64E-164 6.12E+163
ApoE4 Dosage 1484 1338 1 - 1.52E-15 1 1 0 inf
Logistic Regression Nottingham
Statistical results from the tests run on the variant at genomic position 19:1056958. N = number of non-missing individuals used in analysis (for example, some may be removed from 
analysis due to not having all of the covariant data present, F_A = frequency of the minor allele in cases, F_U = frequency of minor allele in controls, STAT = coefficient t-statistic (in 
Logistic Regression test), P = exact p -value or asymptomatic p -value for t-statistic (in logistic regression tests only), OR = Odds Ratio, L95 = lower 95% Confidence Interval, U95 = 
upper 95% Confidence Interval. For this variant there was no American cohort with which to merge the Nottingham genotyping data and, as can be seen, this did not return results with 
p -values of <0.05, likely due to rarity of the variant and the relatively small sample size. 
Table 3.10
Statistical Test Samples Used Covariates N(cases) N(controls) F_A F_U STAT P OR L95 U95
Fisher's Exact Nottingham 1630 1403 0 0 - NA NA NA NA
Fisher's Exact Nottingham & Mayo 5356 5649 0.0004284 0.001547 - 0.01394 0.2767 0.09247 0.8279
Logistic Regression Nottingham - 1630 1403 - - NA NA NA NA NA
ALL 1484 1338 - - NA NA NA NA NA
Phenotype 1484 1338 - - NA NA NA NA NA
Sex 1484 1338 - - NA NA NA NA NA
Age 1484 1338 - - NA NA NA NA NA
Centre 1484 1338 - - NA NA NA NA NA
ApoE4 Dosage 1484 1338 - - NA NA NA NA NA
Logistic Regression Nottingham & Mayo - 5356 5649 - - -2.299 0.02151 0.2764 0.09233 0.8273
ALL 5208 5580 - - -0.001635 0.9987 1.18E-06 0 inf
Phenotype 5208 5580 - - 0.1145 0.9088 9.01E+26 0 inf
Sex 5208 5580 - - 0.045 0.9641 1.70E+05 2.95E-223 9.74E+232
Age 5208 5580 - - -0.6856 0.493 0.9153 0.7106 1.179
Centre 5208 5580 - - 0.06457 0.9485 47.52 6.03E-50 3.74E+52
ApoE4 Dosage 5208 5580 - - 1.357 0.1749 7.546 0.4071 139.9
Statistical results from the rests run on rs59851484 at genomic position 19:1047337. N = number of non-missing individuals used in analysis (for example, some may be 
removed from analysis due to not having all of the covariant data present), F_A = frequency of the minor allele in cases, F_U = frequency of minor allele in controls, 
STAT = coefficient t-statistic (in Logistic Regression test), P = exact p -value or asymptomatic p -value for t-statistic (in logistic regression tests only), OR = Odds 
Ratio, L95 = lower 95% Confidence Interval, U95 = upper 95% Confidence Interval. As can be seen, no minor alleles for this variant were found in the Nottingham 
samples therefore all results return a "NA" result, although some of the combined data sets return a p -value of less then 0.05 and these are highlighted in red. 
However, as shown, these results do not withstand correction for covariants or multiple testing.
Logistic Regression Nottingham
Logistic Regression Nottingham & Mayo
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3.4 Discussion 
This chapter has examined the relationship between five variants, predicted to be 
damaging to the function of the ABCA7 protein, and the late onset Alzheimer’s 
disease phenotype. Despite three of the variants (rs3752239, rs59851484 and 
19:1056958) returning tentative results, none of the statistical tests performed 
survived correction for covariates or multiple testing. There was an extremely high 
success rate of genotyping these variants (all above 94%) and the failures among these 
are presumed to be due to poor quality DNA as the majority failed to amplify through 
PCR as well. The genotyping assays were also confirmed through Sanger sequencing 
a selection of these samples, confirming highly accurate genotyping assays. Sanger 
sequencing was utilised as it is still considered the gold standard of sequencing and 
therefore ascertaining genotypes (Wetterstrand, 2014). One caveat to this study was 
that all control samples used were population controls and therefore they may have 
gone onto developing AD after donation of their DNA. 
In order to ascertain the associations, two statistical tests were performed: Fishers 
exact test and Logistic Regression analysis. Fisher’s exact test is a straight forward 
association test whereas Logistic Regression analyses the dosage of the minor allele, 
not just the presence of it taking into account as to whether the individual is 
heterozygous or homozygous for this minor allele. The Logistic Regression test can 
also be corrected for covariates which, in this case were sex, age of diagnosis (in the 
case samples) or age of sampling (in the control samples), centre of origin (see Table 
3.5 for a list of these) and, most importantly in this phenotypic analysis, ApoE4 allele 
dosage. In terms of inheritance patterns, the majority of minor alleles seen were 
carried in as compound heterozygotes. Only rs37552233 and rs3752239 were seen in 
a homozygous manner, to be expected as these are the two commonest variants when 
looking at the MAFs in dbSNP and 1000Genomes. However, even then, only 15 and 
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16 samples respectively are seen carrying these variants in a homozygous pattern out 
of a total of 11,005 each. 
For rs3752233, there were no significant tests for the Nottingham cohort alone but 
when these samples were combined with the American cohort, this subsidised dataset 
did improve the p-value, dropping from approximately 0.46 to 0.08 in both the 
Fisher’s exact test and the Logistic Regression analysis.  he Fisher’s exact test also 
returns minor allele frequencies (MAFs) in both cases and controls and, for this 
variant, there was virtually no difference between the two; 3.69% in cases and 4.18% 
in controls. This marginally higher frequency in controls returns an odds ratio of 
below 1 (0.88 in both statistical tests performed), indicating a protective action of the 
minor allele of this variant if it did have an effect on phenotype, which seems unlikely 
given these insignificant results.  
The association tests performed on rs3752239, on the other hand, do return some 
results with p-values less than 0.05. Unsurprisingly none of these are from data sets 
only containing the Nottingham samples due to limited numbers, but both the Fisher’s 
exact and Logistic Regression tests return p-values of 0.04 when the American cohort 
of samples are also included in the analysis. Despite this significant test, there is not a 
large difference in MAFs between cases and controls, with Fisher’s exact test 
returning a MAF of 4.3% in controls and 3.7% in cases. The ORs for both statistical 
tests are 0.86, again implying a protective action of the minor allele (C). This 
protective result further increases doubt as to whether this result is meaningful due to 
ABCA7 returning risky ORs (>1) in all GWAS studies (see Table 1.2). However, the 
Fisher’s result does not withstand correction for multiple testing  due to five variants 
analysed, the p-value needs to be less than 0.01 to be considered significant, as per the 
Bonferroni correction). Likewise, the logistic regression effect disappears when the 
data is adjusted for known covariates. 
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When examining the results for rs114782266 from just the Nottingham samples, 
although not significant, there is a relatively large difference of MAFs between case 
and controls: 0.46% compared to 0.74%. These are both quite different to any MAF 
recorded in any of the databases examined in Chapter 2: an average of 2.8% across the 
four databases. However, when the MAFs in different populations are examined in the 
1000Genomes database  as opposed to the combined “All” option used in Chapter 2 , 
it can be seen that the frequency in European samples is a lot lower at only 1%. This is 
also apparent when the American samples are merged with the Nottingham samples, 
increasing the power but not the significance (the p-value goes from 0.30 to 0.86) as 
well as increasing the OR from 0.62 to 0.96. The difference in MAFs between the two 
groups is also almost eliminated - 0.68% in cases and 0.71% in controls - in the 
merged dataset. This contradiction could be explained by examining the differences in 
population MAFs. The MAF in African populations, according to the 1000Genomes 
database, is 10% which, given the nature of American ancestry, may explain the 
skewing of these results.  his effectively “nullifies” the apparent protective effect 
seen in analysis of just the British samples. However, studies looking at the effect of 
rare variants (<5%) in asthma have suggested that the association of these rare 
variants with complex disease are ethnic specific and therefore do not contribute to the 
“missing heritability” of complex diseases such as asthma and LOAD (Igartua et al., 
2015). Studies such as these, therefore, need to be more ethnicity focused and, in this 
particular case, the British sample size needs to be increased. Alternatively, if the data 
were available, the results could be adjusted for the population stratification to control 
for this potential confounder.   
The effect of ethnic dependant population substructure is also seen in rs59851484. 
The first obvious finding is that there are no minor alleles found at all in the British 
samples. This correlates with the findings relating to this variant shown in Figure 2.4 
where the minor allele was not found in any of the 1000Genome Phase 1 samples (and 
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therefore an LD score could not be calculated) and the fact that no positive control 
could be identified in our DNA bank. This suggested that this variant may be rarer 
than first thought, at least in certain populations. Again, looking at the MAF in 
different populations in the 1000Genomes Phase 3 data, even though the “All” MAF 
is 3%, the MAF in European, East and South Asian is all 0% (European/ American 
MAF is seen as 0.02% in EVS). It is the American and African MAFs which pulls the 
overall MAF up, with ethnic specific MAFs of 1% and 12% respectively. Despite the 
fact that the samples from the Mayo Clinic are labelled as “American,” there is likely 
to be cryptic African ancestry (including the controls as well as the cases) and a wide 
range of ancestry in American samples is known to skew genetic association tests 
(Campbell et al., 2005). This has likely artificially increased the MAFs in both groups 
in this test (0.04% in cases and 0.16% in controls). When analysing the merged 
dataset for rs5  514 4, there is a low OR utilising both Fisher’s exact and the 
Logistic Regression tests. In both the OR is around 0.276 and the CI is 0.09-0.83 
which, although quite a wide confidence interval, suggests a potential protective 
influence of the minor allele of this variant (A). However, data correction (for both 
multiple testing and covariates) suggests that in both tests the results are not 
significant. 
The analysis for rs59851484 has emphasised some of the limitations of this study. The 
first limitation has already been highlighted in that examining the cumulative MAF in 
databases such as 1000Genomes is not the most effective methodology, especially 
when there is such a major difference between populations. Such a large difference, as 
exhibited with rs59851484, may require different approaches when it comes to genetic 
testing. For example, this variant requires treating as a rare variant in British and 
European samples (where the MAF is close to 0%) but as a common variant in 
Africans (where the MAF is 12%). Not only was the small sample size of the British 
samples a problem but it highlighted how population stratification can create false 
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positive results within genetic association tests. In order to reduce the chances of this 
happening, family based studies need to be performed, matching samples based on 
ancestry as well as increasing sample sizes as a whole (Cardon and Palmer, 2003). 
Principal Component Analysis (PCA) can also be used in order to correct for this 
population substructure. PCA analyses the proportion of genetic variance and reduces 
it down to a single principal component. If this is large, then one can obtain a value as 
to the presence of population substructure that is present. This can then be used to 
correct for the population substructure in any disease association studies performed. 
However, whole genome data is required for any samples in order to perform PCA, 
something which was not available for these samples, both the Nottingham and the 
Mayo cohorts. 
Sample size was also an issue when testing the novel variant at genomic position 
19:1056958 although this was expected to be a problem due to its known low 
frequency. This variant was validated in the NGS data but still only had a MAF of 
0.66% in this cohort of samples. This, as well as the fact that there was no additional 
data from the Mayo Clinic with which to supplement our data, drastically reduced the 
power for this association study. Instead, approximately an extra 1000 samples were 
run in house in order to try and improve the power of this test. However, this was not 
successful in achieving a statistically significant test, categorizing this as purely an 
exploratory test. Although there is no imputation, association or LD data available for 
this variant due to its novelty, it is predicted to be functionally important; it is in a 
conserved region (the area from 19:1056903 to 19:1057085 is known to be highly 
conserved, encompassing this variant (Turton, 2014)) and functionally vital area 
(TMD 10) and is annotated as being probably damaging or deleterious. The fact that 
this variant codes for a Serine to Proline amino acid substitution also means it is likely 
to alter function as this specific deviation is known to produce kinks in alpha-helical 
structures, such as TMDs. This suggests they are not able to adopt the main-chain 
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confirmations seen in other amino acid chains, potentially altering the TMD this 
variant is located in and this modifying the pore ABCA7 forms in cellular membranes 
(Barnes, 2007).  
Despite the lack of power in this assay (a power of only 57.7% was achieved), the 
results are suggestive of an effect. The MAF in cases is three-fold higher than in 
controls  0.13% as opposed to 0.04%  and the Fisher’s exact test yields an OR of 
3.53, tentatively suggesting that this variant notably increases the risk of LOAD. 
However, the CI is extremely wide, ranging from 0.40 to 31.63, emphasising that this 
assay needs to be repeated in many more samples (thousands) in order to determine if 
this observation is accurate. At the beginning of this project, this variant was classed 
as “novel,” having been seen in our NGS data but none of the online datasets. 
However, it has now been identified in other studies and assigned an rs ID number: 
rs778244634. This is reported in the dbSNP as being part of the ExAC dataset and 
reports a MAF of 0.0008%, being seen in only one individual out of 60,706. However, 
it has not been validated as part of this study so any further information is not 
available.  
Due to the rarity of this variant, 2281 case-control matched pairs would be required in 
order to receive 75% power, 3360 in order to achieve 90% power. Single variant 
association tests, such as the ones performed in this chapter, frequently fail to detect 
rare variants purely due to their lower MAF. In order to make these kind of tests 
meaningful and worthwhile, variants of higher MAFs need to be focused on or DNA 
datasets need to be combined in order to obtain the power as a scientific community 
(Lord et al., 2014). However, rare variants still need to be investigated in some shape 
or form as they are known to contribute to the missing heritability of LOAD, mainly 
due to them being missed by high throughput genotyping techniques such as GWAS. 
For example, the TREM2 variant identified in 2013 through exome sequencing is an 
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example of this; a rare variant which contributes to this missing heritability (Guerreiro 
et al., 2013). Another way of obtaining the power required for association testing of 
rare variants is by “collapsing” them or aggregating several rare variants  for example, 
each with a MAF of ~0.01%)  in order to boost their association power. This panel of 
variants can then be genotyped in order to investigate their cumulative effect (S. Lee 
et al., 2014; Steinberg et al., 2015). The variants aggregated can be linked due to 
proximity (for example all within TMD 10) or functionality (for example within both 
TMDs 10 and 11 as these are the domains which identify substrates) (Bansal et al., 
2010; Zhang et al., 2006b). Although these methodologies are still difficult to 
implement due to limited samples available and complex bioinformatics required in 
order to interpret the results, they are going to be required increasingly in the future in 
order to complete the gaps currently present in the knowledge of the genetics of 
LOAD. 
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3.5 Conclusions 
In conclusion, despite the measures taken in Chapter 2, limiting the variants 
investigated to only ones of a minor allele frequency of above 1%, they still were not 
common enough to achieve power when genotyped in the test subjects for which 
DNA is held in this lab. Although the majority of the variants tested here had also 
been genotyped in an American cohort, merging the two datasets in order to increase 
the power often caused more complications, introducing population substructure into 
the samples, making statistical analysis of them problematic.   
Despite some of the data looking promising, that of rs59851484, rs3752239 and 
19:1056958 T>C specifically, none of the test results survived being corrected. They 
all need to be tested in larger datasets, specifically ones of European origin, to 
determine if there is an association with the LOAD phenotype before time is invested 
in investigating them functionally. 
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4 Minigene Splicing Assays 
4.1 Introduction 
plicing is a post-translational process whereby introns are removed from 
precursor messenger RNA (pre-mRNA) in order to form mature messenger 
RNA (mRNA) containing only the coding segments (exons). At first 
glance, having such a large proportion of the genome not coding for proteins (it is 
estimated that 95% of nuclear RNA is spliced out) appears remarkably wasteful and 
inefficient. However, introns do play a vital role in eukaryotic gene expression, 
enhancing their efficient expression by containing transcriptional enhancer elements, 
recruiting the machinery required for gene expression and, as discussed in further 
detail later, increasing the variety of the transcriptome through alternate splicing as 
well as offering “mutation buffering” (Elliott, 2010; Scotti and Swanson, 2015). In 
order to facilitate the elimination of these introns, protein complexes bind to 
conserved cis-sequences defining the intron-exon boundaries in the pre-mRNA 
sequence, forming the spliceosome complex. These cis-sequences comprise of the 
donor site  5’ end - GU in mRNA) and the acceptor site  3’ end - AG in mRNA), 
shown in detail in Figure 4.1, creating what is thought to be approximately 50% of the 
information defining splice sites (Wu and Hurst, 2015). There is also a branch site 
 typically 1  to 35 base pairs upstream from the 3’ site  characteristically consisting of 
a polypyrimidine tract leading to the branch point containing an adenine, again shown 
in Figure 4.1 (Taggart et al., 2012). During splicing, five small nuclear RNAs 
(snRNAs), complementary to the cis-sequences (U1, U2, U4, U5 and U6 - so called 
due to the high levels of the nucleotide uridine within their sequences), as well as 
between 50 and 100 other polypeptides, are recruited to the donor and acceptor sites. 
S 
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The 5’ and 3’ ends of the intron are subsequently brought together into close 
proximity, forming the spliceosome (Cartegni et al., 2003).  he 5’ sense strand is first 
cleaved when the -OH group of the branch point adenosine attacks the phosphodiester 
bond between the upstream exon and the intron. This forms a new bond between the 
5’ end of the intron and the branch point, creating a loop of mRNA or the “lariat 
intermediate.”  he 3’ -OH group of the upstream exon then attacks the phosphodiester 
bond between the downstream exon and the intron, releasing the lariat loop (which 
goes on to be rapidly degraded) and ligating the two exons together, forming the 
mature RNA, summarised in Figure 4.2 (Clancy, 2008; Elliott, 2010; Taggart et al., 
2012).  
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Figure 4.1 - cis-sequences vital to 
successful splicing. 
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Figure 4.2 - Three main steps involved in eukaryotic mRNA splicing. 
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Alternative splicing can be achieved by exon skipping, alternating the exon size or 
retaining introns into the mature mRNA product, creating different transcripts or 
altering the reading frames and, consequently, alternative protein isoforms (Elliott, 
2010). It is estimated that 90% of the protein coding genes in the human genome 
undergo alternative splicing, immensely increasing the transcriptome diversity 
through a variety of consequences, as shown in Figure 4.3 (Pan et al., 2008; Scotti and 
Swanson, 2015). This variety is especially important in complex tissues, for example 
the brain, where many alternative spliced isoforms are exhibited, both between areas 
of the brain as well as at different time points during development or along the 
neurological cell lineage (Kang et al., 2011; Vuong et al., 2016). Alternative splicing 
is regulated by cis- and trans-factors, silencing or activating the splice sites (Matlin et 
al., 2005). These modulation cis-acting enhancer regions occur in both exons and 
introns (ESEs and ISEs respectively) as do the silencer regions (ESSs and ISSs 
respectively - all demonstrated in Figure 4.1). Enhancer motifs are identified through 
the binding of serine arginine (SR) proteins, and snRNPs interact with the silencer 
sequences (Clancy, 2008; Pagani and Baralle, 2004). It is predominantly the 
concentration of these proteins which determine whether or not the exon is skipped, or 
included, in the final protein transcript by altering the spliceosome at these splice sites 
(Vuong et al., 2016). However, other factors may also play a role in alternative 
splicing; chromatin architecture, histone modifications and dephosphorylation of 
splicing factors are all examples of these (Matlin et al., 2005; Tilgner et al., 2012).  
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Figure 4.3 - Consequences of alternative splicing. 
Exon 
Intron 
Alternative Exon 
Alternative First Exon Alternative Last Exon 
Independent Cassette Exon Mutually Exclusive Cassette Exon 
Alternative 5’ Splice Site 
Alternative 3’ Splice Site 
Intron Retention 
 i  re     
 he consequences of the complex machinery involved in alternative splicing. 
Alternative first and last exons can be included, introns retained, a cassette exon 
included  either independently or in a mutually exclusive manner  as well as 
alternative 5’ and 3’ splice sites being present. Both cassette exon skipping and intron 
retention are frequent in humans and mammals.  hese patterns can be demonstrated 
through RNA-sequencing  RNA-seq . Adapted from Scotti and Swanson 2015 and 
Vuong       2016. 
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It has been estimated through computational predictions, comparative genomics and 
transcriptome profiling of both normal and diseased tissue that a surprisingly high 
fraction of pathogenic mutations are due to their effect on splicing (Singh and Cooper, 
2012). As such, approximately one in three mutations in the human genome are 
believed to go on to cause aberrant splicing, both somatic and hereditary, and, 
therefore, tight regulation is imperative. These mutations can alter transcription in 
several ways: they can cause loss-of-function by introducing a premature stop codon; 
cause an exon to be spliced out or an intron to be included; reduce the specificity of a 
splice site, varying its location by inserting or deleting amino acids or altering the 
reading frame; previously existing pseudo-splice sites can also be activated, altering 
the balance of splice isoforms or they can displace the splice site, creating longer or 
shorter exons than are coded for originally (Baralle and Baralle, 2005; Singh and 
Cooper, 2012). In addition, variants can also alter the secondary structure of the RNA, 
preventing the enhancer or silencer proteins from gaining proximity to their 
complementary sequences (Pagani and Baralle, 2004). Variants effecting splicing are 
commonly cis-acting, located in the core consensus sequences of the donor and 
acceptor sites, the branch point or the ESEs, ESSs, ISEs and ISSs. Any dysregulation 
of pre-mRNA splicing has the risk of causing pathogenesis although this can be used 
to a biological advantage. The introduction of a premature stop codon, for example, 
can act as an on-off switch for certain genes, such as the male-specific lethal 2 gene in 
female Drosophila (Smith and Valcárcel, 2000).  
Over 90% of synonymous variants known to be associated with disease are thought to 
be associated due to their impact on splicing (Wu and Hurst, 2015) and that splice site 
altering mutations, such as these, cause 15% of all human genetic diseases (Cooper 
and Mattox, 1997). Several variants within genes associated with LOAD have already 
been linked to alternative splicing. For example, MAPT (the gene coding for tau), 
PSEN1, PSEN2, PICALM and CD33 all have documented splice site variants which 
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have been associated with LOAD risk, all confirmed through RT-PCR of alternative 
splice isoforms from brain tissue samples, with the exception of the PICALM variant 
(Cruts and Van Broeckhoven, 1998; Donahue et al., 2006; Malik et al., 2013; Celeste 
Sassi et al., 2014; Sato et al., 1999; Schnetz-Boutaud et al., 2012). APP is also 
documented to have several different isoforms, the ratios of which can alter 
pathological risk  O’Brien and  ong, 2011 . Members of the ABC family have also 
had alternative splicing implicated in disease: two ABCA1 variants, both within 
intronic regions, result in the skipping of exon 7 and exon 32 and cause 
hyperalphalipoproteinaemia and premature coronary heart disease (Rhyne et al., 
2009). ABCA7 itself also has a splice site variant (c.5570+5 G>C, a loss-of-function 
variant  which significantly increases an individual’s risk of LOAD  OR   1. 7, p = 
5.3x10
-10
) when genotyped in 3,419 case and 151,805 control samples (Steinberg et 
al., 2015).  
All of these examples highlight how vital correct splicing is in order to prevent 
pathogenesis, including that of LOAD. In order to address this, during the NGS data 
analysis previously discussed in Chapter 2, the variants identified within the ABCA7 
gene were annotated by the Variant Effect Predictor (VEP) in order to infer if any of 
these variants may affect splicing. This program highlighted six variants which have 
the potential to alter splicing of the ABCA7 protein. However, the original annotation 
of the NGS data using VEP does have drawbacks. In its methodology, it examines the 
variants to see if they are within the first three bases of an exon or within the first 
eight bases of an intron. As seen previously, this does not include the entirety of the 
splicing machinery; spliceosome signals, the branch site, and possibly the enhancer 
and silencer regions are therefore not examined. However, high-throughput analysis 
of possible splicing variants is problematic with only 84% of splice site defects 
detected in silico and, of the ones which are detected in silico, only 50% of these are 
accurate due to splice site sequences being extremely short and degenerate (Houdayer 
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et al., 2008; Smith and Valcárcel, 2000). In an ideal situation, these predicted splice 
site variants would be examined in an in vivo environment with RNA being extracted 
from targeted brain regions and the whole spliceosome examined through RNA 
sequencing (RNA-seq) methodology in correlation with individual genomic 
background (Di Resta et al., 2014). However, this is unfeasible for a small number of 
variants, such as the ones presented here, due to the labour and cost. A commonly 
utilised alternative method for analysing the functional effect of these variants is a 
side-by-side analysis of the two alleles within a minigene assay. This involves cloning 
an insert containing the cis-element(s) of interest including the exon(s) and flanking 
intronic sequences into the Exontrap pET01 vector, specifically designed to examine 
the splicing machinery in eukaryotic cells, as it contains the conserved splice site 
sequences as seen in the human transcriptome. This cloned vector is then transfected 
in specific cell lines where it undergoes translation and the resulting RNA can be 
extracted and examined. This methodology is summarised in Figure 4.4. Minigene 
assays in theory allow for extremely long transcripts (thousands of nucleotides can be 
included in the genomic segment (Cooper, 2005)) to be cloned into cells and are 
relatively quick. In previous studies it has been shown to exhibit a 100% concordance 
with splice site altering variants previously classified using RT-PCR analysis on RNA 
from patient samples within the BRCA1 gene, demonstrating it to be an accurate in 
vitro representation (Steffensen et al., 2014).   
Figure 4.4 - Methodology behind the minigene assay. 
 i  re     
Methodology behind the minigene assay.  he exon s  of interest are inserted into the vector along 
with intronic flanking sequence. Once cloned into the Exontrap pE 01 vector, the insert and vector 
exons are flanked by 5’ and 3’ eukaryotic exonic sequences as well as a polyA tail resulting in the 
intronic sequences being removed through splicing.  his vector also contains the ampicillin 
resistance gene and bacterial eukaryotic enhancer sequences.  he expected product, after undergoing 
transcription within the cells it is transfected into, contains both vector and the inserted exons.  
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The six variants presented in Table 4.1 are those predicted by VEP as having an effect 
on the splicing of the ABCA7 protein. Further annotation of these variants is also 
presented; annotation by PolyPhen-2 has previously been discussed in Chapter 2 and 
predicts the functional effect of the minor allele; the level of conservation of the 
region, vital in the cis-sequences involved in splicing, is annotated by PhastCons; 
ESEfinder examines the binding sites for SR-proteins, and thus the locations of ESEs 
(Cartegni et al., 2003); the Berkeley Drosophila Genome Project (BDGP) annotates 
predicted donor and acceptor sites by examining the degree of base pair 
complementarity between the splice sites and snRNAs, forming the basis of “strong” 
and “weak” splice sites (Reese et al., 1997) and Human Splicing Finder examines 
several different aspects of the splicing machinery including the acceptor and donor 
sites, branch points, ESEs and ESSs (Desmet et al., 2009). All of these programs were 
accessed in March 2015. Only two variants are predicted to be damaging to the 
splicing process by all three of these prediction programs: 19:1054696 (G>C) and 
rs881768 (A>G). The remainder of these putative splicing SNPs will not be examined 
any further due to the predictions in at least one of the three programs (ESEFinder, 
BDGP and Human Splicing Finder) determining no difference between the major and 
minor alleles; a threshold which has been suggested for in silico tools such as these as 
part of this work (Clement et al., 2016).  
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Due to the variant at position 19:1054696 having already been investigated by a 
colleague (Dr James Turton, presented in his thesis (Turton, 2014)), this chapter will 
focus on the A>G variant rs881768 (MAF = 0.25). The in silico prediction for this 
variant is shown in Table 4.1 and pictorially in Figure 4.5. It suggests that the 
introduction of the minor allele G generates a new donor site at the beginning of exon 
32, as well strengthening the existing acceptor site (already weak with a score of 0.56 
in the major allele, increasing to 0.76 in the minor allele transcript). The novel donor 
site introduced is stronger than exon 32’s natural donor site, if only slightly  0.   
compared to 0.93). Although this is not a large difference, it may mean that this novel 
donor site, much further upstream, is utilised instead. This implies that the presence of 
this minor allele may result in the removal of all or the majority of exon 32, similar to 
one of the pathogenic variants reported in ABCA1, mentioned earlier (Rhyne et al., 
2009). A gene fragment, containing exon 32 and its surrounding introns and splicing 
machinery, will therefore be examined utilising the minigene system as previously 
described. In order to attempt to examine the transcripts expressed in the more natural 
neurological environment, RNA will also be extracted from brain tissue samples from 
individuals who are homozygous for both the major allele (A) and the minor allele 
(G), total cDNA will then be synthesised and PCR amplified in order to analysis the 
ABCA7 mRNA present neurologically. This will provide insights as to whether the 
transcripts expressed by both of these genotypes differ in vivo or not.  
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Figure 4.5 - In silico predictions of the splicing variant rs881768 in 
exon 32 of the ABCA7 gene. 
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4.2 Materials & Methods - Minigene Assay 
4.2.1 Primer Design 
Primers were designed to include exon 32 of ABCA7, and its flanking introns, from 
genomic DNA as previously described in Section 3.2.1. The primers were designed so 
that the sense primer contained the digestion site for the restriction enzyme SalI and 
the antisense primer contained the digestion site for XbaI. This was to ensure the 
insert could be digested out of and ligated into vectors. Webcutter 2.0 (Yale 
University, New Haven, CT, USA) was used to confirm that the digestion sites for the 
two enzymes only occurred within the primers themselves within the inserts. The 
manufacturer’s protocols for the vectors to be used were also examined to ensure there 
were no digestion sites within the vectors themselves, other than those present in the 
multiple cloning site. 
4.2.2 Polymerase Chain Reaction 
A selection of heterozygous samples for rs881768, as well as samples containing the 
major and minor alleles were identified through a Perl script written by a college (Dr 
Christopher Medway, personal communication), imputing the genotype of this variant 
from known genotypes in these samples. These samples were held as part of the 
ARUK DNA bank and all samples had been collected with ethical approval and with 
consent of all individuals. The relevant samples were PCR amplified and sequenced in 
order to validate their sequence as well as ensuring that they did not contain any other 
SNPs in the region.  
A high fidelity Taq DNA polymerase was used in order to avoid introducing 
nucleotide substitutions. Amplification was performed on predicted heterozygous 
samples in a 30μl reaction volume and consisted of 1x Fermentas Taq Buffer with 
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(NH4)2SO4 (750mM Tris-HCl, 200mM (NH4)2SO4, 0.1% Tween 20 and 20mM MgCl2 
- Thermo Scientific, Pittsburgh, PA, USA), 2mM MgCl2, 0.2mM dNTPs, 0.25pmol/μl 
of the sense and antisense primers designed as above (see Table 4.2), 2.5U Expand 
High Fidelity Taq (Roche, Burgess Hill, UK) and 50ng DNA template (the samples 
identified as above). PCR was performed using a Veriti 96 Well Thermal Cycler 
(Applied Biosystems, Carlsberg, CA, USA). The thermal cycle was programmed for 2 
minutes at 94°C for initial denaturation, followed by 10 cycles of 15 seconds at 94°C 
for denaturation, 30 seconds at 62°C for annealing and 40 seconds at 72°C for 
extension. A further 20 cycles were performed, identical to the previous cycles, but 
extending the extension step by 5 seconds every cycle before a final extension step 
was then performed at 72°C for 7 minutes. PCR products were examined by 
electrophoresis at 80V for 35 minutes on a 1% agarose gel (30ml 1x TAE buffer, 0.3g 
of peqGOLD Universal Agarose (PEQLAB, Wilmington, DE, USA) and 5μl ethidium 
bromide) in 1x TAE buffer alongside a 1kbp DNA ladder (Thermo Scientific). The 
electrophoresis gel was photographed under UV light.  
 
 
 
Table 4.2- Primers used in the splicing assay. 
Table 4.2
Primer Sequence
rs881768_Forward TGGGGTgtcgac CCCCAGTTCCACTCCCATG
rs881768_Reverse GCCACCtctaga TGCCAGCCTTTGTTGTTGAA
M13_Forward GTAAAACGACGGCCAG
M13_Reverse CAGGAAACAGCTATGAC
pET01_Forward GATCGATCCGCTTCCTG
pET01_Reverse CACTGGAGGTGGCCCG
Exon32_Forward GGCTCTGGGGAAGTGGTTC
Exon32_Reverse GGTTGAGTGTGGTGATGCTG
Sequences of all primers used in this splicing assay. For primer 
rs881768_Forward the digestion site of restriction enzyme SalI  is shown in 
bold and for the primer rs881768_Reverse the digestion site for enzyme 
XbaI  is shown in bold. 
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4.2.3 Sanger Sequencing 
The PCR products were first purified using ExoSAP-IT (Affymetrix; Exonuclease I 
(ExoI) to remove excess primers and Shrimp Alkaline Phosphatase (SAP) to 
dephosphorylate excess dNTPs) This was performed at a ratio of 5μl of PCR product 
to 2µl of ExoSAP-IT. The reaction mix was incubated in the thermal cycler at 37C 
for 15 minutes followed by another 15 minutes at 80°C to inactivate the enzymes. 
The Sanger sequencing reaction took place in a 10μl reaction volume as described in 
Section 3.2.4 with the exception of the rs881768_Forward primer being used at a 
concentration of 0.5pmol/µl. The sequencing products were purified following the 
manufacturer’s protocol of the Performa D R Gel Filtration Cartridges as per Section 
3.2.4 (EdgeBio, Gaithersburg, MD, USA) before being read by capillary 
electrophoresis on a 3130 Genetic Analyser (Applied Biosystems) provided by the 
Molecular Diagnostics Lab.  
4.2.4 Sequence Alignment 
The sequences were received as chromatogram files and analysed using the Chromas 
Lite software (Technelysium, South Brisbane, Australia). The sequence was converted 
into FASTA format and then inputted into the ClustalW2 online program (EMBL-
EBI, Cambridge, UK) along with the reference sequence obtained from Ensembl, 
transcript ENST000000263094 (obtained in January 2014) in order to align the two 
sequences. One sample (AD115) was selected which was heterozygote for rs881768 
whilst matching the remainder of the reference sequence completely. Demographics 
available for this sample (as part of the ARUK DNA database) are shown in Table 
4.3.  
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4.2.5 Cloning of the PCR Products 
The selected sample was then inserted into the pCR©2.1-TOPO vector following the 
protocol of the TOPO TA Cloning kit, chemical transformation pathway (Invitrogen, 
Carlsbad, CA, USA). 0.5µl of fresh PCR product from Section 4.2.2 was combined 
with 1µl of the salt solution provided and 1µl of the TOPO vector before being made 
up to 5µl with dH2O. The products were transformed into the cells immediately and 
the remainder stored at -20°C.  
4.2.6 Transformation 
The cloned products were transformed into One Shot© TOP10 E. coli cells again 
following the TOPO TA Cloning kit protocol. One vial of the TOP10 cells was 
defrosted on ice before 2µl of the TA clone was added. This was incubated on ice for 
15 minutes before being heat shocked at 42°C for 30 seconds. The cells were 
incubated on ice for 2 minutes before 250µl of warmed SOC media (Super Optimal 
Broth with Catabolite repression - Invitrogen) was added and the mixture shaken 
horizontally (250rpm) at 37°C for one hour.  
10µl and 50µl of the cells were incubated on plates containing Circlegrow® bacterial 
growth media (4% – MP Biomedicals, Santa Ana, California, USA), agarose (1.5%), 
ampicillin (0.1%) and X-gal (1.6mg per plate – Fisher Scientific, Waltham, MA, 
USA), made up to 100µl with SOC media.  
Table 4.3 - Sample demographics of the sample used in this splicing assay. 
Table 4.3
Sample ID Sex Centre of Origin Age at Death Age at Onset Disease Status ApoE Status
AD115 Female Nottingham 94 NA Confirmed AD 2 4
Sample demographics of the sample used to create the constructs for this minigene assay. This sample is heterozygous 
for the variant rs881768 (genotype A/G). The individual this DNA was obtained from was female and 94 when she died 
and AD was confirmed as part of a post mortem. The age of onset of the disease is unknown (NA), however, it is 
known that she carried one ε2 and one ε4 allele of the ApoE gene. 
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4.2.7 Plasmid DNA Extraction 
Positive colonies, ones containing the cloned vector, were coloured white. This was 
due to the inserted genomic region interrupting the β-galactosidase gene in the vector, 
inhibiting its production. When this protein is produced, it hydrolyses the X-gal to 
form a blue pigment, highlighting the colonies containing the vector without the 
insert. The positive, white colonies were, therefore, incubated in 5ml of liquid media 
(identical to the media used in Section 4.2.6 with the exception of agarose being 
omitted) for a further 18 hours at 37°C, shaking horizontally at 250rpm before their 
plasmid DNA was extracted following the PureYield Plasmid Miniprep System 
protocol (Promega, Southampton, UK). 3ml of this liquid media was centrifuged at 
maximum speed in order to pellet the bacterial cells. This cell pellet was resuspended 
in 600µl of dH2O before 100µl of Cell Lysis Buffer was added. The tubes were mixed 
well to allow complete lysis of the cells before being deactivated with 350µl of chilled 
Neutralization Solution and mixed well. Samples were then centrifuged for 3 minutes 
at maximum speed in order to pellet the cell debris. The supernatant was transferred to 
a PureYield Minicolumn and placed in a PureYield Collection tube. This was 
centrifuged at maximum speed for 15 seconds to anneal the plasmid DNA to the 
column, with the flow through being discarded. The column was then washed with 
200µl of Endotoxin Removal Wash and 400µl of Column Wash, being centrifuged 
under the same conditions as previously for both wash steps. The elute was discarded 
and the columns transferred to fresh 1.5ml tubes. 30µl of the Elution Buffer was 
added to the column and incubated at room temperature for 1 minute before being 
centrifuged at maximum speed for 30 seconds to elute the plasmid DNA. The plasmid 
DNA concentration was then determined using the Nanodrop 1000 Spectrophotometer 
(Thermo Scientific) as per manufacturer’s protocol.  
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4.2.8 Sanger Sequencing 
The plasmid DNA was sequenced following the protocol for the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems) using the M13_Forward primer (see 
Table 4.2 for sequence – binds to the vector region ahead of the insert). The 
sequencing reaction took place as previously described in Sections 3.2.4 and 4.2.3, 
utilising 150-300ng of plasmid DNA and 0.5pmol/μl M13_Forward primer. A thermal 
cycle was performed and the sequencing product purified as mentioned above. The 
sequence was then aligned in order to identify colonies containing the major and 
minor alleles but no other variations from the reference sequence. 
4.2.9 Restriction Enzyme Digest 
Digestion of the two plasmid DNA samples was performed in a 20μl reaction volume 
consisting of 1000ng of the plasmid DNA, 1x FastDigest Green Buffer (Fermentas, 
Vilnius, Lithuania), 0.05U μl of SalI and 0.05U μl of XbaI.  
Another digestion reaction was set up with the pET01 vector, a vector which is 
specifically designed to assess splicing activity. This reaction took place in a 50μl 
volume containing 5000ng of the vector, 1x FastDigest Green Buffer, 0.03U μl of 
SalI, 0.03U μl of XbaI and 0.04U μl of FastAP Alkaline Phosphatase in order to 
remove the 5’ phosphate groups at the ends of the digested vector to prevent it from 
self-ligating (Thermo Scientific). 
A thermal cycle was performed on a TRIO-Thermoblock (Biometra, Göttingen, 
Germany). The thermal cycle programmed consisted of 37°C for 30 minutes to digest 
the product and 65°C for 20 minutes to inactivate the enzymes. The products – as well 
as undigested plasmids as a comparator - were then examined by electrophoresis at 
80V for 25 minutes on a 1% agarose gel, containing 4μl SYBR Safe (Life 
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Technologies, Carlsbad, CA, USA) alongside a 1kbp DNA ladder (Thermo Fisher 
Scientific, Massachusetts, USA). This was examined under a DarkReader 
Transilluminator (Clare Chemical Research, Dolores, CO, USA). 
4.2.10 Gel Extraction 
The two inserts and the linearized, dephosphorylated vector were extracted from the 
SYBR Safe gel following the protocol of the QIAquick Gel Extraction Kit (QIAGEN, 
Hilden, Germany). All bands of the correct size were excised from the gel using a 
sharp scalpel under the DarkReader and placed in 1.5ml tubes. The weight of the 
agarose slices were calculated before three volumes of QG buffer was added per gel 
volume. The gel was melted by incubating the tubes at 50°C, vortexing every few 
minutes, until the gel was completely dissolved. The pH was corrected by the addition 
of 3M sodium acetate, if indicated by the pH indicator within the buffer, before 1 gel 
volume of isopropanol was added and mixed. This was then added to a QIAquick 
column and centrifuged at maximum speed for 1 minute to anneal the DNA to the 
column, before a further 0.5ml of QG buffer was added and centrifuged again, 
removing the flow through, in order to remove all traces of agarose. 0.75ml of the PE 
wash buffer was added and again centrifuged for a further 2 minutes. The columns 
were then transferred to fresh 1.5ml tubes and 30µl of EB elution buffer was added, 
incubating for 1 minute at room temperature to disassociate the DNA from the column 
before centrifuging at maximum speed for 1 minute to elute the DNA. The 
concentration of the products was determined using the Nanodrop 1000 
Spectrophotometer (Thermo Scientific) before being stored at -20°C. 
4.2.11 Ligation 
The inserts and the vector were ligated together following the protocol of the T4 DNA 
Ligase Kit (Invitrogen). A vector ligated to itself was also created as a control for the 
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ligation reaction. 100ng of vector was ligated to each of the inserts. The following 
equation was used to calculate the amount of insert needed: 
100𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 𝑋 665𝑏𝑝 𝑖𝑛𝑠𝑒𝑟𝑡 𝑠𝑖𝑧𝑒
4461𝑏𝑝 𝑣𝑒𝑐𝑡𝑜𝑟 𝑠𝑖𝑧𝑒
 𝑋 3 = 44.7𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 
The reaction itself took place in a 20μl reaction volume consisting of 100ng of vector, 
44.7ng of insert (not required in the control reaction), 1x T4 DNA Ligase Buffer and 
0.05U μl of T4 DNA ligase. This was incubated at room temperature for 1 hour. 
4.2.12 Transformation 
The ligation products (including the vector ligated to itself) were transformed 
separately into the NEB High Efficiency 5-alpha chemically competent E. coli cells 
C2987I (New England BioLabs, Ipswich, MA, USA) by adding 2μl of each of the 
ligation products to 50μl of these cells.  hey were incubated on ice for 30 minutes 
before being heat shocked at 42°C for 30 seconds.  hey were then incubated in  50μl 
of SOC media at 37°C for 1 hour, horizontally shaking at 250rpm. 
Two plates were created for each transformation product; one containing 50µl (made 
up to 100µl with SOC media) and one containing 100µl of the cells and all were 
incubated at 37°C overnight. The plates were identical to the ones used previously 
(see Section 4.2.6) with the exception of X-gal which was omitted. The plates 
containing the cells transformed with the vector ligated to itself act as a control. These 
plates produced considerably fewer colonies than those containing the insert, showing 
that the transformation and ligation reactions had been performed successfully. 
Colonies from each of the plates containing the inserts (one containing the major and 
one the minor allele) were then selected and incubated in 25ml of media (consisting of 
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4% Circlegrow® and 0.1% of ampicillin) at 37°C for 18 hours, horizontally shacking 
at 250rpm. 
4.2.13 Endotoxin Free Plasmid DNA Extraction 
The plasmid DNA was extracted from these colonies following the protocol for the 
NucleoBond Xtra Midi Plus EF Kit (Fisher Scientific). The bacteria were pelleted by 
centrifuging the full 25ml of liquid culture at 6000 x g for 15 minutes before 
resuspending the pellet in 4ml of the Resuspension Buffer. 4ml of the Lysis Buffer 
was then added and the tubes inverted before incubating for 5 minutes at room 
temperature in order to lyse the cells completely. 4ml of the Neutralization Buffer was 
added and, again, the tubes inverted in order to terminate the lysing. The mixture was 
transferred to the NucleobondXtra Midi Columns which, prior to, had been hydrated 
with 15ml of Equilibration Buffer. The cell mixture was filtered through these, 
discarding the flow-through, before washing the columns with three different wash 
buffers (FIL-EU (5ml), ENDO-EF (35ml) and WASH-EF (15ml)) in turn. The 
columns were then transferred to fresh 50ml tubes and 5ml of Elution Buffer was 
added and filtered through the columns in order to elute the DNA. The DNA was 
precipitated by the addition of 3.5ml of room temperature isopropanol, vortexing well, 
before centrifuging at 4°C, 6000 x g for 90 minutes. The supernatant was removed 
and the pellet washed with the addition of 3ml of endotoxin-free 70% ethanol, 
centrifuging again at 4°C, 6000 x g for 20 minutes. The pellet was air-dried for 10 
minutes before being resuspended in 100µl of endotoxin-free TE buffer (10mM Tris, 
1mM EDTA) overnight at 4°C. The concentrations were then determined using the 
Nanodrop spectrophotometer. The samples were sequenced to ensure consistency 
following the BigDye Terminator v3.1 Cycle Sequencing Kit protocol as before (see 
Section 3.2.4) except the primer pET01_Forward was used (see Table 4.2). 
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4.2.14 Glycerol Stocks 
All colonies confirmed to contain the vectors expected, in both Sections 4.2.8 and 
4.2.13, had glycerol stocks made of them in order to prevent having to retransform the 
plasmid if more DNA was necessary. This was done by combining 200µl of the liquid 
culture with 800µl of glycerol in a 1.5ml tube. This was labelled well and stored at  
-80°C long term.  
4.2.15 Culturing Cells 
COS-7 cells are monkey African green kidney cells and were obtained from the 
European Collection of Cell Cultures. These cells are known to represent accurately 
the eukaryotic splicing environment, containing a complex spliceosome, as is seen in 
vivo. COS-7 were cultured in Dulbecco’s Modified Eagle Medium  DMEM  with 
10% foetal bovine solution (FBS), 2mM L-Glutamine, 100U/ml penicillin-
streptomycin (Sigma, St Louis, Missouri, USA) and 100U/ml fungizone (Gibco, 
Walton, MA, USA) to prevent bacterial and fungal contamination.  
BE(2)-C cells are neuroblastoma cells and were therefore cultured to examine the 
splicing products under a neurological specific spliceosome, linking these results to 
the location of LOAD pathology and to demonstrate reproducibility. These were 
cultured in a 1:1 ratio of Eagle’s Minimal Essential Medium  EMEM  to Ham’s F12 
with 1% non-essential amino acids, 2mM Glutamine, 15% FBS, 100U/ml penicillin-
streptomycin (all Sigma) and 100U/ml fungizone (Gibco). 
All cell work (including transfections and RNA extractions) was performed in a 
category II biological cabinet in order to reduce the risk of contamination (Labcard 
Class II Biological Safety Cabinet, Triple Red, Long Crendon, UK). All media and 
additives used were pre-warmed to 37°C in a water bath before use, in order to 
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prevent shocking the cells, and all were filtered through 0.22µm sterile filters prior to 
use. Cells were maintained in 75cm
2
 Corning Tissue Culture flasks (Corning, New 
York, USA) in 13ml of their respective media in an incubator set at 37°C with a 
humidified atmosphere of 5% CO2 in air (ICNFlow Automatic CO2 Incubator Model 
106, Thermo Scientific). Once they reached ~90% confluence they were passaged by 
removing the old media, washing the adhered cells with 10ml of Phosphate-buffered 
Saline (PBS - Sigma) and incubating for 5-10 minutes in the incubator with 3ml of 
trypsin (Sigma) in order to digest the adherent proteins which attach the cells to the 
base of the flask. Once the cells were microscopically free from the flask base, they 
were re-pipetted with 3ml of their respective media in order to deactivate the trypsin 
enzyme and split between two flasks.  
In order to create stocks of all cells, once they were trypsinised and re-pipetted, they 
were transferred to a 15ml tube and centrifuged at 300 x g for 15 minutes. These cells 
were then re-suspended in 6ml of 90% FBS and 10% dimethylsulfoxide (DMSO - a 
cyroprotective agent) and 1ml was transferred to 2ml screw topped tubes. These were 
stored at -80°C for at least 24 hours in a CoolCell© LX (BioCision, Larkspur, CA, 
USA) to delay the cooling process (cooled by 1°C per minute) in order to reduce the 
amount of ice crystals formed. They were then removed from the CoolCell© and 
stored in liquid nitrogen indefinitely. Upon removal of the cells from the liquid 
nitrogen store, they were kept on dry ice before being defrosted in a water bath 
warmed to 37°C. The cells were then transferred to a 25cm
2
 Corning Tissue Culture 
flask containing 5ml of the respective media, warmed to 37°C. This flask was 
incubated until the cells were ~90% confluent upon which they were transferred to a 
75cm
2
 flask using 3.5ml of PBS and 1.5ml of trypsin, following the methodology 
previously described. They were again incubated until ~90% confluent before being 
passaged as above, replacing the media if necessary. 
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4.2.16 Transfection  
COS-7 cells were transferred to 60mm plates at a concentration of 3.5 x 10
5
 cells per 
plate and BE(2)-C at a concentration of 6 x 10
5 
cells per plate and incubated for 24 
hours before the two DNA samples were transfected into both cell lines following the 
TransFact protocol (Promega). TransFact is a lipid reagent which creates lipid vesicles 
around the DNA, delivering it into eukaryotic cells. 
9μl of TransFact (9nl of TransFact per 1ng of DNA), 1000ng of plasmid DNA and 
2ml of serum-free media were incubated at room temperature for 15 minutes. The 
media was then removed from the plates of cells and the TransFact mixture was 
added. These were incubated at 37°C, 5% CO2 for 1 hour before a further 4ml of 
complete media (either DMEM or EMEM:F12 depending on the cell line) was added 
to the plates. These were then incubated for a further 24 hours.  
4.2.17 RNA Extraction 
Total RNA was extracted from the COS-7 and BE(2)-C cells following the RNeasy 
Mini Kit protocol (QIAGEN). The cells were first trypsinised as previously described, 
washing them with warmed PBS before releasing them from the plates with 1.5ml of 
trypsin per dish. The cells were transferred to 15ml tubes and pelleted by centrifuging 
at 300 x g for 5 minutes. They were resuspended in 600µl of RLT Buffer and 6µl of β-
Mercaptoethanol in order to lyse the cells as well as reduce RNase activity by 
reducing its’ disulphide bonds. The cells were homogenised by passing them at least 
10 times through a 20-guage needle fitted to a sterile 10ml syringe before the addition 
of 600µl of 70% ethanol (in order to remove salts), mixed and transferred to the 
RNeasy Mini Column. The columns were centrifuged at 10,000 x g for 30 seconds 
and the flow through discarded, in order to anneal the total RNA to the column. The 
column was washed with 350µl of the RW1 buffer before an additional DNase step 
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was performed in order to ensure complete removal of genomic DNA. This was 
achieved by the addition of 1U of RNase free DNase I diluted in 70µl of Buffer RDD 
(QIAGEN) to the columns and incubating at room temperature for 15 minutes. The 
columns were washed again with 350µl of RW1 buffer, centrifuged, and the flow 
through discarded. An additional wash step was performed with 500µl of RPE buffer 
before the columns were transferred to fresh 1.5ml tubes where 30µl of RNase-free 
dH2O was added and incubated at room temperature for 1 minute before being 
centrifuged at 10,000 x g for 1 minute in order to elute the RNA. The total RNA was 
quantified on the Nanodrop spectrophotometer and stored at -80°C. 
4.2.18 cDNA Synthesis 
Total cDNA was synthesised from the total RNA extracted following the protocol for 
the AffinityScript Multiple Temperature cDNA Synthesis kit (Stratagene, La Jolla, 
CA, USA). In this synthesis step, two different primers were used: oligo(dT) and 
random primers. Control reactions were also performed where the enzymes were 
absent to ensure that the entirety of the genomic DNA was removed in the previous 
step. 
In all of the reactions, 2μg of RNA was required in a reaction volume of 15.7μl. To 
this, 500ng of oligo(dT) primer or 300ng of random primer were added. These were 
incubated at 65°C for 5 minutes and then cooled to room temperature for 10 minutes 
to allow the primers to anneal to the RNA and to prevent the enzymes about to be 
added from being heat inactivated. 
The reaction volume was made up to 20μl with 1x AffinityScript RT Buffer and 
1.6mM of dNTP mix. To the positive reactions, 1U/μl of RNase Block Ribonuclease 
Inhibitor and 1U of AffinityScript Multiple Temperature Reverse Transcriptase were 
also added. A thermal cycle was then performed on a TRIO-Thermoblock (Biometra) 
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consisting of 25°C for 10 minutes to extend the primers, 42°C for 60 minutes for the 
cDNA synthesis and 70°C for 15 minutes to inactivate the reaction. The resulting total 
cDNA was then stored at -20°C. 
4.2.19 cDNA Polymerase Chain Reaction 
Amplification of the target cDNA, i.e. the inserted genetic region, was performed in a 
30μl reaction volume and consisted of 1x LongAmp Taq Reaction Buffer (60mM 
Tris-SO4, 20mM (NH4)2SO4, 2mM MgSO4 at pH 9.1 - New England BioLabs), 0.2mM 
dNTPs,, 1ng/μl of the sense and antisense primers (designed for the pET01 vector - see 
Table 4.2), 0.5U LongAmp Taq DNA Polymerase (New England BioLabs) and 1μl 
cDNA template. PCR was performed using a Veriti 96 Well Thermal Cycler (Applied 
Biosystems). The thermal cycle was programmed for 30 seconds at 94°C for initial 
denaturation, followed by 30 cycles of 15 seconds at 94°C for denaturation, 30 
seconds at 59°C for annealing and 50 seconds at 65°C for extension and 10 minutes at 
65°C for the final extension. PCR products were examined by agarose gel 
electrophoresis as described above (see Section 4.2.2). 
4.2.20 Sanger Sequencing 
The PCR products were sequenced to allow comparison of the two sequences. The 
PCR products were first treated with ExoSAP-IT as described previously in Section 
3.2.4 and were then sequenced utilising the BigDye methodology as previously 
mentioned, using the pET01_Forward primer (see Table 4.2). 
The sequencing product was purified following the manufacturer’s protocol for the 
EdgeBio Performa DTR Gel Filtration Cartridges. The products were then read by 
capillary electrophoresis and analysed using the ChromasLite and ClustalW2 
software.  
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4.3 Materials & Methods - RNA Extraction from 
Brain 
4.3.1 RNA Extraction from Brain 
RNA was extracted from cortex brain tissue samples containing both the major and 
minor alleles of this variant in order to examine the ABCA7 isoforms present, 
endorsing the results obtained in the minigene assays. Samples which we held brain 
tissue for and with the genotype of homozygous major or minor alleles for this variant 
were identified in Sections 4.2.2 to 4.2.4 and their demographics are available in 
Table 4.4. Unfortunately, no data is available regarding the age of these individuals at 
death. 
All equipment during this protocol was cleaned with 2% trigene and 70% ethanol and 
was cooled on dry ice prior to use in order to keep the brain tissue as cold as possible 
for as long as possible in an attempt to reduce any further RNA degradation. The 
RNeasyPlus Universal Midi Kit (QIAGEN) protocol was followed. 250mg of tissue 
for each sample were first homogenised by covering them in liquid nitrogen before 
crushing with a pestle and mortal to a fine powder. This was transferred to a pre-
cooled 50ml tube before 5ml QIAzol Lysis Reagent was added and passed through a 
19-guage needle and 1ml syringe until the tissue powder was homogenised as much as 
possible. This was then incubated at room temperature for 5 minutes, in order to 
promote the disassociation of nucleoprotein complexes, before 500µl of the genomic 
Table 4.4 - Sample demographics of samples used to examine mRNA ABCA7 isoforms from 
brain tissue samples. 
Table 4.4
Sample ID Sex Centre of Origin Age at Death Age at Onset Disease Status ApoE Status
M647 Female Manchester NA NA Confirmed AD 3 4 
M648 Female Manchester NA NA Confirmed AD 3 4
Sample demographics of the samples used to examine the RNA of ABCA7  isoforms in brain tissue, related to the 
rs881768 genotype. Sample M647 was identified as carrying the major allele (AA) and M648 the minor allele (GG) of this 
variant. These samples were chosen as brain tissue was available as part of the ARUK DNA Brain Bank. The sex of the 
individuals, the centre of origin, disease state (both confirmed Alzheimer's disease (AD) at post-mortem for these 
samples) and the two ApoE alleles carried are presented. For both of these samples, their age at death and the age of 
disease onset are unknown (NA). 
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DNA Elimination Solution was added and mixed vigorously for 15 seconds. 1ml of 
chloroform was then added, again mixed vigorously for 15 seconds, before being 
incubated at room temperature for 3 minutes in order to promote phase separation. 
The samples were then centrifuged at 5000 x g for 17 minutes at 4°C to separate the 
solution into three phases: the upper, colourless, aqueous phase containing the RNA, 
the middle, white phase as well as a lower, red, organic phase. The upper, aqueous 
phase was transferred to a new tube, 1 equal volume of 70% ethanol was added and 
mixed well before being transferred to the RNeasy Midi Spin Column. This was 
centrifuged at 5000 x g for 5 minutes, to anneal the RNA to the column, and the flow-
through discarded. 4ml of Buffer RWT was added and an identical centrifuge 
performed in order to wash the membrane. An additional wash step was performed by 
adding 2.5ml of Buffer RPE and again centrifuging. This was repeated, creating a 
total of three wash steps, before the column was transferred to a fresh tube and 200µl 
of RNase-free dH2O added and incubated for 1 minute at room temperature in order to 
disassociate the RNA from the membrane. This was centrifuged at 5000 x g for 3 
minutes in order to elute the RNA. The sample concentrations were then determined 
utilising the Nanodrop 1000 Spectrophotometer (Thermo Scientific) to ascertain the 
success of the extractions.  
4.3.2 cDNA Synthesis 
This was performed as in Section 4.2.18 following the protocol for the AffinityScript 
Multiple Temperature cDNA Synthesis kit. Both oligo(dT) and random primers were 
used. 
4.3.3 cDNA Polymerase Chain Reaction 
Primers within the exons of ABCA7 were designed as in Section 4.2.1. Primers were 
designed to be within exons 30 and 33 in order to ascertain whether exon 32 was 
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included in the transcripts or not. Exon 30 was selected as opposed to exon 31 due to 
exon 31 being so short (33 base pairs). The primer sequences obtained are shown in 
Table 4.2 (Exon32_Forward and Exon32_Reverse). 
All of the products from the cDNA synthesis were PCR amplified in a 30µl volume 
consisting of 1x PCR Buffer with MgCl2 (750mM Tris-HCl, 200mM (NH4)2SO4, pH 
8.8 - Roche), 0.2mM dNTPs, 1pmol/µl of the primers designed (Exon32 primers as 
seen in Table 4.2) and 1U of Taq DNA Polymerase (Roche). The following 
thermocycle was executed: initial denaturation was performed at 94°C for 2 minutes, 
and then a further 30 seconds at 94°C, 58°C for 30 seconds and 72°C for 1 minute 
repeated 30 times. A final extension step was set at 72°C for 7 minutes. The products 
were examined by 1% agarose gel electrophoresis before being Sanger sequenced 
utilising the Exon32_Forward primer located within exon 30, as previously described. 
4.4 Results 
All primers used, including the ones designed specifically for this assay, are listed in 
Table 4.2. The selection of samples PCR amplified and Sanger sequenced in order to 
verify their genotype can be seen in Figure 4.6. These samples contained individuals 
who carried the major and minor alleles in a homozygous fashion as well as those who 
were heterozygous for variant rs881768 and were utilised in both the minigene assays 
and to identify brain tissue samples in order to extract total RNA. Demographics for 
the samples selected for these assays can be seen in Tables 4.3 and 4.4. 
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Once constructs had been created for both the major and minor allele within the 
pCR®2.1-TOPO vector, restriction enzyme digests were performed in order to ensure 
the DNA region had been inserted into the vector. An example of these digests can be 
seen in Figure 4.7, where one major allele construct and one minor allele construct 
can be identified.  
Figure 4.7 - Agarose gel showing plasmid DNA clones created for varinat 
rs881768. 
Figure 4.6 - Agarose gel showing samples amplified to 
ascertain their genotype for varinat rs881768. 
 i  re     
1% ethidium bromide stained agarose gel showing the samples amplified, utilising 
the rs  176  primers presented in  able 4.2, in order to ascertain their genotype for 
this variant by Sanger sequencing these PCR products. Sample AD115 was shown 
to be heterozygote and was therefore used to construct the minigene assays  see 
 able 4.3 , sample M64  carried the minor allele only and sample M647 the major 
allele only. Brain tissue was therefore acquired for these two samples from which 
RNA was extracted to examine the       isoforms present  see  able 4.4 . Sample 
AD211 was also shown to be heterozygous but was not used in these assays. Also 
shown is a 1kbp ladder, to compare the product sizes to, and a no template control 
 N C  to show no contamination was present.  
            
      
    
      
      
           
      
     
 i  re     
Plasmid DNA containing both the ajor    and minor  G  allele of the variant rs  176  
in the pCR 2.1- OPO vector in order to conduct minigene assays for this variant. Every 
second lane shows the vector which has been digested by the restriction digest enzymes 
     and     , run alongside a vector which has not been digested for comparison  lanes 
marked with a - .  he red boxes show vectors containing the insert as this has been 
digested out of the vector to produce a band of 3 6bp.  hese inserts were excised from the 
gel before being ligated into the pE 01 vector and transfected into cells in order to 
examine the RNA isoforms produced. 
            
      
                 
- - - - - - 
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Transfections into both COS-7 and BE(2)-C cells were replicated multiple times (four 
in COS-7 cells and three times in BE(2)-C cells) and all cDNA created from these 
transfections, upon PCR amplification, can be seen in Figure 4.8 (from COS-7 cells) 
and Figure 4.9 (from BE(2)-C cells).  In both Figures 4.8 and 4.9 it can be seen that 
the samples containing the major allele all contain only one band when the 
synthesised cDNA is PCR amplified. This band is of the correct size to be only vector 
exons and Sanger sequencing of this sized product (after gel extraction of the band, as 
in Section 4.2.10) confirms this (see Figure 4.10). Also in Figures 4.8 and 4.9 it is 
apparent that the samples carrying the minor allele show two bands - one of identical 
size to the band present in major allele samples (Sanger sequencing confirms the 
bands are of identical composition - see Figure 4.10) but a larger band is also present. 
Upon Sanger sequencing of this product (see Figure 4.11), it was established that 
(although it does not sequence entirely cleanly) it contains both the vector exons and 
the inserted exon 32 as expected. Upon visualising the gel under the black light and 
excising the section of gel where this band would be present for all samples, 
containing both the major and minor alleles, this larger band was present in all minor 
allele samples and none of the major alleles. All of these bands were Sanger 
sequenced in order to verify that all of the samples were consistent and they were, as 
presented in Figures 4.10 and 4.11. This implies that exon 32 is spliced out in samples 
containing the major allele (G) but included some of the time with the presence of the 
minor allele (A) of this variant.  
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Figure 4.8 - cDNA synthesised from four seperate transfections into COS-7 
cells. 
                
       
       
    
            
            
 i  re     
cDNA synthesised from four separate transfections into COS-7 cells in reference to 
a 1kbp ladder. A   vector transfected into the cells containing an insert containing 
the major allele  A , G   vector transfected with an insert containing the minor allele 
 G . All samples contai  the maller band of approximately 240 base pairs but only 
the minor allele samples contain the larger band of approximately 420 base pairs. 
 he sequence and alignment of both of these bands can be seen in Figures 4.10  
4.11 respectively.  
 he bottom row of wells show the amplification of the “enzyme negative” samples, 
showing no genomic DNA is present, only RNA was amplified.  All sequences of 
the bands were consistent between transfections.  here is also a blank No  emplate 
Control lane  N C  showing no contamination is present.  
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Figure 4.9 - cDNA synthesised from three 
seperate transfections into BE(2)-C cells. 
 i  re     
cDNA synthesised from three separate transfections into BE 2 -C cells in reference to a 1kbp 
ladder. A   vector transfected into the cells containing an insert containing the major allele  A , 
G   vector transfected with an insert containing the minor allele  G . All samples contain the 
smaller band of approximately 240 base pairs but only the minor allele samples contain the 
larger band of approximately 420 base pairs, correlating with what is seen in COS-7 cells.  he 
sequence and alignment of both of these bands can be seen in Figures 4.10  4.11 respectively.  
 he bottom row of wells show the amplification of the “enzyme negative” samples, showing no 
genomic DNA is present, only RNA was amplified with the exceptions of the first transfection 
where genomic DNA was present.  he top band in these lanes was extracted and sequenced and 
shown to be genomic DNA by the presence of intronic DNA.  hese genomic DNA bands are 
also present in the “enzyme positive” lane of the major allele vector of this transfections and the 
sequence also contained intronic DNA.  he minor allele of this transfection showed a weaker 
larger band although DNA was still extracted and sequenced from this region. All sequences of 
the bands were consistent between transfections.  here is also a blank No  emplate Control lane 
 N C  showing no contamination is present.  
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Figure 4.11 - Alignment of band only present in samples 
containing the minor allele. 
Figure 4.10 - Alignment of the band present in all samples. 
Ref.            GATCGATCCGCTTCCTGCCCCTGCTGGCCCTGCTCATCCTCTGGGAGCCCCGCCCTGCCC 60 
14-6            ------------------------------AGYTCCYTCTCTGGGR--CCCGCC-TGCC- 26 
14-1            -----------------------------GGKTTYMTCCTCTGGGR--CCCGCC-TGCCC 28 
H-1             ------------------------------GGTTYCWCCTCTGGGR--CCCGCC-TGCCC 27 
H-5             ------------------------------GGKTTYMMCTCTGGGR---CCGCCCTGCC- 26 
                                                 *    *******    ***** ****  
 
Ref.            AGGCTTTTGTCAAACAGCACCTTTGTGGTTCTCACTTGGTGGAAGCTCTCTACCTGGTGT 120 
14-6            AGGYTTTTGTCAA-CAGCACCTTTGTGGTTCTCACTTGGTGGAAGCTCTCTACCTGGTGT 85 
14-1            AGGCTTTTGTCAA-CAGCACCTTTGTGGTTCTCACTTGGTGGAASYTCTCTACCTGGTGT 87 
H-1             AGGYTTTTGTCAA-CAGCACCTTTGTGGTTCTCACTTGGTGGAASYTYTCTACCTGGTGT 86 
H-5             AGGYTTTTGTCAA-CASCACCTTTGTGGTTCTCACTTGGTGGMMSYTYTCTACCTGGTGT 85 
                *** ********* ** *************************    * ************ 
 
Ref.            GTGGGGAGCGTGGATTCTTCTACACACCCATGTCCCGCCGCGAAGTGGAGGACCCACAAG 180 
14-6            GTGGGGAGCGTGGATTCTTCTACACMCCCATGTCCCGCCGCGAAGKGGAGGACCCACAAG 145 
14-1            GTGGGGAGCGTGGATTCTTCTACACMCCCATGTCCCGCCGCGAAGTGGAGGACCCACAAG 147 
H-1             GTGGGGAGCGTGGATTCTTCTACACMCCCWTGTCCCGCCGCGAAGKGGAGGACCCACAAG 146 
H-5             GTGGGGAGCGTGGATTCTTCTACMCMCCCWTGTCCCGCCGCGAAGKGGAGGACCCACAAG 145 
                *********************** * *** *************** ************** 
 
Ref.            ATACGGAGGCTTCTCGCTGGGGGGCCGAGACCCAGGCCTGCCCTCGGGCCAAGAGTTGGG 240 
14-6            ------------------------------------------------------------ 
14-1            ------------------------------------------------------------ 
H-1             ------------------------------------------------------------ 
H-5             ------------------------------------------------------------ 
                                                                             
 
Ref.            CCGCTCAGTGGAGGAGTTGTGGGCGCTGCTGAGTCCCCTGCCTGGCGGGGCCCTCGACCG 300 
14-6            ------------------------------------------------------------ 
14-1            ------------------------------------------------------------ 
H-1             ------------------------------------------------------------ 
H-5             ------------------------------------------------------------ 
                                                                             
 
Ref.            TGTCCTGAAAAACCTCACAGCCTGGGCTCACAGCCTGGATGCTCAGGACAGTCTCAAGTG 360 
14-6            ----------------------------------------------------------KG 147 
14-1            ----------------------------------------------------------TG 149 
H-1             ----------------------------------------------------------TG 148 
H-5             ----------------------------------------------------------TG 147 
                                                                           * 
 
Ref.            GCACAACTGGAGCTGGGTGGAGGCCCGTGACCTTCAGACCTTGGCACTGGAGGTGGCCCG 420 
14-6            GCACAACTGGAGCTGGGKGGAGGCCCGTGACCTTCARACCTTGGCACTGGAGGTGGCCCG 207 
14-1            GCACAACTGGAGCTGGGKGGAGGCCCGTGACCTTCARACCTTGGCACTGGAGGTGGCCCG 209 
H-1             GCACAACTGGAGCTGGGKGGAGGCCCGTGACCTTCARACCTTGGCACTGGAGGTGGCCCG 208 
H-5             GCACAACTGGAGCTGGGKGGAGGCCCGTGACCTTCARACCTTGGCACTGGAGGTGGCCCG 207 
                ***************** ****************** *********************** 
 i  re      
Alignment of the band of size 240 base pairs, present in all samples, 
with the reference sequence  Ref. .  he reference sequence contains 
only exonic sequence: the vector exons with the insert exon  exon 32 - 
shown here highlighted in pink  in-between them.  his shows that the 
band which is the major product in both major allele  14-6 and 14-1  
and minor allele samples  H-1 and H-5  does not contain the insert 
exon, indicating it has been spliced out.  
H-3.1TOP        --------TSCYKSYY-------------------MMYYTYTGGG-GRCCCGCCCTGCC- 31 
H-1TOP          --------TK-TYYCY-------------------WYYCYSTGGC-RCCCCGCCCTGCC- 30 
Ref.            GATCGATCCGCTTCCTGCCCCTGCTGGCCCTGCTCATCCTCTGGGAGCCCCGCCCTGCCC 60 
                                                         ***    ***********  
 
H-3.1TOP        MGGYTTTTGTCAA-CAGCACCTTTGTGGTTCTCACTTGGTGGMMSCTCTCTACCTGGTGT 90 
H-1TOP          AGGYTTTTGTCAA-CASCACCTTTGTGGTTCTCACTTGGTGSMMSYTYTCTACCTGGTGT 89 
Ref.            AGGCTTTTGTCAAACAGCACCTTTGTGGTTCTCACTTGGTGGAAGCTCTCTACCTGGTGT 120 
                 ** ********* ** ************************     * ************ 
 
H-3.1TOP        GTGGGGAGCGTGGATTCTTCTACACMCCCATGTCCCGCCGCGAAGTGGAGGACCCACAAG 150 
H-1TOP          GTGGGGAGCGTGGATTCTTCTACACMCCCWTGTCCCGCCGCGAAGTGGAGGACCCACAAG 149 
Ref.            GTGGGGAGCGTGGATTCTTCTACACACCCATGTCCCGCCGCGAAGTGGAGGACCCACAAG 180 
                ************************* *** ****************************** 
 
H-3.1TOP        GKRCRSARSYKKMKCKSKGGGGRGSCSMGWSCCMKGCMKRCCYTSGSRCYRRRRGTKGSS 210 
H-1TOP          KKRCRSAGSYKKMTCKSKGGGGRGSCSMGASCCMKKCCTRCCYTSGSRCMRRRAGTKGSS 209 
Ref.            ATACGGAGGCTTCTCGCTGGGGGGCCGAGACCCAGGCCTGCCCTCGGGCCAAGAGTTGGG 240 
                   *  *       *   **** * *  *  **   *   ** * *  *     ** *   
 
H-3.1TOP        CSRCTCAGTGGAGGAGTTGTGGGCGCTGYTRARTCCCCTGCCTGGCGGGGCCCTCGACCG 270 
H-1TOP          CSRCTCAGTGGAGGAGTTGTGGGCGCTGCTGAGTCCCCTGCCTGGCGGGGCCCTCGACCG 269 
Ref.            CCGCTCAGTGGAGGAGTTGTGGGCGCTGCTGAGTCCCCTGCCTGGCGGGGCCCTCGACCG 300 
                *  ************************* * * *************************** 
 
H-3.1TOP        TGTCCTGAAAAACCTCACAGCCTGGGCTCACAGCCTGGATGCTCAGGACAGTCTCAAGTG 330 
H-1TOP          TGTCCTRAAAAACCTCACAGCCTGGGCTCACAGCCTGGATGCTCAGGACAGTCTCAAGTG 329 
Ref.            TGTCCTGAAAAACCTCACAGCCTGGGCTCACAGCCTGGATGCTCAGGACAGTCTCAAGTG 360 
                ****** ***************************************************** 
 
H-3.1TOP        GCMCAACTGGAGCTGGGTGGAGGCCCGTGACCTTMASACCTTGGCACTGGAGGTGGCCCG 390 
H-1TOP          GCACAACTGGAGYTGGGKGGAGGCCCGTGACCTTCARACCTTGGCACTGGAGGTGGCCCR 389 
Ref.            GCACAACTGGAGCTGGGTGGAGGCCCGTGACCTTCAGACCTTGGCACTGGAGGTGGCCCG 420 
                ** ********* **** **************** * **********************  
  i  re      
Alignment of the band of size 420 base pairs, present in only the 
samples containing the minor alle e, with the reference sequence 
 Ref. . Alt ough these samples have not sequenced very cleanly 
 despite cloning the samples to attempt a clean sequence , they have 
sequence well enough to establish all expected exons are present. 
 his suggests that exon 32  highlighted in pink  is only included in 
the mRNA when the minor allele  G  of variant rs  176  is present.   
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Figure 4.12(A) shows the cDNA amplified from RNA extraction from brain tissue 
samples M647 and M648. It can be seen that there is a no difference between cDNA 
harbouring the major allele (A) and minor allele (G), although there is genomic DNA 
present, shown as a faint band at approximately 1000bp. This was proven to be 
genomic DNA as it is also present weakly in the enzyme negative reactions. This 
genomic DNA is of the size expected if introns are included in this PCR 
amplification. The smaller band of around 400bp was also extracted from the gel and 
Sanger sequenced. Upon alignment with the exonic reference sequence (Figure 
4.12(B)), it can be seen that all ABCA7 exons are present in both samples.  
 
 
Figure 4.12 - Agarose gel and alignment of cDNA amplified from brain tissue samples 
carrying both genotypes of rs881768. 
            
      
   
    
      
   
      
        
        
            
 i  re      
 A  cDNA PCR amplified from RNA extracted from brain tissue carrying both the major  A  and the minor  G  alleles for the splicing 
variant rs  176 . Both samples had total cDNA synthesised utilising both the oligod  and random primers  RP  and both were PCR 
amplified. A positive control cDNA sample  made from RNA extracted from cells  was also PCR amplified in order to ensure the PCR was 
working. As can be seen, the products between the two brain tissue samples were identical with the major product being around 400 base 
pairs, the size expected when all      exons are plicing into the cDNA product.  his band was extracted from the gel and Sanger 
sequenced, confirming it did contain all of the exons expected.  here was also a faint band of size 1000 base pairs, the correct size of 
genomic DNA  i.e. if introns were included  for this region.  his was also present in the enzyme negative reactions  bottom row , proving 
that it was, in fact, genomic DNA.  
 B  Alignment of the band of size of around 400 base pairs, present in both samples carrying the major allele  7 B  and the minor allele 
   B  .  his shows that exon 32 was present in both. 
A   
       
      
       
                      
                                    
 
 
Ref.  CCTGGTGCGCCAGGG CCTGAAGACTAAGAAGTGGGTGAATGAGGTCAG ATACGGAGGCTT 
7+B   CCTGGTGCGCCAGGG CCTGAAGACTAAKAAGTGGGTGAATGAGGTCAG ATACGGAGGCTT 
8+B   CCTGGTGCGCCAGGG CCTGAAGACTAWYWYGCGGGWRKAWGAGGTCAG GTACGGAGGCTT 
      *************** ***********    * ***   * ********  *********** 
 
 
Ref.  CTCGCTGGGGGGCCGAGACCCAGGCCTGCCCTCGGGCCAAGAGTTGGGCCGCTCAGTGGA  
7+B   CTCGCTGGYSKGYWRARACCCAGGCCTGCCCTCGGGCCAAGAGTTGGGCCGCTCAGTGGA  
8+B   CTCGCTGYYSKMMCGARACCCAGGCCTGCCCTCGGGCCAAGAGTTGGGCCGCTCAGTGGA  
      *******        * ******************************************* 
 
 
Ref.  GGAGTTGTGGGCGCTGCTGAGTCCCCTGCCTGGCGGGGCCCTCGACCGTGTCCTGAAAAA  
7+B   GGAGTTGTGGGCGCTGCTGAGTCCCCTGCCTGGCGGGGCCCTCGACCGTGTCCTGAAAAA  
8+B   GGAGTTGTGGGCGCTGCTGWKTCCCCTGMCTGGSGGGGCCCTCGACCGTGTCCTGAAAAA  
      *******************  ******* **** ************************** 
 
 
Ref.  CCTCACAGCCTGGGCTCACAGCCTGGATGCTCAGGACAGTCTCAAG ATCTGGTTCAACAA 
7+B   CCTCACAGCCTGGGCTCACAGCCTGGATGCTCAGGACAGTCTCAAG ATCTGGTTCAACAA 
8+B   CCTCACAGCCTGGGCTCACAGCCTGGATGCTCAGGACAGTCTCAAG ATCTGGTTCAACAA 
      ********************************************** ************** 
 
 
Ref.  CAAAGGCTGGCACTCCATGGTGGCCTTTGTCAACCGAGCCAGCAACGCAATCCTCCGTGC  
7+B   CAAAGGCTGGCACTCCATGGTGGCCTTTGTCARCCGAGCCAGCAACGCARTCCTCCGTGC  
8+B   CAAAGGCTGGCACTCCATGGTGGCCTTTGTSAACCGAGCCAGCAACGCAATCCTCCGTGC  
      ****************************** * **************** ********** 
Exon 30 rs881768 Exon 31 
Exon 32 
Exon 33 
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4.5 Discussion 
This work aimed to identify if the minor allele of a variant, rs881768-G, present at the 
very beginning of exon 32, affected the splicing of the ABCA7 gene. It had been 
highlighted by annotation programs during analysis of NGS data and further scrutiny 
by a variety of programs supported the fact that it may result in alternative splicing of 
ABCA7 (see Table 4.1). Minigene assays in two different cell lines (COS-7 and 
BE(2)-C) showed that only the minor allele forced inclusion of exon 32 while RNA 
extracted from brain tissue showed that exon 32 was included in all transcripts of 
ABCA7, irrespective of rs881768 genotype.  
Unfortunately current in silico tools aiming to identify damaging functional variants 
(whether this functional effect be through splicing or other means) are still imperfect, 
therefore further in vitro validation methods are required. The methodology utilised - 
the minigene splicing assay - has previously been identified as accurately representing 
the pathogenicity of possible splicing variants (Steffensen et al., 2014) although some 
argue that the absence of the flanking sequences in the minigene construct may alter 
the spliceosome formed (Cooper, 2005). However, in this study we have also 
examined total RNA extracted from brain tissue, where the full length pre-mRNA is 
present and splicing takes place in its physiological context. 
The cell lines utilised here were also chosen carefully. The COS-7 cell line is known 
for its high transfection efficiency as well as accurately representing the complex 
eukaryotic splicing environment seen in vivo. The BE(2)-C cell line was selected to 
test the tissue-specificity of splicing, being a neuroblastoma cell line, as different cell 
lines may exhibit different ratios of alternatively spliced products, therefore being 
unrepresentative of the regulation occurring in the tissue of origin (Cooper, 2005). 
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Utilising a neuronal cell line, therefore, will more accurately represent the effect this 
variant may have on AD pathology. 
The synonymous variant rs881768 is located at the first base of exon 32 in ABCA7 
(transcript ID NM_019112). Although it is not thought that the first base of an exon is 
directly involved in the mechanisms of splicing (see Figure 4.1), in silico predictions 
suggest that this A to G allele substitution creates a new donor site with a similar 
score to the original donor site, located only 126bp away (a score of 0.98 compared 
with 0.99) and changes the binding of two ESE proteins (Table 4.1). These predictions 
suggest the G allele could activate a cryptic splice site or cause a change in protein 
isoform ratios. Additionally, score predictions for the acceptor site shows that the A 
allele has a lower score than the G allele (0.56 compared to 0.76) which could lead to 
exon skipping. This makes in silico functional prediction and interpretation of this 
variant very difficult. Population data from 1000Genomes shows that the G allele has 
an allele frequency of 0.44 (combined across all populations although when this 
variant was analysed in the NGS dataset utilising the CRISP tool (see Section 2.1), the 
minor allele was identified as having a frequency of 0.25. The discrepancy in these 
allele frequencies could suggest that this variant may also have some kind of 
pathological effect, perhaps protective of disease due to the lower frequency in the 
disease population. 
ABCA7 has an interesting pattern of alternative splicing, with many introns consisting 
of multiples of three, potentially allowing in-frame addition and deletion of introns, 
although no such transcripts have been identified (Kaminski et al., 2000b). However, 
elimination of exon 32 does results in a frame-shift change creating a termination 
codon and causing early truncation of the protein at amino acid position 1457, located 
within the subsequent exon (exon 33). Exon 32 codes for part of the extracellular loop 
between TMDs 7 and 8, shortening it. It is not known whether the deletion of exon 32 
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affects the binding areas, and therefore the function, of this extracellular loop. 
However, this truncated protein is non-functional as it lacks the last five 
transmembrane domains and the second nucleotide binding domain. A similar splicing 
variant has been identified in the ABCA1 protein upon analysis of patient obtained 
cDNA from a familial sufferer of low serum HDL and premature coronary heart 
disease. This variant is also located at the exon/intron junction of exon 32 and causes 
skipping of exon 32, introducing eight new amino acids and a premature stop codon. 
This produces a protein of 1496 amino acids in length compared to the normal 
ABCA1 protein of 2261 amino acids (Rhyne et al., 2009). rs881768 truncates ABCA7 
in a similar manner - shortening the protein from the typical 2146 amino acids to 1457 
when exon 32 is eliminated. 
This shortening of the protein (quite dramatically due to ABCA7 having 47 exons and 
2146 amino acids in total) may suggest, therefore, that a surveillance pathway, such as 
nonsense-mediated decay (NMD) may eliminate the truncated mRNA, causing sole 
expression of the complete isoform in vivo. NMD is a surveillance pathway present in 
all eukaryotes and identifies mRNA transcripts containing premature stop codons 
which may produce damaging isoforms. It goes on to eliminate these isoforms, 
limiting the translation of abnormal proteins. This would explain why, when total 
RNA from brain tissue is examined, only the full isoform is present, as these 
surveillance pathways, or secondary structures affecting transcription, are present in 
this environment (Wadkins, 2000). An alternative explanation may be that the deletion 
of exon 32 results in the protein breaks down naturally, with no premature stop codon 
introduced, therefore making NMD unnecessary.  
The primary limitation of this study is that the minigene methodology only examines 
the RNA produced in cell lines, with only one exon present, making it a very artificial 
system. In order to examine what occurs to exon 32 in vivo, RNA from brain sections 
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of carriers of both the major and minor alleles was examined, mapping it to the 
location of LOAD pathology. However, studies involving RNA from post-mortem 
tissue must always be viewed with caution. The handling and treatment of the tissue 
prior to it being stored in our laboratory at -80°C was unknown and, therefore, RNA 
might have degraded at source and consequently be un-representative of what occurs 
in vivo. Further studies could also be performed by creating clones containing more 
than just exon 32, increasing the amount of the natural splicing machinery in the 
minigene assays. 
Further issues, especially with this particular assay, may be the accuracy of the RT-
PCR. This may mean that the ratios of the two PCR amplicons are not representative 
of the different mRNA splice variants or that low levels of transcripts are not even 
shown upon electrophoresis examination. This caveat can be addressed by removing 
aliquots of the PCR reaction following a range of cycle numbers and quantifying the 
bands. If they both increase linearly then the PCR is representative of the correct 
ratios. 
Since the start of this project, new expression databases have become available, for 
example, an expressed sequence tag dataset known as GTEx (GTEx Consortium, 
2015). When ABCA7 isoforms are examined within this dataset, it can be seen that 
exon 32 is incorporated in all ABCA7 transcripts, expressed at the same level (if not 
higher) than the surrounding exons (Version 6p, accessed October 2016). This was 
demonstrated in all neurological tissue this database incorporates (pituitary, 
cerebellum and cerebral hemisphere) as well as whole blood and spleen which had 
relatively high expression levels of ABCA7 when compared to other tissues. 
Examining the effect of rs881768 on transcript data in GTEx shows the variant has no 
effect on splicing, corroborated this chapter’s findings in brain tissue where exon 32 
of ABCA7 is incorporated regardless of the rs881768 genotype.  
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From this data it can be seen that, in vitro, variant rs881768-G, stabilises the splice 
site, increasing the inclusion of exon 32 in the mRNA. However, in the more natural 
environment, in the total RNA extracted from brain tissue and in the GTEx database, 
where the entirety of the gene is present, exon 32 is included in samples containing 
both the major and minor alleles. This suggests that, in the in vivo environment, 
something may stabilise the splice site, such as secondary structure interactions 
throughout the pre-messenger RNA during splicing (Wadkins, 2000).  
Upon analysis of the protein when exon 32 is deleted, it is also apparent it is a frame 
shift deletion, truncating the protein within the subsequent exon. This is a remarkably 
shortened protein considering ABCA7 contains 47 exons and may, therefore, suggest 
that a surveillance pathway, such as nonsense-mediated decay, may eliminate the 
truncated mRNA, causing only the full protein, including exon 32, to be expressed. 
Therefore, assays were performed in lymphoblastoid cell lines, containing the entire 
ABCA7 genomic region, in order to inhibit nonsense-mediated decay to see if this is 
indeed the case.  
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4.6 Conclusions 
Upon analysis of cDNA extracted from cells transfected with minigene vectors 
containing both the major and minor alleles of the rs881768 variant, it is apparent that 
only the minor allele forces the inclusion of exon 32 into the transcript. However, this 
is not the case when RNA is extracted and RT-PCR performed from brain tissue 
samples containing these two alleles. This suggests that there may be a surveillance 
pathway in place, controlling which isoform of ABCA7 is expressed. Further assays 
will therefore be performed in order to examin the possible mechanisms of these 
surveillance systems.  
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5 Nonsense Mediated Decay 
Nonsense mediated decay (NMD) is a post-transcriptional mechanism, active in all 
eukaryotic organisms, in order to control the quality of mRNA translated. It acts as a 
surveillance pathway in order to eliminate any mRNA present which would result in 
abnormal transcripts, the most common situation being the presence of a premature 
stop codon (PTC) in the mRNA (Elliott, 2010). This would result in a truncated 
protein, due to premature termination of translation, which can cause deleterious gain-
of-function or dominant-negative functions (Sonenberg, 2000). Not all PTCs have 
negative functions; they can encourage molecular diversity: cellular adaptability and 
improve viability (Elliott, 2010). They may be introduced through incomplete or 
inaccurate splicing, chromosomal translocations, deletions, insertions and point 
mutations.  As mentioned previously, approximately 55% of human pre-mRNA 
undergoes alternative splicing, providing a dramatic increase in genomic diversity 
although this can lead to introduction of these PTCs, usually due to a frameshift effect 
(Maquat, 2004). Point mutations can also initiate alternative splicing, occasionally 
through altering a cis-acting splicing element but it is thought that the principal 
pathological action of splicing affecting nonsense mutations are due to them 
introducing a PTC. To emphasise this it is thought that around one third of inherited 
diseases are due to the premature termination of proteins (Elliott, 2010; Maquat, 2004; 
Sonenberg, 2000). 
Two things are required in order to initiate NMD post-translation; a ribosome halted at 
a stop codon and a downstream cis-sequence (Elliott, 2010). In mammals, this cis-
sequence is the exon-junction complex, occurring around 20 base pairs upstream of 
the exon-exon junction and at least 50 base pairs downstream of the termination 
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codon. These aspects of NMD and their locations are illustrated in Figure 5.1. This 
implies that, if the premature termination codon is present in the last exon of a gene 
(where there is no downstream exon-exon junction), NMD will not be initiated but as 
long as there is a “spliceable” intron downstream of the P C, NMD will take place 
(Elliott, 2010; Maquat, 2004).  
 
The exon-junction complex compromises of a protein core, anchoring it to the 
complementary mRNA sequence, and plays a part, not just in NMD, but also in 
mRNA export to the cytoplasm, translation and localization. This protein complex 
involves the Regulator of Nonsense Transcript (UPF) proteins, which are the main 
contributors to NMD, recruiting the mRNA degradation machinery. UPF1 is initially 
recruited upon translation release factors being liberated when the ribosome 
encounters a stop codon. It then interacts with UPF2 and UPF3, consequently 
phosphorylating UPF1 and forming the activated surveillance complex. This complex 
then recruits factors which initiate both 5’ to 3’ and 3’ to 5’ decay, either through 
removal of the 5’ cap and then degradation by the exonuclease 1 enzyme or 
deadenylation from the 3’ end.  he importance of NMD in controlling and surveying 
correct gene expression is confirmed by the fact that the UPF proteins are conserved 
Figure 5.1 - cis-sequences required to initiate nonsense mediated decay. 
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Pictorial representation of the   s-sequences required in order to initiate nonsense mediated decay. 
 he premature termination codon exists approximately 50 base pairs upstream of the exon junction 
complex which itself is approximately 20 base pairs upstream of the exon-exon junction between this 
exon and the downstream intron.  he premature termination codon stalls the ribososome, causing 
translation release factors to be liberated, recruiting protein complexes to the exon junction complex 
and stimulating nonsense mediated decay.   
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throughout all eukaryotic organisms. Additionally mice embryos with NMD 
inactivated are fatally reabsorbed by their mothers (Elliott, 2010; Maquat, 2004; 
Sonenberg, 2000). 
As shown previously, the variant rs881768 appears to alter the inclusion of the exon 
32 in ABCA7. The G allele appears to be the only allele which causes the inclusion of 
this exon in the artificial minigene environment. However, when RNA from brain 
tissue which harbours both genotypes of this variant is examined, exon 32 appears to 
always be included. It is therefore postulated that a surveillance pathway, such as 
NMD, is degrading the mRNA not containing exon 32. This is thought to be as the 
deletion of exon 32, caused by the A allele of rs881768, is a frameshift mutation and 
causes a subsequent termination codon in the next exon, truncating the protein by 13 
exons, including vital functional domains such as the final five transmembrane 
domains and the second nucleotide binding domain.  
It is known that aminoglycoside antibiotics bind to ribosomes, affecting their fidelity 
and allowing stop codons to be read as amino acids, inhibiting NMD (as do a selection 
of other ribosomal binding drugs and molecules). Using these antibiotics, inhibition of 
NMD will therefore be attempted in cell lines containing known human genetic 
material in order to identify if NMD is controlling the expression of this truncated 
ABCA7 isoform. Epstein-Barr transformed B-lymphoblastoid cell lines (LCLs) 
containing genetic material from two 1000Genomes individuals identified as carrying 
the major allele (HG00255 - AA) and the minor allele (HG00137 - GG) were obtained 
after being identified using the 1000Genomes browser (accessed April 2014).  
Puromycin is an aminoglycoside antibiotic which will inhibit NMD. It does this 
through inactivating the 60S ribosomal subunit, preventing the reading of the mRNA 
and, therefore, protein synthesis. Transcripts which undergo NMD are targeted by the 
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60s ribosome and, as such, treatment with puromycin will interrupt this process and  
prevent the transcript from being targeted by NMD (Carter et al., 1995). Following a 
literature search (performed in January 2015) it was confirmed that there is no 
commonality in the concentration and incubation period for puromycin to definitively 
impede NMD in cell lines. Several papers examined (Andreutti-Zaugg et al., 1997; 
Castellsagué et al., 2010; Lamba et al., 2003; Nguyen-Dumont et al., 2011; Noensie 
and Dietz, 2001; Ware et al., 2005) as well as personal communication with a 
colleague (Dr Anne Braae) showed that the puromycin concentrations used to 
successfully inhibit NMD ranged from 10µg/ml to 1000µg/ml. The incubation times 
also varied widely; from two to six hours. It was therefore decided that a range of both 
concentrations and time points would be used in order to ascertain the potential effect 
of NMD inhibition on this truncated form of ABCA7. These concentrations and time 
points reflect the conditions that have shown to be successful in the literature. There is 
a risk that, if the concentration or incubation time is too high, all of protein synthesis 
could be inhibited, killing the cells due to no proteins being made. Due to this, a 
positive control was also identified in order to ensure that NMD had been inhibited in 
these assays, consisting of a four base pair deletion in the CD33 gene. Total RNA was 
extracted from both of the cell lines (HG00255 of the AA genotype and HG00137 of 
the GG genotype) and cDNA synthesised which was then PCR amplified, both for 
ABCA7 and for the positive control, and Sanger sequenced in order to establish the 
action of NMD. 
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5.1 Materials & Methods 
5.1.1 Culturing Cells 
The two LCLs (HG00255 and HG00137) were obtained from the Coriell Cell 
Repositories from the National Human Genome Research Institute Sample repository 
for Genetic Research. They were cultured in Roswell Park Memorial Institute (RPMI) 
1640 media supplemented with 2mM L-glutamine, 15% FBS, 1% Fungizone and 1% 
Penicillin-Streptomycin (all Sigma). Cells were maintained in suspension in 25cm
2
 
Corning Tissue Culture flasks in 15ml of media in a 37°C, 5% CO2, humidified 
environment at a cell density of between 200,000 and 500,000 cells/ml. In order to 
transfer, passage and plate out the cells, the cell culture media was transferred to a 
50ml tube before being centrifuged at 300 x g for 5 minutes. The spent media was 
removed and the cells were re-suspended in fresh media. All other basic cell culture 
methodology described previously was followed, as in Section 4.2.15.  
5.1.2 Treatment of Cells with Puromycin 
The cells were plated out into 12 well plates, at a concentration of 2 x 105 cells/ml 
with 2ml of cells per well. Four wells were seeded for each cell line in order to 
accommodate the different concentrations of puromycin being used (50µg/ml, 
100µg/ml, 200µg/ml and 1000µg/ml) as shown in Figure 5.2. A plate was created for 
each of the four time points being examined - 0.5 hours, 2 hours, 6 hours and 10 
hours. An extra plate was also created in order to extract control RNA to see what 
ABCA7 isoforms were produced in cells with no puromycin treatment. The cells were 
plated out and 48 hours later, once the cells were well established, the appropriate 
concentration of puromycin (Sigma) was added to each well. The plates were 
incubated for the appropriate period of time at 37°C, 5% CO2 with humidity before 
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their RNA was extracted. Each plate for each time point was repeated in order to show 
the results were replicable. 
5.1.3 RNA Extraction 
Total RNA was extracted from all cell cultures following the RNeasy Mini Kit 
protocol (QIAGEN), as described in Section 4.2.17, before being quantified.  
5.1.4 cDNA Synthesis 
The AffinityScript Multiple Temperature cDNA Synthesis kit (Stratagene) was used 
to synthesis total cDNA as in Section 4.2.18. Due to the low concentrations of RNA 
obtained, only 500ng of each sample was used to synthesis cDNA and only the 
random primers were utilised to synthesis the cDNA. These primers were selected (as 
opposed to the oligo(dT) primers) due to them synthesising better quality cDNA from 
total RNA from brain (see Section 4.3.2 and Figure 4.12(A)). Negative synthesis 
reactions (with the enzymes eliminated) were also performed to determine if genomic 
DNA was present.  
Figure 5.2 - 12 well plate created to examine the affect of nonsesne 
mediated decay on the ABCA7 isoform. 
HG00137 
HG00255 
50 g ml 100 g ml 200 g ml 1000 g ml 
 i  re     
Representation of the 12 well plates  denoted by the dark blue lines  created in order to examine 
the effect of nonsense mediated decay inhibition on the isoform of       transcribed in two 
lymphoblastoid cell lines - HG00137 and HG00255 - which contain different alleles for the 
rs  176  variant. Due to only two cell lines used, the third row of the plate was not used. 
Different concentrations of puromycin are utilised to inhibit NMD due to conflicting literature 
reports. Four of these plates are created in order to examine four time points of incubation  0.5 
hours, 2 hours, 6 hours and 10 hours .  hese were all replicated twice. 
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5.1.5 cDNA Polymerase Chain Reaction 
PCR was performed as in Section 4.3.3 utilising primers designed to be within exons 
30 and 33 of ABCA7, with the reverse primer being located prior to the PTC created 
within exon 33 upon elimination of exon 32 (see Table 4.2). All cDNA synthesised, 
including the negative reactions, was PCR amplified. The PCR conditions in Section 
4.3.3 were followed and the results examined by gel electrophoresis (1% agarose gel 
run for 55 minutes at 80V). A selection of samples were also Sanger sequenced (at 
least two samples per time point were sequenced) in order to confirm whether exon 32 
was included or not. This sequencing (utilising the forward primer located in exon 
30), and analysis of the sequencing results, was performed as previously described.  
5.1.6 cDNA Polymerase Chain Reaction - Positive Control 
A colleague (Braae, 2016), had previously used these cell lines to examine a variant in 
the CD33 gene (rs201074739) which codes for a four base pair deletion (CCGG/-), 
creating a PTC and therefore creating a target for NMD. This project involved 
synthesising cDNA from these cell lines treated with 200µg/ml of puromycin for six 
hours and demonstrated that NMD does, in fact, regulate the form of CD33 expressed, 
eliminating the isoform containing the four base pair deletion due to it creating a PTC. 
The primers used in this study (Forward: ACAGGCCCAAAATCCTCATC and 
Reverse: CTGTAACACCAGCTCCTCCA) were therefore used to amplify the cDNA 
synthesised in Section 5.1.4 in order to see if the puromycin treatments in Section 
5.1.2 had, in fact, inhibited NMD. The cDNA from both cell lines not treated with 
puromycin, as well as from cells treated with 200µg/ml of puromycin for 6 hours were 
PCR amplified in a 30µl reaction volume consisting of 1x Roche PCR Buffer 
(750mM Tris-HCl, 200mM (NH4)2SO4, pH 8.8), 0.2mM dNTPs, 1pmol/µl of the 
primers stated above and 1U of Taq DNA Polymerase (Roche). The following 
thermocycle was executed: initial denaturation was performed at 94°C for 2 minutes, 
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and then a further 30 seconds at 94°C, 59°C for 30 seconds and 72°C for 1 minute 
repeated 30 times. A final extension step was set at 72°C for 7 minutes. The products 
were examined under electrophoresis before being Sanger sequenced as previously 
described utilising the forward primer as above, at a concentration of 0.5pmol/µl.  
5.2 Results 
Figure 5.3 depicts the ABCA7 cDNA PCR amplified from the half hour incubations of 
the LCL cells with puromycin. This gel is identical to ones produced for all of the 
remaining time points (two hours, six hours and ten hours) with the exception that the 
bands are slightly fainter as the time course increased due to a lower concentration of 
RNA being extracted from the cells. This is thought to be due to the fact that the 
puromycin, when exposed to the cells for longer periods of time, especially at higher 
concentrations, begins to kill the cells due to it inhibiting ribosomes. It is also 
representative of cells not treated with puromycin. Figure 5.3 and the other gels 
acquired for the remaining time points show that only one PCR product is produced 
for all concentrations of puromycin. This PCR product is the correct size to contain 
exon 32 and this was confirmed upon Sanger sequencing.  
Two samples per time point were sequenced (usually the ones which had PCR 
amplified best upon electrophoresis examination) and this sequence was aligned to the 
reference sequence. All sequences aligned to the sequence for exon 32, showing it to 
be included in all samples. This sequence was also very clear, with minimal 
background noise, suggesting that an isoform not containing exon 32 was not even 
present at low levels, as demonstrated in Figure 5.4. This was also apparent in cDNA 
extracted from cells not treated with puromycin; indicating exon 32 is present in the 
ABCA7 isoform produced naturally by these cells, irrespective of the rs881768 
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genotype. All of these results were replicated in two puromycin treatments performed 
for each time point and each concentration.    
Figure 5.3 - Example of an agarose gel depicting the affect of nonsense mediated 
decay inhibition on the ABCA7 isoform produced. 
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Figure 5.4 - Electropherogram showing the 
affect of nonsense mediated decay inhibition 
on the ABCA7 isoform. A
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The electropherogram in Figure 5.5 shows the cDNA amplified with the positive 
control primers in both cell lines when they were not treated with puromycin. Here it 
is apparent that the four base pair deletion was not present. However, in cells treated 
with 200µg/ml of puromycin for 6 hours, the deletion becomes apparent in the 
HG00137 cell line which is heterozygous for this variant (see Figure 5.6). This 
validated the experimental approach performed in Section 5.1.2, demonstrating that 
NMD has been inhibited in these assays, suggesting NMD is unlikely to be 
responsible for eliminating the truncated form of ABCA7 with the 32
nd
 exon spliced 
out.  
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Figure 5.5 - Electrohpherogram showing the positive control used to 
unsure nonsense mediated decay had been inhibited in these 
experiments. 
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Figure 5.6 - Sequencing results of this positive control to 
show nonsense mediated decay had been inhibited. 
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5.3 Discussion 
Upon examination of cDNA extracted from lymphoblastoid cell lines containing both 
the minor allele (G) and major allele (A) of the variant rs881768, exon 32 of ABCA7 
is included in all transcripts, contradicting the results obtained in Section 4.4 where 
this exon was only included at low levels in the presence of the G allele. These cells 
were therefore treated with puromycin at a variety of concentrations and incubation 
periods in order to see if the surveillance pathway nonsense mediated decay controls 
the isoform expressed in the in vivo environment. As can be seen in Figures 5.3 and 
5.4, puromycin treatment had no apparent effect on the isoform of ABCA7 expressed, 
indicating that either NMD is not the surveillance pathway controlling this expression 
pattern or that the rs881768 variant does not regulate this isoform ratio. This was 
despite NMD being shown to be inhibited in these assays by PCR amplifying an area 
known to be controlled by NMD and showing a difference between cells treated with 
puromycin and those which had not been.   
Alternative treatments of the cells could be attempted to see if different compounds, 
for example cycloheximide, would perhaps act in a slightly different mechanism in 
order to inhibit NMDs action on this isoform (Cuyvers et al., 2015). However, from 
this data, it would appear that NMD may not be regulating gene expression in this 
instance, at least not in LCLs. There are several alternative surveillance pathways, for 
example, non-stop decay and no-go decay. However, these are unlikely to act in this 
situation as they are known to be activated by a ribosome stalled at the 3’ end of the 
mRNA (due to the absence of stop codons) or stalled at non-functional ribosomes 
respectively (Doma and Parker, 2006; Vasudevan et al., 2002). It appears, therefore, 
that the splicing out of exon 32, seen in Figures 4.8 and 4.9, may be artefact of the 
minigene assay and the presence of the whole ABCA7 genomic region, as seen Figures 
4.12 and 5.3, create some form of secondary structure interaction, forcing the 
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inclusion of exon 32 in the ABCA7 isoform. This could be examined further by 
designing alternative minigene constructs including more of the ABCA7 gene, for 
example including the exons either side of exon 32.  
Aberrant splicing may still play a part in LOAD pathology; therefore, the splicing of 
GWAS genes does still require investigation. However, the methodology used in this 
chapter is clearly able to generate false positive results and therefore alternatives need 
to be found. Exon arrays or RNA-seq are examples of this, both high throughput 
technologies examining alternative isoforms in the tissue of choice, in this case the 
brain.  
 
5.4 Conclusions 
Within the minigene assay system, the minor allele of rs881768 (G) is the only 
genotype which incorporates exon 32 into the ABCA7 isoform due to it strengthening 
the acceptor site at the start of this exon. However, when the total RNA is examined 
from brain tissue samples and transformed cell lines exhibiting both genotypes, exon 
32 is always incorporated. This is apparent even when the surveillance pathway 
nonsense mediated decay is inhibited, suggesting that this truncated isoform is not 
expressed at all in vivo. The truncated isoform seen in the minigene assays may, 
therefore, be an artefact of this particular methodology. This suggests that the in silico 
prediction programs used to predict splice site variants may not be entirely reliable 
and more dependable methodologies are required in order to identify potential 
pathological splice site variants. 
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6 Dual Luciferase Assays  
6.1 Introduction & Background 
s previously described, the primary aim of a Genome Wide Association 
Study (GWAS) is to identify genetic variations which are associated 
with a particular phenotype, for example,  LOAD. However, as many as 
half of the variants identified are not located in, or near, any coding genes. So the 
question remains as to how do they actually impact on pathology (Schierding et al., 
2014)? The matter is further convoluted by complex linkage disequilibrium (LD) plots 
between the GWAS tag SNPs and any actual causative variants, possibly genomically 
distant from these tag SNPs. However, it has been noted that a large proportion of loci 
identified through GWAS for complex diseases are, in fact, expression quantitative 
trait loci (eQTLs) implying that gene regulation may play a role in the risk of these 
complex disorders (Albert and Kruglyak, 2015; Li et al., 2016; Zhu et al., 2016). The 
fact that so many of these variants are within “gene deserts” supports this theory as, 
despite the fact that they may be distant linearly from any gene, DNA folding and 
interactions with proteins, mean they can act to regulate multiple distant genes 
(Schierding et al., 2014). In fact, recent studies have substantiated the idea that the 
causal genes behind GWAS signals are frequently not the nearest gene to that signal 
(Zhu et al., 2016). How, therefore, do these variants regulate gene expression? 
Virtually any step of gene expression can be controlled, with the process of promoter 
activity to transcription to mRNA expression to translation to protein expression being 
a sequential cascade with all steps being regulated (Li et al., 2016). However, the first 
step - that of transcription of DNA to RNA - is modulated through a wide variety of 
A 
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actions: transcription factors binding to specific DNA sequences; chromatin 
accessibility; DNA methylation; alternative splicing; small or long, intronic, non-
coding RNA; RNA editing as well as mRNA degradation. Transcription factor (TF) 
proteins bind to consensus DNA sequences in order to initiate mRNA transcription 
and are therefore vital in controlling many cellular processes. They contain a 
sequence-specific DNA-binding domain as well as other domains in order to interact 
with other proteins, for example, recruiting RNA polymerase enzymes or other TFs 
and co-factors, in order to initiate transcription (Rice and Correll, 2008). Commonly it 
is the promoter region of DNA which is responsible for initiating transcription of its 
gene, located on the same strand and upstream of the gene, usually no more than 
1000bp away. There are also enhancer elements, generally cis-acting, either upstream 
or downstream. Repressor and silencer regions also exist with the repressor site 
located close to or even overlapping the promoter region in order to block 
transcription when regulated by certain transcription factors. Silencer sequences 
mimic this but can be located elsewhere, although it is usually upstream of the gene in 
question (Albert and Kruglyak, 2015). RNA processing and transport is also highly 
regulated. Despite the fact that 40% of the human genome is transcribed to RNA, less 
than 2% goes on to be translated to proteins, highlighting the importance of these 
regulatory pathways (Rice and Correll, 2008). The flexibility of this gene regulation 
means that gene expression can be highly specific, as well as highly diverse, altering 
between cell types, even altering during differentiation of related cell types, and acting 
over large distances. It is also highly complex, with the distal regulatory components 
for just one cell equating to tens of thousands of elements, something especially vital 
in complex tissues such as the brain (Kitchen et al., 2014).  
Many eQTLs are SNPs which affect the binding of TFs or chromatin function, 
altering the DNA secondary structure and therefore the accessibility of the TF binding 
sites (TFBS), within these enhancer or promoter regions (Albert and Kruglyak, 2015). 
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These eQTLs may, therefore, alter protein levels even though they are often 
physically or genomically distant (even up to 2Mbp away in the human genome) from 
the gene in question (Albert and Kruglyak, 2015). In fact, only 25% of eQTLs are 
thought to act on the gene closest to them and only 50% on sites within 50kbp of their 
location (Schierding et al., 2014; Stamatoyannopoulos, 2016). It is thought that the 
majority of variants affecting gene regulation do so through their effect on TF 
binding, more commonly insertion or deletion variations as opposed to single 
nucleotide polymorphisms, or their effect within promoter or enhancer sites (Albert 
and Kruglyak, 2015).  
Due to this degeneracy, it is remarkably problematic to attempt to identify variants 
which may alter gene regulation and, subsequently, phenotype. There have been an 
increasing number of studies attempting to piece GWAS data together with expression 
data in an attempt to fill this gap (Gusev et al., 2016; Zhu et al., 2016). A systemic 
genomics approach, involving genetic, transcriptome, proteomic and phenotypic data 
would give a much more thorough and complete biological picture (Ritchie et al., 
2015). Identifying eQTLs through studies such as eGWAS (GWAS complimented 
with expression data) will also make identifying the disease associated gene much 
easier due to the mRNA levels being from a single gene as opposed to a GWAS loci 
highlighting one LD block (Zou et al., 2012). Examining gene expression also 
provides an “intermediate phenotype” between genetic variation and the higher 
phenotype - particularly useful in conditions such as LOAD where diagnosis cannot 
be confirmed until post mortem, making any results much more biologically 
interpretable and clinically relevant (Gamazon et al., 2015; Gusev et al., 2016). 
However, mapping these eQTLs in order to analyse them in combination with genetic 
studies is no easy feat, the primary issue being that eQTLs are very much tissue (and 
even cell type) specific. They therefore need to be mapped in all biologically relevant 
tissues in order to achieve this.  
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Most expression studies mentioned here, and in the further literature, all focus on 
mRNA levels as a measure of gene expression. However, protein levels also need to 
be considered as they could be more clinically accurate and can themselves be 
independently regulated, as mentioned earlier. Unfortunately specimen availability 
and costs of these expression studies make projects like this rare, although costs are 
decreasing as well as technology improving, possibly making these studies much 
more accessible in the future (Ritchie et al., 2015; Zou et al., 2012). Despite these 
problems, the importance of performing such studies has become apparent. As 
previously mentioned, there is a significant enrichment of regulatory variants within 
disease associated SNPs. In a recent study, approximately 80% of the chip-based 
heritability of disease risk for 11 different complex diseases are present in 
deoxyribronuclease (DNase) I hypersensitivity sites which play a role in chromatin 
accessibility and, therefore, transcription, highlighting the importance of gene 
regulation in disease processes (Gamazon et al., 2015; Zou et al., 2012). This is 
despite the fact that, when expression GWAS are carried out on a variety of brain 
tissue samples, it has been estimated that only a maximum of 18% of expression 
variance is due to the “best” e  Ls. (Zou et al., 2012). The remaining variation in 
gene expression is predominantly caused by environmental components or due to 
alteration by the trait itself in a reverse causal effect (Below, 2016; Gamazon et al., 
2015; Zou et al., 2012). However, this 18% is particularly vital in neurological 
disorders as regulation of gene expression is essential in brain function due to its 
complex structures, sub-structures and cell type varieties (Kitchen et al., 2014). 
Gene regulation has already been shown to play a role in LOAD pathogenesis. 
MicroRNAs (miRNAs - noncoding and involved in post-translational gene regulation 
by interacting with mRNA and silencing genes) have been shown to differ in 
expression between AD cases and controls and, consequently, affect the expression of 
some AD related proteins such as BACE1 (Shewale, 2012). There has also been a 
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huge range of genes that have been shown to be differentially expressed between AD 
brains and controls (Bai et al., 2013; Golde, 2016; Nho, 2016). 
Regulation of the ABCA protein family has also been linked with disease: an eQTL 
shown to alter ABCA1 expression levels has been associated with coronary 
atherosclerosis, a minor form of Tangier disease which ABCA1 loss-of-function 
mutations are known to cause (Kyriakou et al., 2004). Regulation of ABCA7 itself has 
also been linked to LOAD. Previous studies have suggested that ABCA7 mRNA levels 
are elevated during AD and cognitive decline (Karch et al., 2012) and the GWAS tag 
SNP rs3764650 is itself negatively correlated with ABCA7 mRNA levels in human 
brain tissue (Vasquez et al., 2013). Other SNPs within the ABCA7 locus have shown 
to significantly increase ABCA7 mRNA levels in human cerebellum and temporal 
cortex samples (Allen et al., 2012). In fact, in a large parallel re-sequencing project, a 
low frequency intronic SNP within ABCA7 (rs78117248) was the most significant 
associated variant (Cuyvers et al., 2015). This SNP is in LD with all three of the 
GWAS SNPs (rs3764650, rs4147929 and rs3752246) and seems to account for all of 
the disease risk presented by these tag SNPs due to its association with LOAD 
remaining after these three minor alleles were corrected for in a conditional logistic 
regression test (Cuyvers et al., 2015). What is even more interesting is that this SNP is 
located in an area of DNase I hypersensitivity and in a transcription factor biding 
region. When analysed using RegulomeDB (a database utilising features from the 
ENCODE project to score SNPs falling in regulatory elements (Boyle et al., 2012)), a 
score of 4 was assigned, indicating this variant has slight regulatory potential. Could, 
therefore, dysregulation of messenger levels of ABCA7 be the mode of action for 
pathogenic mutations within this locus? 
In order to identify these putative, possibly pathogenic, regulatory variants, colleagues 
in the Mayo Clinic, Jackson, Florida (including Dr Christopher Medway, Professor 
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Steven Younkin, Dr Mariet Allen, Dr Nilüfer Ertekin-Taner and Dr Minerva 
Carrasquillo), analysed data from RegulomeDB in order to highlight the most likely 
variations. One of the most promising results was that of rs2020000, scoring 1f in 
RegulomeDB indicating it is likely to affect binding of TFs and therefore be linked to 
expression of gene targets. This is mirrored in its annotation by HaploReg which, 
again, utilises chromatin state and protein binding annotations from ENCODE and the 
Roadmap Epigenomics projects (Ward and Kellis, 2011). In HaploReg rs2020000 
shows an enormous amount of data for regulatory potential in brain regions, including 
the hippocampus (Ward and Kellis, 2011). However, it does not appear to be the 
causative variant of ABCA7’s association with LOAD due to it not being in linkage 
disequilibrium (LD) with the GWAS tag SNP (D` = 0.829 and r
2
 = 0.013, see Figure 
6.1).  
Genomically rs2020000 is located upstream of ABCA7 (see Figure 6.1 , within the 3’ 
UTR of the gene directly upstream of ABCA7: CNN2.  Although it is located almost 
1Kbp upstream of ABCA7’s defined promoter region  see Figure 6.1 and (Iwamoto, 
2006)), the evidence for its regulatory potential is compelling. In Figure 6.2, taken 
from the UCSC Genome Browser (Kent et al., 2002), it can be seen that it is not only 
in an area of transcription factor binding (based on ChIP-seq data), it is also in a 
known area of DNase hypersensitivity and is linked to histone modification and 
chromatin binding in many cell lines, including neurological cell lines. This variant 
may be surprisingly far upstream of the gene of effect (see Figure 6.1). However, as 
previously discussed, eQTLs can be cis-acting and, therefore, up to 1Mbp away from 
their target gene. In fact, regulatory variants even further upstream of ABCA7 have 
been computationally identified, for example, the variant rs3087680 at genomic 
position 1038290 on chromosome 19, a further 67 base pairs upstream of rs2020000 
(19:1038223), as shown in Figure 6.1 (Nho, 2016). 
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Figure 6.1 - Representation of the genomic 
          f            h w       ’ 
relationship with other ABCA7 variants. 
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Figure 6.2 - Genomic region of rs2020000 showing the important regulatory elements present. 
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Variant rs2020000 was therefore genotyped in 271 cerebellum samples and 290 
temporal cortex samples (as part of the Mayo eGWAS dataset, presented by Allen et 
al., 2012 with the same sample demographics, gene expression measurements and the 
quality control of raw probe levels as presented in this study). Genotype and mRNA 
levels were then correlated through the Whole Genome DASL assay (Illumina, San 
Diego, CA, USA), utilising a linear regression model in order to correct for both 
disease-related and technical covariates including diagnosis, age-at-death, sex, APOE 
ε4 allele dose, plate number and RNA integrity. This confirmed that there is a highly 
significant association between the rs2020000-C minor allele and elevated levels of 
ABCA7 mRNA, confirmed by both ABCA7 probes (ILMN_1743205 and 
ILMN_2259319) as shown in Table 6.1. For both probes the most striking effect was 
seen in cerebellum samples but the direction of the effect was comparable in temporal 
cortex tissue. Due to the genomic location of this variant being within the 3’ U R of 
the CNN2 gene, association between rs2020000 allele dosage and CNN2 mRNA 
levels were also examined. However, these results were not significant due to the 
CNN2 probe on the WG-DASL microarray (ILMN_1770290) harbouring a 
polymorphism, this association did not pass quality control so no definitive 
comparison could be made (Zou et al., 2012).  
Table 6.1 - Increases of mRNA seen per minor allele dosage of rs2020000. 
Table 6.1
Cerebellum Temporal Cortex
p  = 1.19e
-10
p  = 2.36e
-03
Fold = 1.16 - 1.31 Fold = 1.04 - 1.17
p  = 8.39e
-04
p  = 4.39e
-02
Fold = 1.06 - 1.23 Fold = 1.00 - 1.21
ILMN_1743205
ILMN_2259319
Fold increase of mRNA per allele dosage of the minor allele (C) of 
rs2020000. ABCA7  mRNA levels were assayed utilising the probes 
ILMN_1743205 and ILMN_2259319 in cerebellum and temporal cortex 
samples in the Whole Genome DASL assay as part of the Mayo eGWAS 
dataset (previously described in Allen et al 2012). It can be seen that in all 
brain regions, both probes presented a significant association between 
this minor allele and an increase in ABCA7  mRNA expression. 
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Reporter gene assays were therefore designed in order to ascertain the true regulatory 
effect of this variant. These assays are based on the measurement of a reporter gene 
protein, in this case the bioluminescent firefly luciferase protein, following 
transfection of vectors coding for this protein as well as containing the DNA fragment 
under investigation. This reporter gene is not produced by mammalian cells and 
therefore should give a representative measurement of how this DNA sequence alters 
gene expression. However, inter-experimental variations are still likely to affect 
expression levels, for example cell number, pipetting error, transfection efficiency, 
cell lysis efficiency and assay efficiency. This can be minimised by utilising a second 
reporter vector, in this case the Renilla luciferase gene within a second vector, in order 
to normalize the activity of the experimental reporter protein with respect to 
experimental errors as well as adjusting for well-to-well variability and efficiency.  
The dual luciferase reaction assay system (Promega) was therefore utilised in order to 
compare promoter activity between the major allele (G) and the minor allele (C) 
promoter-luciferase constructs of this variant, in order to establish its regulatory 
nature in vitro. 
6.2 Materials & Methods 
6.2.1  Identification of Positive Controls 
Utilising the Perl script written by Christopher Medway (as described in Section 
3.2.1), samples were obtained from the ARUK DNA Bank which contained the two 
alleles in homozygous fashions for the variant rs2020000. Several of each genotype 
were selected to be PCR amplified and sequenced in order to ensure they only differed 
at the location of the variant. All samples within this DNA bank were collected with 
ethical approval and consent of all individuals. 
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6.2.2 Primer Design 
Primers were designed in order to amplify approximately 250bp either side of the 
variant, creating an insert of around 500bp. The methodology described in Section 
3.2.2 was followed with the exception of once the primer sequences were finalised, 
they were altered in order to incorporate attB sites into both the forward and reverse 
primers. This allowed the insert to be introduced into Gateway converted vectors 
containing the attR sites. The primers were modified as in Figure 6.3. 
6.2.3 Polymerase Chain Reaction and Sanger Sequencing 
The samples identified in Section 5.2.1 were PCR amplified and sequenced in order to 
validate their genotype. The reactions consisted of 1x Roche Expand High Fidelity 
PCR Buffer (Roche Diagnostics), 2mM MgCl2, 0.2mM dNTPs, 1pmol/µl of the 
primers designed as in Figure 6.3, 1U of High Fidelity Taq polymerase (Roche 
Diagnostics) and approximately 10ng of DNA in a volume of 30µl. They were 
thermocycled as follows: initially denatured at 94°C for 2 minutes then a further 15 
seconds at 94°C, annealed at 60°C for 30 seconds and extended at 72°C for 45 
seconds. This was repeated 10 times before the program was altered slightly in order 
to obtain a higher yield of the amplification products: the reactions were denatured 
again at 94°C for 15 seconds, annealed at 60°C for 30 seconds but the extension time 
was dropped to 40 seconds with an additional 5 seconds added every cycle, still at 
72°C. This was repeated for 20 cycles before a final extension step of 72°C was 
performed for 7 minutes.  
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All PCR products were examined by 1% agarose gel electrophoresis as described in 
Section 3.2.3 and sequenced as in Section 3.2.4 utilising the forward primer designed 
above at a concentration of 0.5pmol/µl. Demographics of the samples identified to be 
carrying the two alleles for variant rs2020000 upon analysis of this sequence, as 
performed in Section 3.2.4, are shown in Table 6.2. 
 
6.2.4 Polymerase Chain Reaction Product Purification 
In order to ensure the PCR products were pure and clean (for example all primer-
dimers, excess primers and dNTPs were removed), the QIAquick PCR Purification kit 
(QIAGEN) was utilised. 5 volumes of the binding Buffer PBI were added per volume 
of PCR product to allow binding of any single- or double-stranded PCR products in 
the solution. The pH was corrected with 10µl of 3M sodium acetate, pH 5.0 if 
indicated by the pH indicator within the buffer, before the mixture was transferred to a 
QIAquick spin column. This was centrifuged at 17,900 x g for 1 minute in order to 
bind the DNA to the column. 0.75ml of the wash Buffer PE was then added and the 
columns centrifuged, again at 17,900 x g for 1 minute. The flow through was removed 
and the centrifuge step repeated in order to remove all ethanol present from the 
addition of the wash buffer. The columns were then transferred to fresh tubes and 
30µl of the elution Buffer EB was added and incubated at room temperature for 1 
minute to uncouple the DNA from the column. The DNA was then eluted by 
Table 6.2 - Sample demographics of samples used to create the constructs for the 
dual-luciferase assays. 
Table 6.2
Sample ID Sex Centre of Origin Age at Death Age at Onset Disease Status ApoE Status
AD445 Male Nottingham NA NA Confirmed AD 3 3
BRI138 Female Bristol NA 58 Confirmed EOAD 4 4
Sample demographics of the samples used to create the constructs for these regulatory assays. The 
sample AD445 carries the major (C) allele for the variant rs2020000. This individual was a male with 
confirmed AD and carrying two ε3 alleles for ApoE, however, the age he died or the age the disease was 
diagnosed is unknown (NA). Sample BRI138 carried the minor (G) allele for the variant and was 
confirmed early onset AD (EOAD) with symptoms presenting at the age of 58. She was known to carry 
two ε4 alleles of the ApoE gene.
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centrifuging the columns at 17,900 x g for 1 minute before the products were 
quantified as described in Section 4.2.7. 
6.2.5 Gateway BP Recombination Reaction 
All of the Gateway protocols were performed following those from the manufacturer 
(Invitrogen). This recombination reaction was performed in order to introduce the 
attB-PCR products into the pDONR221 vector (containing the attP sites) to create an 
entry clone and a by-product as described in Figure 6.4 and allows much more rapid 
and efficient cloning when compared to utilising restriction enzyme digests as in 
Chapter 4. One reaction was performed for both the major and minor allele samples 
by combining 15-150ng of the attB-PCR product with 150ng of pDONR221 and 1x of 
the BP Clonase
TM
 II Enzyme mix, made up to 8µl with TE Buffer. This was then 
incubated at 25°C for one hour before terminating the reaction by the addition of 2µg 
of Proteinase K and incubating at 37°C for 10 minutes. This creates an entry clone 
containing the insert of interest flanked by the attL sites in preparation for the next 
step. 
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6.2.6 Transformation 
Both major and minor allele entry clone constructs were transformed into OneShot 
OmniMax 2T1 Phage-Resistant Cells (Invitrogen). 1µl of each BP reaction product 
was incubated with 50µl of these cells on ice for 30 minutes before being heat 
shocked in a 42°C water bath for 30 seconds. 250µl of SOC Media was then added to 
each vial of cells and these mixtures were shaken horizontally (250rpm) at 37°C for 
one hour. 
The cultures were each spread on plates consisting of 1.5% agarose, 4% Circlegrow® 
and 0.05mg/µl kanamycin (as this is the antibiotic resistance gene present in the 
pDONR221 vector).  All transformed cells were plated out at 20µl and 100µl of cells 
per plate. 80µl of SOC media was also added to the 20µl plates. These were incubated 
at 37°C for 16 to 18 hours. 
Four of the grown colonies were picked for each genotype the next day and grown up 
in 5ml of liquid media consisting of 4% Circlegrow® and 0.05mg/µl kanamycin. 
These were incubated at 37°C, shaking horizontally (250rpm) for 16-18 hours before 
their plasmid DNA was extracted.  
6.2.7 Plasmid DNA Extraction 
The plasmid DNA for the colonies grown above was extracted following the 
PureYield Plasmid Miniprep System protocol as per Section 4.2.7 (Promega). The 
plasmid DNA was quantified to determine its concentration using the Nanodrop 1000 
Spectrophotometer (Thermo Scientific) following the manufacturer’s protocol.  
All were then sequenced to validate the transformation had worked as previously 
described in Section 3.2.4. The primer used for this sequencing was the M13 Forward 
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primer (GTAAAACGACGGCCAGT) at a concentration of 0.5pmol/µl, the site of 
which is present upstream of the attP site in the pDONR221 vector. 
6.2.8 Gateway LR Recombination Reaction 
Once constructs of each genotype were identified, the LR Clonase
TM
 reaction was 
performed in order to introduce them into the destination vectors which would then be 
used as the reporter constructs. The destination vectors used in this instance were the 
pGL3 vectors (three in total - Basic, Promoter and Enhancer - Promega) which can be 
seen in Figure 6.5 B-D. All three of these had been previously modified (by a 
colleague - Dr Sally Chappell) in order to introduce the attR sites, as part of the 
Gateway Cassettes, by ligating a blunt-ended cassette containing the attR sites into 
either the 5’ or 3’ multiple cloning sites of theses vectors  see Figures 6.4 and 6.5). 
All vectors have both 5’ and 3’ cloning sites (in relation to the luciferase gene) and 
versions of all three vectors with the Gateway cassettes in both cloning sites were 
created. Due to the nature of the variant under examination and owing to its location 
in relation to the ABCA7 gene (nearly 1Kbp upstream of it), constructs of all three 
vectors were created with the insert in the 5’ cloning site.  he pGL3-Basic vector was 
used to initially ascertain whether the 500bp region containing the variant had, as a 
whole, any promoter activity when compared to the identical vector not containing 
this insert. The pGL3-Promoter and pGL3-Enhancer vectors were then used in order 
to amplify the differences, if any, between the major and minor constructs. The 
differences in signals between the two constructs, if small, would be more apparent in 
these two vectors due to the presence of the Simian vacuolating virus 40 (SV40) 
promoter and enhancer regions in these vectors respectively, as seen in Figure 6.5 C & 
D. The pGL3-Promoter vector was used, in this instance, to examine whether this 
region was acting as an enhancer in combination with the SV40 Promoter region (as it 
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would with the ABCA7 promoter region) and the pGL3-Enhancer vector was used to 
examine whether this region had promoter activity in isolation. 
In order to introduce the inserts into these destination vectors, 150ng of the products 
from the plasmid DNA extractions in Section 5.2.7 were incubated with 150ng of each 
of the destination vector and 1x of the LR Clonase
TM
 II enzyme mix, made up to 8µl 
with TE Buffer. This was incubated at 25°C for one hour before terminating the 
reaction by the addition of 2µg of Proteinase K and incubating at 37°C for 10 minutes. 
This created a destination vector (containing either the major or minor allele inserts in 
each of the three vectors) and a by-product as shown in Figure 6.4. 
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Figure 6.5 - Circle maps of the pGL3 vectors. 
 i  re     
Circle maps of the pGL3 Vectors. All contain the ampicillin resistance gene        guaranteeing 
ampicillin resistance in        , cDNA coding for the modified firefly luciferase       , f1 ori 
 origin of replication derived from filamentous phage  and ori  origin of plasmid replication in    
     . Arrows in the      and      genes indicate direction of transcription and the arrow in f1 
ori indicates direction of strand synthesis. Multiple cloning sites are also shown with specific 
restriction enzyme sites listed.  his is the location the Gateway Cassettes  A and B—both 
containing the    R site  were ligated. 
A 
 he pGL3-Control vector contains both the 
SV40  eukaryotic  promotor and enhancer 
sequences.  his results in a strong 
expression of the luciferase protein and is 
therefore used to monitor transfection 
efficiency. 
  
 he pGL3-Basic vector contains no 
promotor or enhancer elements, therefore 
luciferase activity is solely dependant on 
the insertion of a promotor sequence 
upstream of     . Enhancer elements may 
also be inserted downstream of     . 
  
 he pGL3-Promoter contains an SV40 
promoter upstream of the      gene. 
Putative enhancer regions can be inserted 
upstream or downstream of the SV40      
unit. 
D 
 he pGL3-Enhancer vector contains a 
SV40 enhancer downstream of the      
reporter gene. Putative promotor sequences 
can be inserted upstream or downstream of 
the      SV40 unit.  he presence of the 
enhancer unit will enhancer any action of 
the cloned promoter regions. 
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6.2.9 Transformation 
All of these vectors are transformed again, following the protocol as in Section 5.2.6. 
The only variation from this protocol was kanamycin was substituted with ampicillin 
(as this was the resistance gene the pGL3 vectors contain - see circle maps in Figure 
6.5) at a concentration of 0.1%. 
After an overnight incubation on agar plates, colonies were picked (two colonies per 
vector transformed) and incubated at 37°C in 25ml of liquid media (consisting of 4% 
Circlegrow® and 0.1% of ampicillin) shaking horizontally at 250rpm. 
6.2.10 Endotoxin Free Plasmid DNA Extraction 
These colonies had their total plasmid DNA extracted in an endotoxin free manner in 
order to reduce the chances of them contaminating the cells upon transfection. The 
NucleoBond Xtra Midi Plus EF Kit was utilised, following the protocol as in Section 
4.2.13, with samples then being quantified (as previously described) and sequenced 
following the BigDye Terminator v3.1 Cycle Sequencing Kit protocol as before (see 
Section 3.2.4). Samples were sequenced in both the forward and reverse direction in 
order to substantiate that the sequences of the inserts were correct. The primers used 
to sequence were the RV3 primer (CTAGCAAAATAGGCTGTCC), the site of which 
is located upstream of the 5’ multiple cloning site in the pGL3 vectors and the GL2 
primer (CTTTATGTTTTTGGCGTCTTCCA), the site of which is located 
downstream of the 5’ multiple cloning site in the pGL3 vectors.  
All vectors were examined by 1% agarose gel electrophoresis as in Section 3.2.3 in 
order to ensure they were intact.  
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6.2.11  ro i   “ mpty” Vectors 
In order to reduce variability and to allow the detection of small expression changes, 
alongside the experimental vectors, “empty” vectors were also transfected, containing 
no insert, as an inter-experiment comparison. This was alongside the pGL3-Control 
vector (see Figure 6.5A) which was also transfected alongside the above in order to 
provide a known level of luciferase activity i.e. a positive control. The pRL vector, 
containing the Renilla luciferase gene was also co-transfected with the experimental 
vectors, the “empty” vectors and pGL3-Control in order to normalize the firefly 
luciferase expression levels. 
In order to provide enough of all of these vectors to perform repeat transfections, more 
were grown in XL1-Blue Competent Cells (Stratagene, San Diego, California, USA). 
100µl of the cells were thawed on ice and, in pre-chilled 1.5ml tubes, combined with 
1.7µl β-mercaptoethanol. These are gently mixed before being incubated on ice for 10 
minutes. 50ng of the appropriate vector was then added to the tube, incubated on ice 
for 30 minutes before being heat shocked in a water bath heated to 42°C for 45 
seconds. They were chilled on ice for a further 2 minutes before being incubated with 
0.95ml of SOC media at 37°C for 1 hour being shaken horizontally at 250rpm. 
These cells were plated out on agar plates consisting of 4% Circlegrow®, 1.5% agar 
and 0.1% ampicillin. 80µl and 20µl of cells are both plated out, both being made up to 
100µl with SOC media. These were then incubated overnight at 37°C. 
Two colonies were selected per transformed vector, cultured overnight and extracted 
in an endotoxin-free manner before being sequenced as described above in Section 
5.2.10. The RV3 and GL2 primers were used in order to ensure the vectors 
transformed correctly. The reference sequences for the pGL3-Control, pGL3-Basic, 
pGL3-Promoter, pGL3-Enhancer vectors were obtained from the Promega website in 
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September 2015. The pRL vector did not contain any of these primer sites so, in order 
to ensure the transformation efficiency, this vector was restriction enzyme digested 
utilising the enzymes BamHI and HindIII, following the protocol as described in 
Section 4.2.9. The products were run on a 1% agarose gel, as in Section 3.2.3, to 
ensure two fragments were achieved for each digestion reaction - one of 1463bp and 
one of 224bp, confirming the presence of the pRL vector.  
6.2.12 Glycerol Stocks 
All colonies confirmed to contain the vectors expected in Sections 5.2.10 and 5.2.11 
had glycerol stocks made of them in order to prevent having to retransform the 
plasmid if more preparations were necessary. This was done by combining 200µl of 
the liquid culture with 800µl of glycerol in a 1.5ml tube. This was labelled well and 
stored at -80°C long term.  
6.2.13 Cell Culture 
All transfections were performed in BE(2)-C cells which were cultured and 
maintained as in Section 4.2.15.  
6.2.14 Transfection 
In preparation for transfection, BE(2)-C cells were plated into 12 well plates at a 
concentration of 3 x 10
5 
cells per well in 1ml of complete, filtered EMEM:F12 media. 
These were incubated in the plates at 37°C with a humidified atmosphere of 5% CO2 
in air for 24 hours. 
All vectors to be transfected were quantified as previously described and then diluted 
1µl in 9µl of dH2O in order to increase pipetting accuracy. The pRL Renilla 
Luciferase vector was also included here in order to co-transfect it into all of the cells 
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to provide an internal control value to which expression of the experimental firefly 
luciferase could be normalized.  
For each well 400µl of serum-free EMEM:F12 media, 20ng of pRL and 200ng of the 
appropriate vector were combined along with 9nl of TransFact
TM
 (Promega) per 
nanogram of vector DNA in order to facilitate the transport of the DNA into the cells 
through liposomes. Each vector was transfected in triplicate. These mixtures were 
vortexed well and incubated at room temperature for 15 minutes. The media was then 
removed from the cells plated out the day before and the 400µl of the prepared 
mixture added to each well. The plates were incubated at 37°C, 5% CO2 for 1 hour 
before a further 800µl of complete, filtered EMEM:F12 media was added to each well 
in order to enable cell growth. The plates were incubated at 37°C, 5% CO2 for 24 
hours in order to allow the firefly luciferase and Renilla luciferase proteins to be 
translated.  
6.2.15 Dual Luciferase Reporter Assay 
All reagents mentioned in this section are provided as part of the Dual Luciferase 
Reporter Assay System protocol (Promega). 
 Once the 24 hour incubation was complete, the media was removed from the cells 
and they were washed in warmed PBS twice in order to remove any traces of the 
media. 200µl of 1x Passive Lysis Buffer was then added to each well in order to 
rapidly lyse the cells. This was incubated for 20-40 minutes on a plate tipper in order 
to ensure all cells were lysed and their proteins released. In order to measure the 
activity of both firefly luciferase and Renilla luciferase two different reagents were 
prepared. Luciferase assay reagent II (LAR II) was prepared beforehand by 
resuspending the lyophilized Luciferase Assay Substrate in 10ml of the supplied 
Luciferase Assay Buffer II. This was aliquoted out in 1ml aliquots and stored at -80°C 
Page | 206 
 
before being defrosted on ice prior to use. This reagent activates the firefly luciferase 
when combined with the products of the cell lysis. The Stop&Glo® reagent was 
prepared just prior to use. 1 volume of 50X Stop&Glo® substrate was added to 50 
volumes of Stop&Glo® Buffer. This reagent quenches the firefly luminescence whilst 
simultaneously initiating the Renilla luciferase reaction.  
All measurements were performed on a  D 20 20 Luminometer   urner Design’s, 
San Jose, California, USA) by pre-loading 50µl of the LARII into an adequate number 
of 2ml disposable cuvettes. 20µl of the cell lysis was then added to each cuvette, 
mixed and loaded onto the machine. Upon being loaded, the machine delayed for 2 
seconds before taking a 10 second luminescence reading. This was repeated with 50µl 
of the Stop&Glo® for the same sample before that tube was discarded and the rest of 
the samples were measured. The luminometer then calculated a ratio of firefly 
luciferase:Renilla luciferase for each sample and an average ratio for each vector as 
well as standard deviation (SD) and a percentage coefficient of variation (CV) for 
these triplicate measurements. Readings were only accepted when the CV was below 
21% within each experimental triplicate as any higher than this implied that there was 
too much intra-experimental variability present. 
6.2.16 Statistical Analysis 
All statistical analysis was performed on SPSS Statistics version 23 (IBM 
Corporation, New York, USA). After elimination of any readings with a CV of 21% 
or greater, as well as any transfections where the luciferase levels in the pGL3-Control 
vectors were low  less than 10x the values in the other “empty” pGL3 vectors , the 
remaining values were checked for their distribution by plotting histograms containing 
a normal distribution curve. None of the vectors presenting as containing normally 
distributed luciferase to Renilla ratios, also corroborated by Kolmogoroz-Smirnov 
tests performed within SPSS, therefore dictating which statistical tests were 
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performed. The luciferase levels for the experimental constructs were normalised to 
the luciferase levels for the pGL3 vectors not containing an insert. Due to the skewed 
distribution of these datasets and the fact that the data was paired (as the readings 
were from the same transfections), a Wilcoxon signed rank test was performed 
between the normalised major allele and the normalised minor allele constructs in 
order to establish the effect of the minor allele on firefly luciferase expression. Fold 
differences between this set of vectors as well as between the experimental vectors 
containing the major allele and the “empty” pGL3 vectors were also calculated within 
SPSS, utilising the “transform variable” function. Medians and interquartile ranges 
(IQR) for these fold changes were also calculated in order to obtain a numerical value 
for the effect of both the variant in question, and the 500bp region as a whole, upon 
expression.  
6.3 Results 
One sample was identified to be homozygous for the G allele and one for the C allele 
of the rs2020000 variant within the ARUK DNA Bank. These samples were PCR 
amplified and sequenced utilising the primers presented in Table 6.3, incorporating 
the attB sites into the clones and validating their genotypes. The electrophoresis gel of 
the samples can be seen in Figure 6.6, showing amplicons of the correct size (498bp).  
 
 
 
Table 6.3 - Primers used to amplify the genomic region of rs2020000. Table 6.3
Primer Sequence Product Size Tm (°C)
Sense GGGGACAAGTTTGTACAAAAAAGCAGGCTGTGAGTGTCAGCGTGGGAT 
Antisense GGGGACCACTTTGTACAAGAAAGCTGGGTTTTCACTTCCTTGTACGGCC 
498 60
Primers designed in order to PCR amplify a region containing the variant rs2020000 to clone into reporter vectors. These primers contain 
the att B sites in order to introduce this clone into entry clones containing the att L sites. The product size achieved by these primers as 
well as the annealing temperature optimised for them are also shown (Tm). 
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The two samples (AD445 and BRI138) do not differ in their genetic sequence except 
at the location of the rs2020000 variant (position 19:1038223) and at a location 223bp 
downstream of this, 19:1038446, with the sample carrying the minor allele of 
rs2020000 (C), carrying a C allele at this genomic location (reference allele T). This 
was examined closer and the variant rs10419707 is present at this location, a T to C 
SNP with a MAF of 0.17. As this MAF is identical to that of rs2020000, the LD 
between these two variants was examined utilising Haploview (Barrett et al., 2005). 
As can be seen in Figure 6.7 these two variants are in complete LD, with a D` of 1.00 
and an r
2
 value of 0.947, implying that there is very little, if any, recombination 
between these two variants. Therefore, a sample containing the minor allele of both 
these variants was used as the minor allele construct. 
 
 
 
Figure 6.6 - Agarose gel showing the samples amplified to determine 
their genotype for variant rs2020000. 
            
      
                 
 i  re     
Ethidium bromide stained 1% agarose gel run at  0V for 25 minutes to amplify the genomic 
region for the variant rs2020000  expected product 4  bp .  he samples identified here 
 AD445 and BRI13   were subsequently sequenced and confirmed to carry the major  C  
and minor  G  alleles for this variant respectively. Also shown is a No  emplate Control 
 N C  demonstrating there was no contamination present. As can be seen, there was a large 
amount of primer-dimer present so these PCR products were purified before sequencing 
 utilising ExoSAP-I   as well as before they were used to create the clones  employing the 
 IAquick PCR Purification Kit .  
Page | 209 
 
 
 
Clones were therefore created utilising these samples. Examples of the pGL3-
Enhancer clones created can be seen in Figure 6.8(B). Also shown in Figure 6.8 are 
the pRL vectors grown for these transfections, digested by the restriction enzymes 
BamHI and HindIII in order to check the transformation worked efficiently. Two 
bands are shown, one of size 2242bp and one of 1463bp, indicating that this plasmid 
DNA is indeed the pRL vector.  Also shown in Figure 6.8 is the pGL3-Control vector 
of approximately 5256bp, where the majority of the DNA is supercoiled, indicating it 
is suitable for use in transfections. The identity of this plasmid DNA was confirmed 
through sequencing using the RV3 and GL2 primers. 
 
 
Figure 6.7 - LD plot between rs2020000 and rs10419707. 
 i  re     
Linkage Disequilibrium  LD  plot between the variants rs2020000 and rs1041 707 which have very similar 
minor allele frequencies  MAFs  of 0.1675 and 0.1661 respectively. A D  of 1 indicates there is an absence 
of recombination between the two loci.  he r2 value differs from 1 slightly due to the slight difference in 
their MAFs.  he log of the likelihood odds ratio  LOD  is also presented which is a measure of confidence 
in the value of D . A score of  2 obtains a dark red colour on the heat map, identifying that this score of 25 
indicates extremely high levels of confidence in this D  score.  
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The median luciferase readings, corrected to the Renilla readings, for all of the vectors 
transfected (pGL3-Basic, pGL3-Enhancer and pGL3-Promoter all with no insert and 
with inserts containing both the G and the C alleles) are presented in Table 6.4. From 
these values it can be seen that, in all three vectors, the reporter protein activity is 
greatly increased in the constructs containing the G allele when compared to the 
constructs with no insert but this activity is reduced in the constructs containing the 
minor allele C. These values for each vector, as well as the IQRs and any outlier 
readings are presented graphically in Figures 6.9-11. 
 
Figure 6.8 - Agarose gel showing the vectors used in the dual-luciferase assays performed. 
            
      
    
    -        
 i  re     
 A  shows vectors run on a 1% agrose gel, stained with ethidium bromide, alongside a 1kbp ladder.  he lanes with a “ ” 
show the         luciferase  pRL  vectors which have been digested with the       and         restriction enzymes, 
producing bands of 1463bp and 2242bp, in order to demonstrate that this transformation was successful. Alongside these 
digested plasmids, the uncut plasmids are also shown as a comparison. Here it can be seen that the majority of the 
plasmid DNA is supercoiled.  he pGL3-Control vector is also shown, this vector was Sanger sequencing in order to 
validate the transformation. 
 B  shows the vectors used in a transfection with the pGL3-Enhancer clones. All vectors transfected are shown including 
the pRL vector again, the pGL3-Control vector, the pGL3-Enhancer vector without the insert and the pGL3-Enhancer 
vector with the inserts containing both the major  G  and minor  C  alleles.  hese vectors appear slightly higher on the 
gel due to their heavier molecular weight as they contain the insert of 4  bp. All of these vectors are suitable for 
transfection due to the majority of the plasmid DNA being supercoiled.  
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Figure 6.9 - Median values for the pGL3-Basic vector. 
Table 6.4 - Median values for the luciferase level in all three reporter vectors. 
Table 6.4
Vector Allele Median IQR n
pGL3-Basic - 0.037 0.024 - 0.050 9
pGL3-Basic G 0.166 0.111 - 0.226 8
pGL3-Basic C 0.095 0.067 - 0.156 10
pGL3-Enhancer - 0.024 0.014 - 0.069 7
pGL3-Enhancer G 0.082 0.064 - 0.118 7
pGL3-Enhancer C 0.062 0.022 - 0.081 7
pGL3-Promoter - 0.869 0.434 - 1.185 8
pGL3-Promoter G 2.865 2.196 - 5.610 8
pGL3-Promoter C 2.785 2.146 - 4.990 8
Median values for the luciferase levels corrected to the Renilla levels in all three 
reporter vectors: pGL3-Basic, pGL3-Enhancer (containing the SV40 Enhancer 
region) and the pGL3-Promoter (containing the SV40 Promoter region). The 
va ues in th  presence of no insert (-), th ins rt containing the major allele (G) 
and the insert containing the minor allele (C) are all presented. The 25% and 75% 
interquartile ranges (IQR) are also displayed as well as the number (n ) of 
transfections performed in order to obtain these values. Each transfection was 
performed in triplicate.
 i  re     
Median values for the pGL3-Basic vector containing no insert  pGL3-Basic , the insert containing the 
major allele  GG  and the insert containing the minor allele  CC , all denoted by the thick black lines. 
 he edges of the blue boxes indicate the 25% and 75% interquartile ranges, the whiskers of the boxes 
mark the maximum and minimum values and the asterisk     shows an outlier value.  hese values are 
also shown numerically in  able 6.4.   for pGL3-Basic is  ,   for GG and 10 for CC, all performed in 
triplicate.    indicates the statistical test for the difference between the two vectors indicated returns a  -
value of  0.02. 
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Figure 6.10 - - Median values for the pGL3-Promoter vector. 
Figure 6.11 - - Median values for the pGL3-Enhancer vector. 
 i  re      
Median values for the pGL3-Enhancer vector containing no insert  pGL3-Enhancer , the insert containing 
the major allele  GG  and the insert containing the minor allele  CC , all denoted by the thick black lines. 
 he edges of the blue boxes indicate the 25% and 75% interquartile ranges, the whiskers of the boxes marks 
the maximum and minimum values and the circle  °  shows an outlier value.  hese values are also shown 
numerically in  able 6.4.   for all of these vectors is 7, all performed in triplicate.   indicates the statistical 
test for the difference between the two vectors indicated returns a  -value of  0.05 while    indicates the  -
value returned is  0.02. 
   
  
   
 i  re      
Median values for the pGL3-Promoter vector containing no insert  pGL3-Promoter , the insert containing the 
major allele  GG  and the insert containing the minor allele  CC , all denoted by the thick black lines.  he 
edges of the boxes indicate the 25% and 75% interquartil  ranges and the whiskers of the boxes indicate the 
maximum and minimum values.  hese values are also shown numerically in  able 6.4.   for all of these 
vectors is  , all performed in triplicate.    indicates the statistical test for the difference between the two 
vectors indicated returns a  -value of  0.02. If no markings are shown between the two vectors, this indicates 
that the  -value obtained was  0.05. 
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The median fold differences between the major and minor allele constructs as well as 
between the major allele constructs and the vector with no insert are presented in 
Table 6.5 alongside the IQRs and p-values as determined by the Wilcoxon signed rank 
tests performed. All of these fold changes indicate that the cloned 500bp region as a 
whole acts as an extremely strong promoter and enhancer region with an average fold 
increase of 5.1, 2.7 and 5.5 in the pGL3-Basic, pGL3-Enhancer and pGL3-Promoter 
vectors respectively with all of these tests returning a p-value of less than 0.02 and all 
of the 25% interquartile ranges being above one. The three tests between the major 
and minor allele also show similar patterns although only the pGL3-Basic and pGL3-
Enhancer tests produce p-values below 0.05. All three fold differences indicate that 
the minor allele (C) has a weaker promoter activity than the major allele (G), 
decreasing expression by about 30% in the two significant tests (see Table 6.5). 
 
 
Table 6.5 - Fold differences between the reporter vectors containing the 
major and minor alleles of rs2020000. 
Table 6.5
Vector Allele 1 Allele 2
Median Fold 
Difference
IQR p
pGL3-Basic C G 0.694 0.604 - 0.952 0.018
pGL3-Basic G - 5.089 3.681 - 8.640 0.018
pGL3-Enhancer C G 0.738 0.360 - 0.983 0.043
pGL3-Enhancer G - 2.667 1.918 - 5.619 0.018
pGL3-Promoter C G 0.832 0.735 - 1.050 0.263
pGL3-Promoter G - 5.484 2.409 - 6.203 0.012
Fold differences between two different vectors containing the major allele insert (G) and 
the minor allele insert (C) or no insert (-). A fold increase of < 1 indicates that   Allele 1 
decreases reporter gene expression while a fold increase of > 1 signals that  Allele 1 
increases reporter gene activity in the constructs. The 25% and 75% interquartile ranges 
(IQR) are also presented as well as the p -values for these different tests. Tests showing 
a p -value of less than 0.05 are highlighted in red. 
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6.4 Discussion 
rs2020000 is a common variant (MAF = 0.17) located upstream of the ABCA7 gene, 
within a sequence that is predicted to be regulatory based on compelling epigenetic 
and in silico data from the ENCODE Project and the Epigenetics Roadmap Project. In 
the Mayo brain eGWAS cohort, the minor allele of this SNP (C) was found to be 
associated with increased messenger levels of ABCA7 within the cerebellum 
(p<0.005) and was also the SNP with the strongest regulome score within 
RegulomeDB (1f), prompting us to further investigate its functional potential. The 
accuracy of this computational data was therefore assessed by in vitro assays. 
Promoter constructs identified that the region inserted into these constructs acted as a 
strong promoter region as a whole, creating a fold increase in reporter protein 
expression of 5.09 (p<0.02) within the pGL3-Basic vector. This is comparable in the 
pGL3-Enhancer vector but not to the same degree (fold increase of 2.67, p<0.02). 
However, this may be due to the high variation present in the measurements for the 
pGL3-Enhancer vector with no insert (see Figure 6.10). It appears that the fold 
increase would be higher without this high variation.  
It is also apparent that the region has some enhancer activity, with a fold increase of 
5.48 in the pGL3-Promoter vector with a p<0.02. This implies that this region acts as 
a strong enhancer in combination with a promoter region further downstream of it, 
shown by the high increase in enhancer activity in the pGL3-Promoter vectors, 
containing the SV40 promoter site downstream of the multiple cloning region where 
our clone was introduced. This increases the likelihood that this region acts as an 
enhancer to the ABCA7 gene due to its genomic location upstream of the documented 
ABCA7 promoter region (see Figure 6.1).  
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The eGWAS data for this variant predicted that the minor allele (C) was associated 
with increased messenger levels of the ABCA7 gene (see Table 6.1). Contradicting 
this, these promoter constructs showed that this allele decreased expression of the 
luciferase protein. In both the pGL3-Basic and pGL3-Enhancer the minor allele 
decreases expression by approximately 30% (p<0.05 in both).  This pattern is also 
shown in the pGL3-Promoter construct but not to the same extent, decreasing 
expression by approximately 25% but returning a p-value of >0.05. 
When examining this variant in GTEx, an expression database recently available, this 
also shows the minor allele (C) increasing ABCA7 expression, as shown in Figure 
6.12 (effect size of 1.35, p = 2.1e-8). This supports the results from the microarray 
results presented in Section 6.1, even to approximately the same degree with GTEx 
estimating the C allele to increase expression by 35% and the eGWAS 20%.  
Figure 6.12- Single tissue expression data for rs2020000 from the GTEx  database. 
 i  re      
Single tissue expression data for rs2020000 transcript ENSG000000646 7.         , measured in brain 
cerebellum tissue.  hese measurements are taken from volunteer samples and, as such, are unrelated to clinical 
status.  his demonstrates that the minor allele  Homo Ref  allele of rs2020000  C  up regulates       
expression levels when carried in a heterozygous and homozygous fashion  effect size of 0.35,     2.1e-  .  he 
confusion between the alleles in this figure is explained by the fact that the minor allele  C  is labelled as the 
reference allele in hg1  GRCh37 as shown in Figure 6.2.  he fewer numbers of alleles present in the “Homo 
Ref” and “Het” datasets    25 and   2 respectively  endorses this.  his RNA-seq study therefore confirms the 
microarray data presented in Section 6.1, contradicting the dual luciferase assays performed in Chapter 6.  his 
image was taken from gtexportal.org  accessed October 2016 . 
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This inconsistency may be due to the eGWAS and GTEx examining mRNA levels 
whereas the luciferase assays examine protein levels, would proteomics work in brain 
tissue be more descriptive despite it being much more challenging (Golde, 2016)? The 
fact that the eGWAS data was acquired from AD brains and this disease state itself 
may affect the messenger expression levels must also be taken into account. An 
alteration in gene expression levels can be a consequence of disease, in a reverse 
causal effect, as opposed to the causal event (Albert and Kruglyak, 2015). Of course, 
all data acquired in vitro does not necessarily represent what happens in vivo. Despite 
many previous studies finding that dual-luciferase assays are extremely sensitive and 
reproducible (Brasier and Ron, 1992), in vitro inaccuracies may occur due to temporal 
regulation, tissue specificity or the remaining genetic background (Cirulli and 
Goldstein, 2007). It has also been shown that regions function differently depending 
on whether they are integrated into the cellular chromosome or acting as an episome, 
as the transfected vectors are in these assays (Inoue et al., 2016). This is thought to be 
due to the altered binding of chromatin and that chromosomally integrated sequences 
have a more replicable and reproducible activity then those of identical sequences in 
episomes. Action of the integrated sequence are also more foreseeable by ENCODE 
annotations (Inoue et al., 2016). However, in 2003, Hoogendoorn et al showed that if 
putative promoter constructs met three criteria, then the reproducibility of these 
promoters was extremely high. These three criteria were: statistically significant 
differences in expression between the constructs with p<0.05; replication with 
independent construct preparations and  1.5-fold difference in expression between 
haplotypes (Hoogendoorn et al., 2003). The first two of these criteria are met in all 
tests highlighted as red in Table 6.5, although, the fold difference between the two 
alleles is not big enough to be defined as an enhancer haplotype as per this criteria. 
However, this study did not include any constructs which down-regulated expression, 
therefore leaving a gap in these proposed standards (Hoogendoorn et al., 2003).  
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The contradiction seen between the microarray data and these promoter constructs 
may also be due to several other factors. For example, the haplotype this variant 
occurs in should also be considered. It may be that the minor allele (C) of rs2020000 
is in strong LD with another, stronger, eQTL which increases expression of ABCA7. 
This may counteract the decrease in expression rs2020000-C provides, explaining 
both the microarray and cellular assay results presented here. The cell line used in 
these assays should also be considered. BE(2)-C cells are a transformed cancer cell 
line and may, therefore, not be entirely representative of what occurs in vivo. 
Consequently, an alternative cell line should be used to replicate these assays, for 
example, primary neuronal cells which would obviously be the most representative of 
the in vivo environment. However, these cells are difficult to acquire, as well as 
maintain, therefore an alternative may be stem cells which have been differentiated 
into neuronal cells. The difficulty of transfecting into these cells is also unknown, so 
future work would involve looking into this. 
As mentioned previously, a link between levels of ABCA7 mRNA and the risk of 
LOAD has already been established. In 2013 it was noted that the minor allele of the 
GWAS tag SNP rs3764650 (G - associated with increased risk of LOAD) was also 
associated with a dose-dependent decrease in ABCA7 mRNA levels (Vasquez et al., 
2013). However, increased expression of ABCA7 has been associated with more 
advanced cognitive decline, as seen in LOAD pathogenesis (Karch et al., 2012). The 
authors explain these links through ABCA7’s postulated function in phagocytosis 
(Vasquez et al., 2013): the knockdown of ABCA7 leads to a significant reduction of 
phagocytosis of apoptotic cells and increased expression of ABCA7 increases the 
phagocytosis of multiple substrates, decreasing Aβ cellular uptake in mouse models 
(Jehle et al., 2006; Kim et al., 2013). Immune response, including phagocytosis, is a 
pathway that has been linked to AD neuropathogenesis previously (see Figure 1.5), 
suggesting that ABCA7 may reduce AD risk through activating phagocytosis, 
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therefore increasing the removal of apoptotic debris as well as the uptake of Aβ 
(Morgan, 2011). However, this does not explain the fact that increased ABCA7 mRNA 
levels have been seen in AD individuals. This may be due to compensatory changes: 
long-term over-expression of ABCA7, as exhibited by the rs3764650 major (T) allele, 
reduces an individual’s risk of AD and, therefore, the increased expression of ABCA7 
seen in AD cases, may be an inadequate, late, compensatory change (Vasquez et al., 
2013). The under-expression of ABCA7, as seen in the minor allele of this SNP in the 
promoter constructs, may therefore be a risk factor for developing LOAD but is over-
compensated for further down the disease process by alternative regulatory 
mechanisms, increasing ABCA7 levels again, perhaps explaining the association seen 
in AD cases in the eGWAS cohort. 
However, the association of this variant with disease is unclear and is something 
which does need to be established before this variant can be classed as possibly 
disease-causing (MacArthur et al., 2014). As mentioned previously, this variant is 
unlikely to be the causative, pathogenic  variant within ABCA7 due to the lack of LD 
between this SNP and the GWAS tag SNP rs3764650 (D` of 0.829 and a r
2
 of 0.013). 
In the same genotyping project performed in the Mayo Clinic, Jacksonville (USA) 
discussed in Chapter 3, this variant was also genotyped, alongside the GWAS tag SNP 
rs3764650. A brief association test utilising this data, acquired in Chapter 3 (a 
Fisher’s exact test as performed in Section 3.2.   was carried out and the results are 
presented in Table 6.7. Here it can be seen that, although rs3764650 is strongly 
associated with LOAD as expected (OR = 1.32, p = 3.28e-7), rs2020000 was not (OR 
= 0.9674, p = 0.50).  
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Regardless of this, as previously discussed, the levels of ABCA7 do seem to be 
associated with AD risk. Could it, therefore, be this GWAS tag SNP rs3764650 that is 
regulatory? As already stated, the major allele of this variant has been associated with 
increased messenger levels of ABCA7 (Vasquez et al., 2013). However, it only scores 
2a in RegulomeDB and there is no evidence in the HaploReg database of it having 
regulatory potential in neurological tissue, although there may be some evidence here 
of its putative regulatory action in other tissues, such as blood. The minor allele of 
rs3764650 could, therefore, be a tag for haplotypes with actual regulatory variants or 
with variants coding for isoforms which are subjected to nonsense mediated decay in 
order to decrease ABCA7 expression. As a consequence of this, the risk presented by 
the minor allele of rs3764650 may be due to the protective effect of its major allele in 
multiple haplotypes with relatively weak regulatory variants which increase ABCA7 
messenger levels, such as the major allele of rs2020000. These weak variants do not, 
therefore, show an association with AD as they present with the major allele of 
rs3764650, masking them. 
As mentioned previously, a recent DNA sequencing project, specifically looking at 
ABCA7, sequenced 772 LOAD patients and 757 controls. The most significant 
association with disease was an intronic variant, rs78117248. This variant is located 
within a transcription factor binding region, DNase hypersensitivity site and had a 
RegulomeDB score of 4 indicating a small regulatory effect. The variant is also in 
Table 6.6 - Statsitical results showing the association of rs2020000 and rs3764650 with LOAD as 
outputted by PLINK. 
Table 6.7
CHR SNP BP F_A F_U P OR L95 U95
19 rs2020000 1038223 0.1249 0.1286 0.5009 0.9674 0.8803 1.063
19 rs3764650 1046521 0.1106 0.08607 3.28E-07 1.32 1.187 1.468
Statistical results from the Fisher's Exact tests run on rs2020000 and rs3764650 from the Mayo genotyping 
data acquired as part of the work presented in Chapter 3. CHR = chromosome the variant is present on, SNP = 
SNP ID (in this case the rs number of both SNPs), BP = base pair position of the SNP, F_A = frequency of the 
minor allele in cases, F_U = frequency of minor allele in controls, P = exact p -value, OR = Odds Ratio, L95 = 
Lower 95% Confidence Interval, U95 = Upper 95% Confidence Interval. As can be seen, only the test for the 
rs3764650 variants returned a significant result. 
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high LD with all of the ABCA7 GWAS tag SNPs (see Figure 6.1),  highlighting what a 
potentially vital role regulatory variants play in disease association (Cuyvers et al., 
2015). This is not the first tentative regulatory variant highlighted in ABCA7. In 2012, 
the same dataset used to elucidate rs2020000 was used to computationally identify the 
minor alleles of rs7247087 and rs2072102 as being associated with elevated levels of 
ABCA7 mRNA. It could be any, or all, of these putative regulatory variants in LD 
with rs3764650 which, therefore, alter ABCA7 levels pathologically. However, none 
of these variants have been confirmed to be regulatory through assays such as the ones 
performed here (Pers. Comm. Dr Medway). 
Although this variant does appear to have regulatory effects, the mechanism behind 
this is unknown. Figure 6.13 demonstrates the output from the MatInspector program 
(Genomatix, Munich, Germany) which annotates TFBS within DNA sequences 
(Cartharius et al., 2005). As this demonstrates, it appears that the minor allele of 
rs2020000 alters the binding of several transcription factors, eliminating a TFBS and 
introducing a further three. This may be the cause of the regulatory effect seen in 
these functional assays. Future work would involve performing Electrophoretic 
Mobility Shift Assays (EMSAs) utilising nuclear proteins extracted from the BE(2)-C 
cells in order to see if there is a difference in binding of these proteins between 
oligonucleotides containing both the major and minor alleles. These EMSAs were 
started as part of this project  but were not able to be optimised in the time available. 
Two of the TFBS introduced by the minor allele of rs2020000 are part of the X-box 
binding protein (XBP) family (see Figure 6.13). Interestingly in 2011, one member of 
this protein family (XBP1) was associated with neuroprotective actions in AD models 
by reducing the neurotoxicity of Aβ, causing the authors of this study to identify it as 
a potential therapeutic target for AD (Casas-Tinto et al., 2011). 
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The importance of regulatory variants within the pathogenesis of complex disorders, 
such as late onset Alzheimer’s disease, has already been discussed.  he fact that gene 
expression regulation could also provide a therapeutic target, or even as a diagnostic 
marker, for these complex diseases should also be highlighted. Not only can the genes 
themselves be targeted, but also the TFs which regulate them, providing many 
potential therapeutic targets and diagnostic aids (Gamazon et al., 2015; Golde, 2016; 
Nho, 2016).  
 
Figure 6.13 - Transcription factor binding sites around the region of rs2020000. 
 ajor Allele -  
 i or Allele -   
 i  re      
 ranscription factor binding sites predicted for the genomic regions both containing the major allele  G  and the minor allele  C  of 
rs2020000.  he minor allele appears to remove a site for the Myc associated zinc finger and introduces a binding site for Myocyte 
enhancer factor 3  MEF3  as well as two X-box binding  XBP  factor sites. Images taken from MatInspector  Cartharius       2005 . 
Page | 222 
 
6.5 Conclusions 
In conclusion, both the functional and computational analysis of rs2020000 has 
suggested that it is significantly associated with altered messenger levels of ABCA7. 
The functional studies suggest that the minor allele of this variant is associated with 
decreased levels of proteins and the rationale behind this association will need to be 
examined through Electrophoretic Mobility Shift Assays. It will be important to 
establish the role of this particular variant in relation to AD risk. However, the 
methodology utilised here provides a direction for further functional variant discovery 
within GWAS loci hits for any complex disorder.  
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7 General Discussion 
he ABCA7 protein is a member of the ATP-Binding Cassette family, all 
of which are transmembrane transporter proteins. ABCA7 itself has been 
associated with transporting phospholipids, and to a lesser extent 
cholesterol, as do most of the ABCA family. ABCA7 specifically transports substrates 
across cell membranes to extracellular apolipoprotein A-I and apolipoprotein E (Abe-
Dohmae et al., 2004; Chan et al., 2008; Wang, 2003). However, ABCA7 has also 
been shown to share a high degree of homology with CED-7: a vital protein in 
phagocytosis in nematodes. It is now recognized that ABCA7 also regulates 
phagocytosis in several mammalian cell lines (Iwamoto, 2006; Jehle et al., 2006).  
In 2009 rs3764650-G, located in intron 13-14 of ABCA7, was reported to be 
associated with an increased risk of late onset Alzheimer’s disease  LOAD  
(Hollingworth et al., 2011; Adam C. Naj et al., 2011). However, the mechanisms 
behind the association of this SNP with LOAD, as well as the role of ABCA7 in 
LOAD risk, still remain largely unknown. A large proportion of GWAS hits, 
including rs3764650, are in noncoding regions of the genome. It is possible, therefore, 
that these GWAS hits may instead play a role in the regulation of gene or isoform 
expression, as opposed to the direct protein structure encoded by these genes. 
ABCA7 messenger levels are, in fact, elevated during the AD disease process and 
cognitive decline (Karch et al., 2012) and rs3764650 is itself negatively correlated 
with ABCA7 mRNA levels in human brain tissue (Vasquez et al., 2013). This SNP has 
T 
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also been associated with neuritic plaque burden in AD brain autopsy samples 
(Shulman et al., 2013) and amyloid-beta (Aβ  plaque load when assessed by 
Pittsburgh compound B-positron emission tomography (DiB-PET) (Hughes et al., 
2014). This implies that ABCA7 plays a role in AD pathogenesis, also corroborated 
by genetic studies. In a recent re-sequencing project involving Icelandic, European 
and American populations, loss-of-function ABCA7 variants increased AD risk with a 
combined odds ratio (OR) of 2.03 and p-value of 6.8 x 10-15 (Steinberg et al., 2015). 
This has also been replicated in a Belgium cohort (OR = 4.03 and p = 0.0002) 
(Cuyvers et al., 2015). 
The idea that these functional variants could be one of the reasons for ABCA7’s 
association with LOAD, as well as the fact that predicting functionality of coding 
variants is much better understood then noncoding variants, led to the first three of the 
aims of this thesis. These were to create a catalogue of ABCA7 exonic variants 
utilising previous sequencing projects as well as online catalogues; to analyse these 
variants in order to identify those predicted to affect ABCA7 function before 
performing genotyping assays on these variants to determine if they were associated 
with disease. This full catalogue of variants was created and is available in Appendix 
A. Based on the data collected, as well as the annotations from the prediction 
programmes used, a total of five variants were identified as being potentially 
damaging to ABCA7’s function as well as having a minor allele frequency  MAF  
high enough in order to genotype them in the ARUK DNA bank whilst achieving 
power of at least 75%. All five were therefore genotyped utilising the KASP™ 
genotyping system with rs3752239 (OR = 0.86, p = 0.039), rs59851484 (OR = 0.28, p 
= 0.022) and 19:1056958 T>C (OR = 3.53, p = 0.38) all presenting promising, 
suggestive results. However, no results were significant following correction for 
covariates or multiple testing and replication will therefore be required in a larger 
dataset, especially for the variant at genomic position 19:1056958 due to its rarity. 
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However, what is of interest is the location of rs778244634. This variant is located 
within exon 34 which is the same functional domain (transmembrane eight) as a 
variant in strong LD with the GWAS tag SNP; rs3752246 (Adzhubei et al., 2010; 
Hollingworth et al., 2011). A variant discussed below is also within this exon, 
rs881768, however is not within this transmembrane domain but within the large 
extracellular domain prior to this domain. 
The final aim of this thesis was to design and carry out in vitro assays to analyse 
potential functional ABCA7 variants, presented in Chapters 4, 5 and 6. In Chapter 4, 
the variant rs881768, identified through a Next Generation Sequencing (NGS) project, 
was predicted by in silico tools to affect splicing of exon 32 of ABCA7. The minor 
allele (G) was predicted to remove an SRSF6 site, introduce an SRSF1 site (by the 
ESEfinder programme), introduce a novel donor site (by the BDGP site), activate a 
cryptic donor site and alter both an ESE and an ESS site (by Human Splicing Finder). 
This variant was therefore analysed utilising the minigene assay where it was apparent 
the minor allele (G) was the only genotype which showed inclusion of exon 32, 
corroborating the in silico predictions of the minor allele strengthening the acceptor 
site. However, this was not replicated in expression databases such as GTEx, RNA 
extracted from brain or lymphoblastoid cells, even when the surveillance pathway 
nonsense mediated decay (NMD) was inhibited in Chapter 5; implying this truncated 
isoform is not produced in vivo. LOCATION RE rs3752246 (Hollingworth) 
This data shows that exon 32 is, in fact, incorporated in all transcripts suggesting that, 
perhaps both the in silico and the in vitro tools used here may not be entirely accurate. 
Indeed, at the time the NGS project was performed, the best predictor of splicing 
variants was the Variant Effect Predictor (VEP) which only examines the first three 
base pairs in the exons and the first eight base pairs in the introns, therefore 
potentially missing many splicing mutations. More high-throughput programmes are 
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available now but it is known that numerous splicing variants have been missed or 
incorrectly annotated due to the inaccuracy of programmes such as these (Singh and 
Cooper, 2012). 
In Chapter 6, the variant rs2020000 was examined for its potential to regulate the 
ABCA7 protein after in silico analysis presented it as a strong functional candidate. 
Both assessment of gene expression in brain tissue, through eGWAS (Allen et al., 
2012), and in vitro assessment, performed here; indicate the minor allele (C) does alter 
expression of ABCA7 mRNA although this was in opposite directions. In brain tissue, 
as well as in expression databases such as GTEx, the minor allele appears to increase 
ABCA7 mRNA expression but within the dual luciferase cellular assays, it appears to 
downregulate reporter gene activity.  This contradiction between the cellular assays 
performed here and the microarray and RNA-seq results may be due to several 
caveats. For example, this variant may act in a regulatory haplotype not included in 
the cellular assays, as well as the transformed cell line used (BE(2)-C) may not be 
entirely representative of the gene regulatory architecture in vivo.  
However, there is also little evidence of association between rs2020000 and LOAD, 
shown upon association testing performed upon the same genotyping data acquired 
from the Mayo Clinic as used in Chapter 3. Despite this apparent lack of disease 
association, this variant does still have regulatory potential, although the mechanisms 
behind its action remain unknown. This will be examined through electromobility 
shift assays (EMSAs) in the future to observe if the difference in expression is due to 
a difference in transcription factor binding. Other ABCA7 variants will also be 
examined in the same way - specifically rs2072102 and rs7247087, presented in Allen 
et al., 2012 as part of the same project which identified rs2020000. 
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The pipeline developed as part of this thesis will be invaluable in the future in order to 
identify further regulatory variants, as it is becoming increasingly obvious that gene 
expression plays a key role in complex disease pathology (Gamazon et al., 2015; 
Maurano et al., 2012; Zou et al., 2012). However, expression SNPs still remain 
remarkably difficult to annotate due to the fact that the linear relationship between the 
SNP and the nearest gene cannot be inferred and gene expression can be regulated by 
multiple elements (Corradin et al., 2014). More and more programmes are becoming 
available in order to provide these annotations, for example ENCODE and 
RegulomeDB. However they are not always tissue specific due to the eQTL 
architectures altering significantly between different tissue and cell types.   
The exponential increase in sequencing projects designed to identify the functional 
variations associated with LOAD has led to a vast amount of sequencing data being 
available. However, we are still very much reliant on functional databases and 
prediction programmes in order to annotate this data correctly. These types of 
platforms have become increasingly common and have gained better accuracy over 
the past few years. However, as presented here, they are still not entirely 
representative and there is a need for better predictions. Improvements in these in 
silico databases will allow increasingly accurate functional annotation of sequencing 
data and, therefore, help direct future laboratory experimental design.   
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7.1 AD Genetics Update 
Despite seven years since the original LOAD GWAS were published (Harold et al., 
2009; Lambert et al., 2009), we are still not much closer to identifying the precise 
genetic aetiology of this devastating disease. 
 he hypothesis originally adopted when designing G AS was “common disease - 
common variant” where common diseases, such as LOAD, are caused by a 
combination of common variants, present in all populations (Gibson, 2012). However, 
given that there is still a lack of knowledge of the full heritability of LOAD - 
anywhere from 44% to 60% has been said to still be missing in recent studies (Escott-
Price et al., 2016; Ridge et al., 2016) - alternative hypotheses have been theorised. 
These include large numbers of small-effect common variants, small numbers of 
large-effect rare variants as well as a combination of genotypic, environmental and 
epigenetic factors providing the genetic risk for these diseases (Gibson, 2012). Given 
the vast number of sequencing projects that have been carried out on these LOAD loci 
(NGS, whole genome sequencing, exome sequencing etc.), it is going to be more and 
more problematic to identify the remainder of this “missing heritability.” 
In the past two years the concept of polygenic risk scores (PRS), in relation to AD 
genetics, have gained ground. These work on the hypothesis that there are many 
common variants; each having a small effect on an individual’s risk of a complex 
disorder, and this “genetic background” can be used to give an individual a risk of 
developing these disorders. Most recently, 87,600 SNPs were used to give a PRS for 
LOAD with an accuracy of 82% which may be increased further by incorporating age, 
gender, environmental and clinical data into the algorithm (Escott-Price et al., 2016). 
However, these authors suggest that any further loci or pathways identified as being 
associated with LOAD will not add much more to this accuracy as the majority of 
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them will be so rare. Although additional rare variants have been detected to be 
associated with AD, for example in the TREM2 (Guerreiro et al., 2013), AKAP9 
(Logue et al., 2013), PLD3 (Cruchaga et al., 2014), and UNC5C (Wetzel-Smith et al., 
2014) loci, these have been few and far between.  
 his “missing heritability” has also been attributed to epigenetic factors, including 
hard-to-detect gene interactions, as well as exogenous environmental factors. A small 
number of these epigenetic factors can be examined through the notoriously difficult 
to annotate noncoding variants. Despite this difficulty, their role in complex disorders 
is vital, with 90% of GWAS hits being in noncoding regions (Schaub et al., 2012), 
where they may in fact, still be functional. For example, up to 80% of GWAS hits 
have been shown to be in DNase hypersensitivity sites, possibly playing a role in 
transcription (Gamazon et al., 2015). Functional annotation programmes for these 
noncoding variants are more common (for example GTEx, RegulomeDB, HaploReg, 
BDGP and ESEfinder as used in this project). However, tissue and cell specificity of 
these interactions, as well as gene expression regulation, still need to be considered 
and are not in databases such as these. Therefore, integrating additional elements into 
these programmes will only allow increased utilisation of them in order to improve the 
accuracy in annotating these noncoding variants. 
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7.2 Future of AD Genetics 
As previously discussed, identifying additional rare variants associated with LOAD 
may not add a huge amount more to our knowledge of this disease’s genetic 
architecture. Further work may, therefore, focus on understanding the molecular 
mechanisms behind the disease process. Examples of this could include examining 
chromatin structure within the LOAD loci, in order to explore gene regulation, as well 
as the use of induced pluripotent stem cells (iPSC). These iPSC, generated from 
patient samples, provide an excellent alternative to in vitro systems currently used, for 
example the minigene and dual luciferase assays used in this project. The 
differentiation of human stem cells to neurones, as well as other neuronal cell types 
such as astrocytes, microglia and oligodendrocytes, will allow the identification and 
validation of new disease pathways, including possible therapeutic targets, within the 
background of AD patients’ genomes.  his will provide further understanding as to 
how the complex genetic architectures act, in order to appreciate the susceptibility and 
response to environmental factors these provide. This will possibly supply 
pharmacologically modifiable targets in these AD patients (Goldstein et al., 2015). 
 he idea of “risk haplotypes” is becoming more likely, as opposed to single variants 
defining disease risk, especially with the recent development of PRSs. The indication 
of an ABCA7 risk haplotype was discussed in Chapter 6 (see Section 6.4), as well as in 
Cuyvers et al., 2015. Here the authors identified a four times enrichment of rare, loss-
of-function mutations in LOAD patients within ABCA7. These mutations are 
predicted to result in loss of ABCA7 transcript due to NMD, reducing ABCA7 
expression, suggesting that haploinsufficiency may be the mode of action of any 
pathogenic ABCA7 mutations (Cuyvers et al., 2015). 
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However, what is unknown is the molecular mechanism of these loss-of-function 
variants and why they associate with LOAD risk. Is it because of ABCA7’s postulated 
function within phagocytosis (Jehle et al., 2006)? Does a decrease in ABCA7 lower 
the ability of microglia to clear apoptotic debris or amyloid plaques? Or altered lipid 
metabolism (Abe-Dohmae et al., 2004), especially vital in the lipid rich brain? These 
functionalities - impaired or not - are the kind of processes that could be examined in 
iPSCs carrying these loss-of-function variations. 
 
  
Page | 232 
 
7.3 Conclusions 
This thesis has focused on identifying functional variants within the late onset 
Alzheimer’s disease candidate gene ABCA7. Five potential variants (rs3752233, 
rs3752239, rs59851484, rs114782266 and 19:1056958 T>C) were identified in 
Chapter 2 and genotyped in Chapter 3. Three of these (rs3752239, rs59851484 and 
19:1056958) showed tentative results. However, further patient samples are required 
in order to completely clarify their association with LOAD risk. 
In Chapters 4 and 5, putative splicing variants (rs881768) and regulatory variants 
(rs2020000) were examined. Both of these variants did appear to have some 
functional activity. However, improved functional databases are required, for both 
coding and noncoding variants, in order to advance identification of such variants out 
of deep re-sequencing project results. Enhanced in vitro assays, for example the use of 
iPSCs, are also required, in order to assist with the accurate analysis of these 
functional variants in more biologically relevant systems. 
Genetic studies into LOAD, such as GWAS, have provided a massive insight into the 
molecular mechanisms behind the disease - imparting directions for drug 
development, disease treatment, diagnosis and screening. With further work, these 
avenues can be exploited to an even greater extent, in order to put a halt on the 
advancement of this catastrophic disease.  
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Appendix A 
Complete catalogue of ABCA7 exonic variants acquired from the Exome Variant 
Server (EVS) and Next Generation Sequencing (NGS) performed in this lab. The 
genomic position and rs ID number of each of these variants are presented as well as 
the location within the ABCA7 gene, and the position of cDNA and protein changes 
they code for. Also shown are the minor allele frequencies (MAF) in five databases; 
HapMap (showing the European population MAF), EVS (the combined "All" 
frequency), dbSNP and 1000Genomes (again the collective "All" population). All 
MAFs are shown in percentage format. Also shown are the MAFs from the CRISP 
programme which was calculated as part of the NGS project. The affect this protein 
substitution has on the protein is also shown according to three different prediction 
programmes: the Grantham Score; Polyphen-2 and SIFT. The origin of each of the 
variants are indicated by dots in the EVS and NGS columns, the only exonic ABCA7 
GWAS variant is also highlighted in the GWAS column. 
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Appendix B - URLs Used 
All URLs utilised during this project. The URL itself, as well as a description of what 
it was used for is presented.  
Appendix B
Name Description URL
1000Genomes
1000Genomes database - a deep catalogue of 
human genetic variation
http://browser.1000genomes.org/index.html
ABCMdb
The ABC mutations database contains mentions of 
ABC protein mutations extracted from the 
literature using automated data mining method and 
also annotated infromation on variants from other 
databases and sources.
http://abcmutations.hegelab.org/
Alzheimer's Association
Alzheimer's Association website for up-to-date 
statistics on AD
www.alz.org
Alzheimer's Research UK
ARUK website for information on AD specific to 
the UK population
www.alzheimersresearchuk.org
Berkeley Drosophila Genome Project (BDGP)
Annotation tool to identify features of DNA 
sequence
http://www.fruitfly.org/
BioGPS
Gene annotation portal to identify gene and protein 
functions
http://biogps.org/#goto=genereport&id=10347
Clustalw2
Multiple alignment sequence programme for protein 
and DNA sequence
https://www.ebi.ac.uk/Tools/msa/clustalo/
dbSNP Variant annotation within the genome https://www.ncbi.nlm.nih.gov/projects/SNP/
ENCODE
Comprehensive list of functional elements within 
the human genome
https://www.encodeproject.org/
Ensembl Genome browser for vertebrate genomes http://www.ensembl.org
ESE Finder Release 3.0
Web-based resource to identify putative ESEs 
responsive to the human SR proteins
http://krainer01.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home
Exome Variant Server (EVS)
Data from NGS of the protein coding regions of the 
human genome across diverse populations as part 
of the NHLBI GO Exome Sequencing Project
http://evs.gs.washington.edu/EVS/
GTEx
Computed eQTL results associated with individual 
genotype, expression and clinical data
http://gtexportal.org/home/
HaploReg
Tool for exploring annotations of the noncoding 
genome at variants on haplotype blocks
http://archive.broadinstitute.org/mammals/haploreg/haploreg.php
HaploView
Programme to analyse LD and haplotype 
associations within the 1000Genomes data
https://www.broadinstitute.org/haploview/haploview
HapMap (now retired) Haplotype map of the human genomes https://www.ncbi.nlm.nih.gov/variation/news/NCBI_retiring_HapMap/
Human Splicing Finder 3.0
Algorithmic approach to identify potential splice 
sites and branch points within the human genome
http://www.umd.be/HSF3/
MatInspector
Applies matrix descriptions to locate transcription 
factor binding sites within DNA sequences
https://www.genomatix.de/online_help/help_matinspector/matinspector
_help.html
National Center for Biotechnology Information (NCBI) Open access genomic information http://www.ncbi.nlm.nih.gov
NHS Alzheimer's Disease Information
NHS Choices information of Alzheimer's diseases, 
targeted at educating the public interested in the 
condition
http://www.nhs.uk/Conditions/Alzheimers-
disease/Pages/Introduction.aspx
NICE Dementia Recommendations
National Institute for Clinical Excellence 
recommendations for dementia conditions including 
therapeutic interventions and diagnostic pathways
https://www.nice.org.uk/guidance/conditions-and-diseases/mental-
health-and-behavioural-conditions/dementia
PLINK (v1.07)
Open-source whole genome association analysis 
toolset
http://pngu.mgh.harvard.edu/purcell/plink/
PolyPhen-2
Polymorphism Phenotyping v2 predicts possible 
impact of amino acid substitution on the structure 
and function of human proteins
http://genetics.bwh.harvard.edu/pph2/
Primer3
Source forge hosted programme to design PCR 
primers
http://bioinfo.ut.ee/primer3/
Promega
Promega's manufacture's website to access 
protocols and vector reference sequences
https://www.promega.co.uk/
QUANTO
Program to calculate required sample size and 
power for genetic studies
http://biostats.usc.edu/Quanto.html
RegulomeDB
Identify DNA features and regulatory elements in 
non-coding regions of the human genome
http://www.regulomedb.org/
SeattleSeq Variant Annotation 141
Annotation of SNPs by pooling data from a number 
of sources, provides Grantham Score
http://snp.gs.washington.edu/SeattleSeqAnnotation141/
SIFT
Prediction programme for whether an amino acid 
substitution affects protein function
http://sift.jcvi.org/
SNPCheck3
Tool for checking for the presence of SNPs in 
predicted PCR primer binding sites
https://secure.ngrl.org.uk/SNPCheck/snpcheck.htm;jsessionid=169B98
42F7E80DE3345BAD2C8137A544
tabix
Generic tool that indexes position sorted files in 
TAB-delimited formats
https://sourceforge.net/projects/samtools/files/tabix/
TMHH Server v. 2.0 Prediction of transmembrane helices in proteins http://www.cbs.dtu.dk/services/TMHMM/
TOPO2 Transmembrane protein display software http://www.sacs.ucsf.edu/TOPO2/
UCSC Genome Browser
On-line genome browser hosted by the University 
of California, Santa Cruz 
http://genome-euro.ucsc.edu
UCSC in-silico PCR Programme
In-Silico  PCR searches a sequence database with 
a pair of PCR primers
http://rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr
UniProt
Comprehensive resource of protein sequence and 
functional information
http://www.uniprot.org/uniprot/Q8IZY2
vcftools
Program package designed for working with 
Variant Call Files files
http://vcftools.sourceforge.net/
Webcutter 2.0
On-line tool for restriction mapping nucleotide 
sequences
http://rna.lundberg.gu.se/cutter2/
All URLs utilised during this project. The URL itself, as well as a description of what it was used for is presented. If any of these tools are not mentioned specifically in this thesis 
